OK
Oklahoma House Bill HB3567

Oklahoma 2024 Regular Session

Oklahoma House Bill HB3567 Compare Versions

OldNewDifferences
1-An Act
2-ENROLLED HOUSE
1+
2+
3+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 1 1
4+2
5+3
6+4
7+5
8+6
9+7
10+8
11+9
12+10
13+11
14+12
15+13
16+14
17+15
18+16
19+17
20+18
21+19
22+20
23+21
24+22
25+23
26+24
27+
28+ENGROSSED SENATE AMENDMENT
29+TO
30+ENGROSSED HOUSE
331 BILL NO. 3567 By: Manger of the House
432
533 and
634
735 Paxton of the Senate
836
937
1038
1139
12-
1340 An Act relating to controlled dangerous drugs;
41+amending 63 O.S. 2021, Sections 2 -101, as last
42+amended by Section 1, Chapter 375, O.S.L. 2023, ***
43+which relate to the Uniform Controlled Dangerous
44+Substances Act; adding and alphabetizing definitions;
45+deleting reference to promulgated rules; clarifying
46+circumstances that provide for the revocation or ***
47+electronic prescriptions under certain circumstances;
48+requiring practitioners to purchase official
49+prescription forms; providing restrictions on use of
50+official prescription forms; modifying scope of ***
51+176, O.S.L. 2023, 2-309 as last amended by Section 1,
52+Chapter 333, O.S.L. 2021, 2 -402, as last amended by
53+Section 1, Chapter 220, O.S.L. 2016 and 2 -406, as
54+last amended by Section 7, Chapter 375, O.S.L. 2023
55+*** Uniform Controlled Dangerous Substance Act; and
56+declaring an emergency.
57+
58+
59+
60+
61+
62+AMENDMENT NO. 1. Page 1, strike the title, enacting claus e and
63+entire bill and insert
64+
65+
66+“An Act relating to controlled dangerous drugs;
1467 amending 63 O.S. 2021, Sections 2 -101, as last
1568 amended by Section 1, Chapter 375, O.S.L. 2023, 2 -
1669 106.2, 2-204, as last amended by Section 1, Chapter
1770 120, O.S.L. 2023, 2-304, as last amended by Section
1871 3, Chapter 375, O.S.L. 2023, 2 -305, as last amended
1972 by Section 4, Chapter 375, O.S.L. 2023, 2 -309, as
2073 amended by Section 2, Chapter 304, O.S.L. 2023 , and
2174 2-406, as amended by Section 2, Chapter 235, O.S.L.
75+
76+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 2 1
77+2
78+3
79+4
80+5
81+6
82+7
83+8
84+9
85+10
86+11
87+12
88+13
89+14
90+15
91+16
92+17
93+18
94+19
95+20
96+21
97+22
98+23
99+24
100+
22101 2023 (63 O.S. Supp. 2023, Sections 2-101, 2-204, 2-
23102 304, 2-305, 2-309, and 2-406), which relate to the
24103 Uniform Controlled Dangerous Substances Act; adding
25104 and alphabetizing definitions; deleting reference to
26105 promulgated rules; adding substances to list of
27106 Schedule I controlled subst ances; updating statutory
28107 reference; clarifying circumstances that provide for
29108 the revocation or suspension of registrations;
30109 deleting certain penalty provision; updating manner
31110 by which controlled dangerous substances are
32111 forfeited; deeming written order as final under
33112 certain circumstances; allowing registrations to
34113 remain in effect under certain circumstances;
35114 authorizing the utilization of electronic
36115 prescriptions under certain circumstances; requiring
37116 practitioners to purchase official prescription
38117 forms; providing restrictions on use of official
39118 prescription forms; modifying scope of certain
40119 prohibited act; repealing 63 O.S. 2021, Sections 2 -
41-101, as last amended by Section 10, Chapter 91,
42-O.S.L. 2019, Section 1, Chapter 235, O.S.L. 2023,
43-Section 1, Chapter 304, O.S.L. 2023, 2-304, as last
44-amended by Section 1 , Chapter 176, O.S.L. 2023, 2-
45-305, as amended by Section 2, Chapter 176, O.S.L.
46-2023, 2-309 as last amended by Section 1, Chapter ENR. H. B. NO. 3567 Page 2
47-333, O.S.L. 2021, 2-402, as last amended by Section
48-1, Chapter 220, O.S.L. 2016 , and 2-406, as last
49-amended by Section 7, Chapter 375, O.S.L. 2023 (63
50-O.S. Supp. 2023, Section s 2-101, 2-304, 2-305, 2-309,
51-2-402 and 2-406), which relate to the Uniform
52-Controlled Dangerous Substances Act; and declaring an
53-emergency.
54-
55-
56-
57-
58-SUBJECT: Controlled dangerous drugs
120+101, as amended by Section 10, Chapter 91, O.S.L.
121+2019, as last amended by Section 1, Chapter 235,
122+O.S.L. 2023, and as last amended by Section 1,
123+Chapter 304, O.S.L. 2023, 2 -304, as amended by
124+Section 1, Chapter 176, O.S.L. 2023, 2 -305, as
125+amended by Section 2, Chapter 176, O.S.L. 2023, 2 -
126+309, as amended by Section 1, Chapter 333, O.S.L.
127+2021, 2-402, as amended by S ection 1, Chapter 220,
128+O.S.L. 2016, and 2-406, as last amended by Section 7,
129+Chapter 375, O.S.L. 2023 (63 O.S. Supp. 2023,
130+Sections 2-101, 2-304, 2-305, 2-309, 2-402, and 2-
131+406), which relate to the Uniform Controlled
132+Dangerous Substance Act; and declaring an emergency.
133+
134+
135+
59136
60137 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
61-
62-SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -101v4, as
138+SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -101, as
63139 last amended by Section 1, Chapter 375, O.S.L. 2023 (63 O.S. Supp.
64-2023, Section 2-101v4), is amended to read as follows:
65-
66-Section 2-101v4. As used in the Uniform Controlled Dangerous
140+2023, Section 2-101), is amended to read as follows:
141+Section 2-101. As used in the Uniform Controlled Dangerous
67142 Substances Act:
143+
144+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 3 1
145+2
146+3
147+4
148+5
149+6
150+7
151+8
152+9
153+10
154+11
155+12
156+13
157+14
158+15
159+16
160+17
161+18
162+19
163+20
164+21
165+22
166+23
167+24
68168
69169 1. “Acute pain” means pain, whether resulting from disease,
70170 accidental trauma, intentional trauma, or other cause that the
71171 practitioner reasonably expects to last only a short period of time.
72172 Acute pain does not include chronic pain, pain being treated as part
73173 of cancer care, hospice or other end -of-life care, or pain being
74174 treated as part of palliative care;
75-
76175 2. “Administer” means the direct application of a cont rolled
77176 dangerous substance, whether by injection, inhalation, ingestion or
78177 any other means, to the body of a patient, animal or research
79178 subject by:
80-
81179 a. a practitioner (or, in the presence of the
82180 practitioner, by the authorized agent of the
83181 practitioner), or
84-
85182 b. the patient or research subject at the direction and
86183 in the presence of the practitioner;
87-
88184 2. 3. “Agent” means a peace officer appointed by and who acts
89185 on behalf of the Director of the Oklahoma State Bureau of Narcotics
90186 and Dangerous Drugs Control or an authorized person who acts on
91-behalf of or at the direction of a person who manufactures, ENR. H. B. NO. 3567 Page 3
187+behalf of or at the direction of a person who manufactures,
92188 distributes, dispenses, prescribes, administers or uses for
93189 scientific purposes controlled dangerous substances but does not
94190 include a common or contract carrier, public warehouser or employee
95191 thereof, or a person required to register under the Uniform
96192 Controlled Dangerous Substances Act;
97193
194+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 4 1
195+2
196+3
197+4
198+5
199+6
200+7
201+8
202+9
203+10
204+11
205+12
206+13
207+14
208+15
209+16
210+17
211+18
212+19
213+20
214+21
215+22
216+23
217+24
218+
98219 4. “Anhydrous ammonia” means any substance that exhibits
99220 cryogenic evaporative behavior and tests positive for ammonia;
100-
101221 3. 5. “Board” means the Advisory Board to the Director of the
102222 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
103-
104223 4. 6. “Bureau” means the Oklahoma State Bureau of Narcotics and
105224 Dangerous Drugs Control;
106-
107225 7. “Chronic pain” means pain that persists be yond the usual
108226 course of an acute disease or healing of an injury. Chronic pain
109227 may or may not be associated with an acute or chronic pathologic
110228 process that causes continuous or intermittent pain over months or
111229 years;
112-
113230 5. 8. “Coca leaves” includes cocain e and any compound,
114231 manufacture, salt, derivative, mixture or preparation of coca
115232 leaves, except derivatives of coca leaves which do not contain
116233 cocaine or ecgonine;
117-
118234 6. 9. “Commissioner” or “Director” means the Director of the
119235 Oklahoma State Bureau of Nar cotics and Dangerous Drugs Control;
120-
121236 7. 10. “Control” means to add, remove or change the placement
122237 of a drug, substance or immediate precursor under the Uniform
123238 Controlled Dangerous Substances Act;
124-
125239 8. 11. “Controlled dangerous substance” means a drug, sub stance
126240 or immediate precursor in Schedules I through V of the Uniform
127241 Controlled Dangerous Substances Act or any drug, substance or
128242 immediate precursor listed either temporarily or permanently as a
243+
244+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 5 1
245+2
246+3
247+4
248+5
249+6
250+7
251+8
252+9
253+10
254+11
255+12
256+13
257+14
258+15
259+16
260+17
261+18
262+19
263+20
264+21
265+22
266+23
267+24
268+
129269 federally controlled substance. Any conflict between stat e and
130270 federal law with regard to the particular schedule in which a
131271 substance is listed shall be resolved in favor of state law;
132-
133272 9. 12. “Counterfeit substance” means a controlled substance
134273 which, or the container or labeling of which without authorization ,
135274 bears the trademark, trade name or other identifying marks, imprint,
136-number or device or any likeness thereof of a manufacturer, ENR. H. B. NO. 3567 Page 4
275+number or device or any likeness thereof of a manufacturer,
137276 distributor or dispenser other than the person who in fact
138277 manufactured, distributed or dispensed the substance;
139-
140278 10. 13. “Deliver” or “delivery” means the actual, constructive
141279 or attempted transfer from one person to another of a controlled
142280 dangerous substance or drug paraphernalia, whether or not there is
143281 an agency relationship;
144-
145282 11. 14. “Dispense” means to deliver a controlle d dangerous
146283 substance to an ultimate user or human research subject by or
147284 pursuant to the lawful order of a practitioner, including the
148285 prescribing, administering, packaging, labeling or compounding
149286 necessary to prepare the substance for such distribution.
150287 “Dispenser” is a practitioner who delivers a controlled dangerous
151288 substance to an ultimate user or human research subject;
152-
153289 12. 15. “Distribute” means to deliver other than by
154290 administering or dispensing a controlled dangerous substance;
155-
156291 13. 16. “Distributor” means a commercial entity engaged in the
157292 distribution or reverse distribution of narcotics and dangerous
293+
294+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 6 1
295+2
296+3
297+4
298+5
299+6
300+7
301+8
302+9
303+10
304+11
305+12
306+13
307+14
308+15
309+16
310+17
311+18
312+19
313+20
314+21
315+22
316+23
317+24
318+
158319 drugs and who complies with all regulations promulgated by the
159320 federal Drug Enforcement Administration and the Oklahoma State
160321 Bureau of Narcotics and Dangerous Drugs Control;
161-
162322 14. 17. “Drug” means articles:
163-
164323 a. recognized in the official United States Pharmacopeia,
165324 official Homeopathic Pharmacopoeia of the United
166325 States, or official National Formulary, or any
167326 supplement to any of them,
168-
169327 b. intended for use in the diagnosis, cure, mitigation,
170328 treatment or prevention of disease in man or other
171329 animals,
172-
173330 c. other than food, intended to affect the structure or
174331 any function of the body of man or other animals, and
175-
176332 d. intended for use as a component of any article
177333 specified in this paragraph;
178-
179334 provided, however, the term drug does not include devices or their
180335 components, parts or accessories;
181- ENR. H. B. NO. 3567 Page 5
182336 18. “Drug paraphernalia” means all equipment, products, and
183337 materials of any kind which are used, intended for use, o r fashioned
184338 specifically for use in planting, propagating, cultivating, growing,
185339 harvesting, manufacturing, compounding, converting, producing,
186340 processing, preparing, testing, analyzing, packaging, repackaging,
187341 storing, containing, concealing, injecting, i ngesting, inhaling, or
188342 otherwise introducing into the human body, a controlled dangerous
343+
344+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 7 1
345+2
346+3
347+4
348+5
349+6
350+7
351+8
352+9
353+10
354+11
355+12
356+13
357+14
358+15
359+16
360+17
361+18
362+19
363+20
364+21
365+22
366+23
367+24
368+
189369 substance in violation of the Uniform Controlled Dangerous
190370 Substances Act including, but not limited to:
191-
192371 a. kits used, intended for use, or fashioned specifically
193372 for use in planting, propagating, cultivating,
194373 growing, or harvesting of any species of plant which
195374 is a controlled dangerous substance or from which a
196375 controlled dangerous substance can be derived,
197-
198376 b. kits used, intended for use, or fashioned specifically
199377 for use in manufacturing, compounding, converting,
200378 producing, processing, or preparing controlled
201379 dangerous substances,
202-
203380 c. isomerization devices used, intended for use, or
204381 fashioned specifically for use in increasing the
205382 potency of any species of plant which is a controlled
206383 dangerous substance,
207-
208384 d. testing equipment used, intended for use, or fashioned
209-specifically for use in identifying or in analyzing
385+specifically for use in identifying, or in analyzing ,
210386 the strength, effectiveness, or purity of controlled
211387 dangerous substances,
212-
213388 e. scales and balances used, int ended for use, or
214389 fashioned specifically for use in weighing or
215390 measuring controlled dangerous substances,
216-
217391 f. diluents and adulterants, such as quinine
218392 hydrochloride, mannitol, mannite, dextrose , and
393+
394+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 8 1
395+2
396+3
397+4
398+5
399+6
400+7
401+8
402+9
403+10
404+11
405+12
406+13
407+14
408+15
409+16
410+17
411+18
412+19
413+20
414+21
415+22
416+23
417+24
418+
219419 lactose used, intended for use, or fashioned
220420 specifically for use in cutting controlled dangerous
221421 substances,
222-
223422 g. separation gins and sifters used, intended for use, or
224423 fashioned specifically for use in removing twigs and
225424 seeds from, or in otherwise cleaning or refining,
226-marijuana, ENR. H. B. NO. 3567 Page 6
227-
425+marijuana,
228426 h. blenders, bowls, containers , spoons, and mixing
229427 devices used, intended for use, or fashioned
230428 specifically for use in compounding controlled
231429 dangerous substances,
232-
233430 i. capsules, balloons, envelopes, and other containers
234431 used, intended for use, or fashioned specifically for
235432 use in packaging small quantities of controlled
236433 dangerous substances,
237-
238434 j. containers and other objects used, intended for use,
239435 or fashioned specifically for use in parenterally
240436 injecting controlled dangerous substances into the
241437 human body,
242-
243438 k. hypodermic syringes, needl es, and other objects used,
244439 intended for use, or fashioned specifically for use in
245440 parenterally injecting controlled dangerous substances
246441 into the human body, except as authorized by Section
247442 2-1101 of this title,
248443
444+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 9 1
445+2
446+3
447+4
448+5
449+6
450+7
451+8
452+9
453+10
454+11
455+12
456+13
457+14
458+15
459+16
460+17
461+18
462+19
463+20
464+21
465+22
466+23
467+24
468+
249469 l. objects used, intended for use, or fashi oned
250470 specifically for use in ingesting, inhaling, or
251471 otherwise introducing marijuana, cocaine, hashish, or
252472 hashish oil into the human body, such as:
253-
254473 (1) metal, wooden, acrylic, glass, stone, plastic, or
255474 ceramic pipes with or without screens, permanent
256475 screens, hashish heads, or punctured metal bowls,
257-
258476 (2) water pipes,
259-
260477 (3) carburetion tubes and devices,
261-
262478 (4) smoking and carburetion masks,
263-
264479 (5) roach clips, meaning objects used to hold burning
265480 material, such as a marijuana cigarette, that has
266481 become too small or too short to be held in the
267482 hand,
268-
269483 (6) miniature cocaine spoons and cocaine vials,
270-
271-(7) chamber pipes, ENR. H. B. NO. 3567 Page 7
272-
484+(7) chamber pipes,
273485 (8) carburetor pipes,
274-
275486 (9) electric pipes,
276-
277487 (10) air-driven pipes,
278-
279488 (11) chillums,
280-
281489 (12) bongs, or
282-
283490 (13) ice pipes or chillers,
284-
285491 m. all hidden or novelty pipes, and
492+
493+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 10 1
494+2
495+3
496+4
497+5
498+6
499+7
500+8
501+9
502+10
503+11
504+12
505+13
506+14
507+15
508+16
509+17
510+18
511+19
512+20
513+21
514+22
515+23
516+24
286517
287518 n. any pipe that has a tobacco bowl or chamber of less
288519 than one-half (1/2) inch in diameter in which there is
289520 any detectable residue of any controlled dangerous
290521 substance as defined in this section or any other
291522 substances not legal for possession or u se;
292-
293523 provided, however, the term drug paraphernalia shall not include
294524 separation gins intended for use in preparing tea or spice, clamps
295525 used for constructing electrical equipment, water pipes designed for
296526 ornamentation in which no detectable amount of an i llegal substance
297527 is found or pipes designed and used solely for smoking tobacco,
298528 traditional pipes of an American Indian tribal religious ceremony,
299529 antique pipes that are thirty (30) years of age or older, or drug
300530 testing strips possessed by a person for p urposes of determining the
301531 presence of fentanyl or a fentanyl -related compound;
302-
303532 15. 19. “Drug-dependent person” means a person who is using a
304533 controlled dangerous substance and who is in a state of psychic or
305534 physical dependence, or both, arising from adm inistration of that
306535 controlled dangerous substance on a continuous basis. Drug
307536 dependence is characterized by behavioral and other responses which
308537 include a strong compulsion to take the substance on a continuous
309538 basis in order to experience its psychic e ffects, or to avoid the
310539 discomfort of its absence;
311-
312540 20. “Harm-reduction services” means programs established to:
541+
542+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 11 1
543+2
544+3
545+4
546+5
547+6
548+7
549+8
550+9
551+10
552+11
553+12
554+13
555+14
556+15
557+16
558+17
559+18
560+19
561+20
562+21
563+22
564+23
565+24
313566
314567 a. reduce the spread of infectious diseases related to
315568 injection drug use,
316- ENR. H. B. NO. 3567 Page 8
317569 b. reduce drug dependency, overdose deaths , and
318570 associated complicat ions, and
319-
320571 c. increase safe recovery and disposal of used syringes
321572 and sharp waste;
322-
323573 21. “Hazardous materials” means materials, whether solid,
324574 liquid, or gas, which are toxic to human, animal, aquatic, or plant
325575 life, and the disposal of such materials is controlled by state or
326576 federal guidelines;
327-
328577 16. 22. “Home care agency” means any sole proprietorship,
329578 partnership, association, corporation, or other organization which
330579 administers, offers, or provides home care services, for a fee or
331580 pursuant to a contract for such services, to clients in their place
332581 of residence;
333-
334582 17. 23. “Home care services” means skilled or personal care
335583 services provided to clients in their place of residence for a fee;
336-
337584 18. 24. “Hospice” means a centrally administered, nonprofit or
338585 for-profit, medically directed, nurse -coordinated program which
339586 provides a continuum of home and inpatient care for the terminally
340587 ill patient and the patient’s family. Such term shall also include
341588 a centrally administered, nonprofit or for -profit, medically
342589 directed, nurse-coordinated program if such program is licensed
343590 pursuant to the provisions of the Uniform Controlled Dangerous
591+
592+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 12 1
593+2
594+3
595+4
596+5
597+6
598+7
599+8
600+9
601+10
602+11
603+12
604+13
605+14
606+15
607+16
608+17
609+18
610+19
611+20
612+21
613+22
614+23
615+24
616+
344617 Substances Act. A hospice program offers palliative and supportive
345618 care to meet the special needs arising out of the physical,
346619 emotional and spiritual stresses which are experienced during the
347620 final stages of illness and during dying and bereavement. This care
348621 is available twenty-four (24) hours a day, seven (7) days a week,
349622 and is provided on the basis of need, regardless of abil ity to pay.
350623 “Class A” Hospice refers to Medicare -certified hospices. “Class B”
351624 refers to all other providers of hospice services;
352-
353625 19. 25. “Imitation controlled substance” means a substance that
354626 is not a controlled dangerous substance, which by dosage un it
355627 appearance, color, shape, size, markings or by representations made,
356628 would lead a reasonable person to believe that the substance is a
357629 controlled dangerous substance , or is a drug intended solely for
358630 veterinary purposes that is not a controlled dangerou s substance and
359631 is being used outside of the scope of practice or normal course of
360632 business, as defined by the State Board of Veterinary Medical
361-Examiners, or is a federal Food and Drug Administration -approved ENR. H. B. NO. 3567 Page 9
633+Examiners, or is a federal Food and Drug Administration -approved
362634 drug that is not a controlled dangerous substa nce and is being used
363635 outside the scope of approval for illicit purposes such as
364636 adulterating or lacing other controlled dangerous substances . In
365637 the event the appearance of the dosage unit or use is not reasonably
366638 sufficient to establish that the substan ce is an imitation
367639 controlled substance, the court or authority concerned should
368640 consider, in addition to all other factors, the following factors as
641+
642+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 13 1
643+2
644+3
645+4
646+5
647+6
648+7
649+8
650+9
651+10
652+11
653+12
654+13
655+14
656+15
657+16
658+17
659+18
660+19
661+20
662+21
663+22
664+23
665+24
666+
369667 related to “representations made” in determining whether the
370668 substance is an imitation controlled substanc e:
371-
372669 a. statements made by an owner or by any other person in
373670 control of the substance concerning the nature of the
374671 substance, or its use or effect,
375-
376672 b. statements made to the recipient that the substance
377673 may be resold for inordinate profit,
378-
379674 c. whether the substance is packaged in a manner normally
380675 used for illicit controlled substances,
381-
382676 d. evasive tactics or actions utilized by the owner or
383677 person in control of the substance to avoid detection
384678 by law enforcement authorities,
385-
386679 e. prior convictions, if any, of a n owner, or any other
387680 person in control of the object, under state or
388681 federal law related to controlled substances or fraud,
389682 and
390-
391683 f. the proximity of the substances to controlled
392684 dangerous substances;
393-
394685 20. 26. “Immediate precursor” means a substance which t he
395686 Director has found to be and by regulation designates as being the
396687 principal compound commonly used or produced primarily for use, and
397688 which is an immediate chemical intermediary used, or likely to be
398689 used, in the manufacture of a controlled dangerous s ubstance, the
690+
691+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 14 1
692+2
693+3
694+4
695+5
696+6
697+7
698+8
699+9
700+10
701+11
702+12
703+13
704+14
705+15
706+16
707+17
708+18
709+19
710+20
711+21
712+22
713+23
714+24
715+
399716 control of which is necessary to prevent, curtail or limit such
400717 manufacture;
401-
402718 27. “Initial prescription” means a prescription issued to a
403719 patient who:
404- ENR. H. B. NO. 3567 Page 10
405720 a. has never previously been issued a prescription for
406721 the drug or its pharmaceutical equiv alent in the past
407722 year, or
408-
409723 b. requires a prescription for the drug or its
410724 pharmaceutical equivalent due to a surgical procedure
411725 or new acute event and has previously had a
412726 prescription for the drug or its pharmaceutical
413727 equivalent within the past year.
414-
415728 When determining whether a patient was previously issued a
416729 prescription for a drug or its pharmaceutical equivalent, the
417730 practitioner shall consult with the patient and review the medical
418731 record and prescription monitoring information of the patient;
419-
420732 28. “Isomer” means the optical isomer, except as used in
421733 subsections C and F of Section 2 -204 of this title and paragraph 4
422734 of subsection A of Section 2 -206 of this title. As used in
423735 subsections C and F of Section 2 -204 of this title, isomer means the
424736 optical, positional, or geometric isomer. As used in paragraph 4 of
425737 subsection A of Section 2 -206 of this title, the term isomer means
426738 the optical or geometric isomer;
427739
740+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 15 1
741+2
742+3
743+4
744+5
745+6
746+7
747+8
748+9
749+10
750+11
751+12
752+13
753+14
754+15
755+16
756+17
757+18
758+19
759+20
760+21
761+22
762+23
763+24
764+
428765 21. 29. “Laboratory” means a laboratory approved by the
429766 Director as proper to be entrusted with the custody of controlled
430767 dangerous substances and the use of controlled dangerous substances
431768 for scientific and medical purposes and for purposes of instruction;
432-
433769 22. 30. “Manufacture” means the production, preparation,
434770 propagation, compounding or process ing of a controlled dangerous
435771 substance, either directly or indirectly by extraction from
436772 substances of natural or synthetic origin, or independently by means
437773 of chemical synthesis or by a combination of extraction and chemical
438774 synthesis. “Manufacturer” i ncludes any person who packages,
439775 repackages or labels any container of any controlled dangerous
440776 substance, except practitioners who dispense or compound
441777 prescription orders for delivery to the ultimate consumer;
442-
443778 23. 31. “Marijuana” means all parts of the plant Cannabis
444779 sativa L., whether growing or not; the seeds thereof; the resin
445780 extracted from any part of such plant; and every compound,
446781 manufacture, salt, derivative, mixture or preparation of such plant,
447782 its seeds or resin, but shall not include:
448- ENR. H. B. NO. 3567 Page 11
449783 a. the mature stalks of such plant or fiber produced from
450784 such stalks,
451-
452785 b. oil or cake made from the seeds of such plant,
453786 including cannabidiol derived from the seeds of the
454787 marijuana plant,
788+
789+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 16 1
790+2
791+3
792+4
793+5
794+6
795+7
796+8
797+9
798+10
799+11
800+12
801+13
802+14
803+15
804+16
805+17
806+18
807+19
808+20
809+21
810+22
811+23
812+24
455813
456814 c. any other compound, manufacture, salt, derivative,
457815 mixture or preparation of such mature stalks (except
458816 the resin extracted therefrom), including cannabidiol
459817 derived from mature stalks, fiber, oil or cake,
460-
461818 d. the sterilized seed of such plant which is incapable
462819 of germination,
463-
464820 e. for any person participating in a clinical t rial to
465821 administer cannabidiol for the treatment of severe
466822 forms of epilepsy pursuant to Section 2 -802 of this
467823 title, a drug or substance approved by the federal
468824 Food and Drug Administration for use by those
469825 participants,
470-
471826 f. for any person or the parents, legal guardians or
472827 caretakers of the person who have received a written
473828 certification from a physician licensed in this state
474829 that the person has been diagnosed by a physician as
475830 having Lennox-Gastaut syndrome, Dravet syndrome, also
476831 known as severe myoclon ic epilepsy of infancy, or any
477832 other severe form of epilepsy that is not adequately
478833 treated by traditional medical therapies, spasticity
479834 due to multiple sclerosis or due to paraplegia,
480835 intractable nausea and vomiting, appetite stimulation
481836 with chronic wasting diseases, the substance
482837 cannabidiol, a nonpsychoactive cannabinoid, found in
838+
839+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 17 1
840+2
841+3
842+4
843+5
844+6
845+7
846+8
847+9
848+10
849+11
850+12
851+13
852+14
853+15
854+16
855+17
856+18
857+19
858+20
859+21
860+22
861+23
862+24
863+
483864 the plant Cannabis sativa L. or any other preparation
484865 thereof, that has a tetrahydrocannabinol concentration
485866 not more than three-tenths of one percent (0.3%) and
486867 that is delivered to the patient in the form of a
487868 liquid,
488-
489869 g. any federal Food-and-Drug-Administration Food and Drug
490870 Administration-approved drug or substance, or
491-
492871 h. industrial hemp, from the plant Cannabis sativa L. and
493-any part of such plant, whether growing or not, w ith a ENR. H. B. NO. 3567 Page 12
872+any part of such plant, whether growing or not, w ith a
494873 delta-9 tetrahydrocannabinol concentration not more
495874 than three-tenths of one percent (0.3%) on a dry -
496875 weight basis which shall only be grown pursuant to the
497876 Oklahoma Industrial Hemp Program and may be shipped
498877 intrastate and interstate;
499-
500878 24. 32. “Medical purpose” means an intention to utilize a
501879 controlled dangerous substance for physical or mental treatment, for
502880 diagnosis, or for the prevention of a disease condition not in
503881 violation of any state or federal law and not for the purpose of
504882 satisfying physiological or psychological dependence or other abuse;
505-
506883 25. 33. “Mid-level practitioner” means an Advanced Practice
507884 Registered Nurse as defined and within parameters specified in
508885 Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
509886 animal euthanasia technician as defined in Section 698.2 of Title 59
510887 of the Oklahoma Statutes, or an animal control officer registered by
888+
889+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 18 1
890+2
891+3
892+4
893+5
894+6
895+7
896+8
897+9
898+10
899+11
900+12
901+13
902+14
903+15
904+16
905+17
906+18
907+19
908+20
909+21
910+22
911+23
912+24
913+
511914 the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
512915 under subsection B of Section 2 -301 of this title within the
513916 parameters of such officer’s duties under Sections 501 through 508
514917 of Title 4 of the Oklahoma Statutes;
515-
516918 26. 34. “Narcotic drug” means any of the following, whether
517919 produced directly or indirectly by extraction from substances of
518920 vegetable origin, or indep endently by means of chemical synthesis,
519921 or by a combination of extraction and chemical synthesis:
520-
521922 a. opium, coca leaves and opiates,
522-
523923 b. a compound, manufacture, salt, derivative or
524924 preparation of opium, coca leaves or opiates,
525-
526925 c. cocaine, its salts, optic al and geometric isomers, and
527926 salts of isomers,
528-
529927 d. ecgonine, its derivatives, their salts, isomers and
530928 salts of isomers, and
531-
532929 e. a substance, and any compound, manufacture, salt,
533930 derivative or preparation thereof, which is chemically
534931 identical with any of t he substances referred to in
535932 subparagraphs a through d of this paragraph, except
536933 that the words narcotic drug as used in Section 2 -101
537-et seq. of this title shall not include decocainized ENR. H. B. NO. 3567 Page 13
934+et seq. of this title shall not include decocainized
538935 coca leaves or extracts of coca leaves, which extracts
539936 do not contain cocaine or ecgonine;
937+
938+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 19 1
939+2
940+3
941+4
942+5
943+6
944+7
945+8
946+9
947+10
948+11
949+12
950+13
951+14
952+15
953+16
954+17
955+18
956+19
957+20
958+21
959+22
960+23
961+24
540962
541963 27. 35. “Opiate” or “opioid” means any Schedule II, III, IV or
542964 V substance having an addiction -forming or addiction -sustaining
543965 liability similar to morphine or being capable of conversion into a
544966 drug having such addiction -forming or addiction-sustaining
545967 liability. The terms do not include, unless specifically designated
546968 as controlled under the Uniform Controlled Dangerous Substances Act,
547969 the dextrorotatory isomer of 3 -methoxy-n-methyl-morphinan and its
548970 salts (dextromethorphan). The terms do include the racemic and
549971 levorotatory forms;
550-
551972 28. 36. “Opium poppy” means the plant of the species Papaver
552973 somniferum L., except the seeds thereof;
553-
554974 37. “Palliative care” means a specialized medical service for
555975 people of any age and at any stage o f a serious illness or life -
556976 altering medical event that focuses on navigating complex medical
557977 decisions while providing patient autonomy and access to
558978 information. Utilizing a holistic and interdisciplinary team
559979 approach, palliative care addresses physica l, intellectual,
560980 emotional, social, and spiritual needs. Palliative care may be
561981 provided in the inpatient, outpatient, or home care setting and
562982 strives to improve quality of life for both the patient and the
563983 family;
564-
565984 38. “Patient-provider agreement” means a written contract or
566985 agreement that is executed between a practitioner and a patient
986+
987+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 20 1
988+2
989+3
990+4
991+5
992+6
993+7
994+8
995+9
996+10
997+11
998+12
999+13
1000+14
1001+15
1002+16
1003+17
1004+18
1005+19
1006+20
1007+21
1008+22
1009+23
1010+24
1011+
5671012 prior to the commencement of treatment for chronic pain using an
5681013 opioid drug as a means to:
569-
5701014 a. explain the possible risk of development of physical
5711015 or psychological depe ndence in the patient and prevent
5721016 the possible development of addiction,
573-
5741017 b. document the understanding of both the practitioner
5751018 and the patient regarding the patient -provider
5761019 agreement of the patient,
577-
5781020 c. establish the rights of the patient in association
5791021 with treatment and the obligations of the patient in
5801022 relation to the responsible use, discontinuation of
581-use, and storage of opioid drugs, including any ENR. H. B. NO. 3567 Page 14
1023+use, and storage of opioid drugs, including any
5821024 restrictions on the refill of prescriptions or the
5831025 acceptance of opioid prescriptions from practitioners ,
584-
5851026 d. identify the specific medications and other modes of
5861027 treatment, including physical therapy or exercise,
5871028 relaxation, or psychological counseling, that are
5881029 included as a part of the patient -provider agreement,
589-
5901030 e. specify the measures the practitioner ma y employ to
5911031 monitor the compliance of the patient including, but
5921032 not limited to, random specimen screens and pill
5931033 counts, and
594-
5951034 f. delineate the process for terminating the agreement,
5961035 including the consequences if the practitioner has
1036+
1037+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 21 1
1038+2
1039+3
1040+4
1041+5
1042+6
1043+7
1044+8
1045+9
1046+10
1047+11
1048+12
1049+13
1050+14
1051+15
1052+16
1053+17
1054+18
1055+19
1056+20
1057+21
1058+22
1059+23
1060+24
1061+
5971062 reason to believe that the patient is not complying
5981063 with the terms of the agreement. Compliance with the
5991064 consent items described in this paragraph shall
6001065 constitute a valid, informed consent for opioid
6011066 therapy. The practitioner shall be held harmless from
6021067 civil litigation for f ailure to treat pain if the
6031068 event occurs because of nonadherence by the patient
6041069 with any of the provisions of the patient -provider
6051070 agreement;
606-
6071071 29. 39. “Peace officer” means a police officer, sheriff, deputy
6081072 sheriff, district attorney’s investigator, invest igator from the
6091073 Office of the Attorney General, or any other person elected or
6101074 appointed by law to enforce any of the criminal laws of this state
6111075 or of the United States;
612-
6131076 30. 40. “Person” means an individual, corporation, government
6141077 or governmental subdiv ision or agency, business trust, estate,
6151078 trust, partnership or association, or any other legal entity;
616-
6171079 31. 41. “Poppy straw” means all parts, except the seeds, of the
6181080 opium poppy, after mowing;
619-
6201081 32. 42. “Practitioner” means:
621-
6221082 a. (1) a medical doctor or ost eopathic physician,
623-
6241083 (2) a dentist,
625-
626-(3) a podiatrist, ENR. H. B. NO. 3567 Page 15
627-
1084+(3) a podiatrist,
6281085 (4) an optometrist,
6291086
1087+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 22 1
1088+2
1089+3
1090+4
1091+5
1092+6
1093+7
1094+8
1095+9
1096+10
1097+11
1098+12
1099+13
1100+14
1101+15
1102+16
1103+17
1104+18
1105+19
1106+20
1107+21
1108+22
1109+23
1110+24
1111+
6301112 (5) a veterinarian,
631-
6321113 (6) a physician assistant or Advanced Practice
6331114 Registered Nurse under the supervision of a
6341115 licensed medical doctor or osteopathic physician,
635-
6361116 (7) a scientific investigator, or
637-
6381117 (8) any other person,
639-
6401118 licensed, registered or otherwise permitted to
6411119 prescribe, distribute, dispense, conduct research with
6421120 respect to, use for scientific purposes or administer
6431121 a controlled dangerous substance in the course of
6441122 professional practice or research in this state, or
645-
6461123 b. a pharmacy, hospital, laboratory or other institution
6471124 licensed, registered or otherwise permitted to
6481125 distribute, dispense, conduct research with respect
6491126 to, use for scientific purposes or administer a
6501127 controlled dangerous substance in the course of
6511128 professional practice or research in this state;
652-
6531129 33. 43. “Production” includes the manufacture, planting,
6541130 cultivation, growing or harvesting of a controlled dangerous
6551131 substance;
656-
6571132 44. “Serious illness” means a medical illnes s or physical
6581133 injury or condition that substantially affects quality of life for
6591134 more than a short period of time. Serious illness includes, but is
6601135 not limited to, Alzheimer’s disease or related dementias, lung
1136+
1137+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 23 1
1138+2
1139+3
1140+4
1141+5
1142+6
1143+7
1144+8
1145+9
1146+10
1147+11
1148+12
1149+13
1150+14
1151+15
1152+16
1153+17
1154+18
1155+19
1156+20
1157+21
1158+22
1159+23
1160+24
1161+
6611162 disease, cancer, heart failure, renal failur e, liver failure, or
6621163 chronic, unremitting, or intractable pain such as neuropathic pain;
663-
6641164 34. 45. “State” means the State of Oklahoma or any other state
6651165 of the United States;
666-
6671166 46. “Straw person” or “straw party”, also known as a “front”,
6681167 means a third party who:
669- ENR. H. B. NO. 3567 Page 16
6701168 a. is put up in name only to take part in a transaction
6711169 or otherwise is a nominal party to a transaction with
6721170 no actual control,
673-
6741171 b. acts on behalf of another person to obtain title to
6751172 property and executes documents and instruments the
6761173 principal may direct respecting property, or
677-
6781174 c. purchases property for another for the purpose of
6791175 concealing the identity of the real purchaser or to
6801176 accomplish some purpose otherwise in violation of the
6811177 Oklahoma Statutes;
682-
6831178 47. “Surgical procedure” means a procedure th at is performed
6841179 for the purpose of structurally altering the human body by incision
6851180 or destruction of tissues as part of the practice of medicine. This
6861181 term includes the diagnostic or therapeutic treatment of conditions
6871182 or disease processes by use of inst ruments such as lasers,
6881183 ultrasound, ionizing, radiation, scalpels, probes, or needles that
6891184 cause localized alteration or transportation of live human tissue by
6901185 cutting, burning, vaporizing, freezing, suturing, probing, or
1186+
1187+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 24 1
1188+2
1189+3
1190+4
1191+5
1192+6
1193+7
1194+8
1195+9
1196+10
1197+11
1198+12
1199+13
1200+14
1201+15
1202+16
1203+17
1204+18
1205+19
1206+20
1207+21
1208+22
1209+23
1210+24
1211+
6911212 manipulating by closed reduction f or major dislocations or
6921213 fractures, or otherwise altering by any mechanical, thermal, light -
6931214 based, electromagnetic, or chemical means;
694-
6951215 48. a. “Synthetic controlled substance” means a substance:
696-
6971216 (1) the chemical structure of which is substantially
6981217 similar to the chemical structure of a controlled
6991218 dangerous substance in Schedule I or II,
700-
7011219 (2) which has a stimulant, depressant, or
7021220 hallucinogenic effect on the central nervous
7031221 system that is substantially similar to or
7041222 greater than the stimulant, depressant, or
7051223 hallucinogenic effect on the central nervous
7061224 system of a controlled dangerous substance in
7071225 Schedule I or II, or
708-
7091226 (3) with respect to a particular person, which such
7101227 person represents or intends to have a stimulant,
7111228 depressant, or hallucinogenic effect on the
7121229 central nervous system that is substantially
7131230 similar to or greater than the stimulant,
714-depressant, or hallucinogenic effect on the ENR. H. B. NO. 3567 Page 17
1231+depressant, or hallucinogenic effect on the
7151232 central nervous system of a controlled dangerous
7161233 substance in Schedule I or II.
717-
7181234 b. The designation of gamma -butyrolactone or any other
7191235 chemical as a precursor, pursuant to Section 2 -322 of
1236+
1237+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 25 1
1238+2
1239+3
1240+4
1241+5
1242+6
1243+7
1244+8
1245+9
1246+10
1247+11
1248+12
1249+13
1250+14
1251+15
1252+16
1253+17
1254+18
1255+19
1256+20
1257+21
1258+22
1259+23
1260+24
1261+
7201262 this title, does not preclude a finding pursuant to
7211263 subparagraph a of this paragraph that the chemical is
7221264 a synthetic controlled substance.
723-
7241265 c. Synthetic controlled substance does not include:
725-
7261266 (1) a controlled dangerous substance,
727-
7281267 (2) any substance for which there is an approved new
7291268 drug application,
730-
7311269 (3) with respect to a particular person any
7321270 substance, if an exemption is in effect for
7331271 investigational use, for that person under the
7341272 provisions of Section 505 of the Federal Food,
7351273 Drug, and Cosmetic Act, 21 U.S.C., Section 355,
7361274 to the extent conduct with respect to such
7371275 substance is pursuant to such exemption, or
738-
7391276 (4) any substance to the extent not intended for
7401277 human consumption before such an exe mption takes
7411278 effect with respect to that substance.
742-
7431279 d. Prima facie evidence that a substance containing
7441280 salvia divinorum has been enhanced, concentrated, or
7451281 chemically or physically altered shall give rise to a
7461282 rebuttable presumption that the substance is a
7471283 synthetic controlled substance;
748-
7491284 49. “Tetrahydrocannabinols” means all substances that have been
7501285 chemically synthesized to emulate the tetrahydrocannabinols of
1286+
1287+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 26 1
1288+2
1289+3
1290+4
1291+5
1292+6
1293+7
1294+8
1295+9
1296+10
1297+11
1298+12
1299+13
1300+14
1301+15
1302+16
1303+17
1304+18
1305+19
1306+20
1307+21
1308+22
1309+23
1310+24
1311+
7511312 marijuana, specifically including any tetrahydrocannabinols derived
7521313 from industrial hemp; and
753-
7541314 35. 50. “Ultimate user” means a person who lawfully possesses a
7551315 controlled dangerous substance for the person’s own use or for the
7561316 use of a member of the person’s household or for administration to
7571317 an animal owned by the person or by a member of the perso n’s
7581318 household;
759- ENR. H. B. NO. 3567 Page 18
7601319 36. “Drug paraphernalia” means all equipment, products and
7611320 materials of any kind which are used, intended for use, or fashioned
7621321 specifically for use in planting, propagating, cultivating, growing,
7631322 harvesting, manufacturing, compounding, con verting, producing,
7641323 processing, preparing, testing, analyzing, packaging, repackaging,
7651324 storing, containing, concealing, injecting, ingesting, inhaling or
7661325 otherwise introducing into the human body, a controlled dangerous
7671326 substance in violation of the Unifor m Controlled Dangerous
7681327 Substances Act including, but not limited to:
769-
7701328 a. kits used, intended for use, or fashioned specifically
7711329 for use in planting, propagating, cultivating, growing
7721330 or harvesting of any species of plant which is a
7731331 controlled dangerous subs tance or from which a
7741332 controlled dangerous substance can be derived,
775-
7761333 b. kits used, intended for use, or fashioned specifically
7771334 for use in manufacturing, compounding, converting,
1335+
1336+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 27 1
1337+2
1338+3
1339+4
1340+5
1341+6
1342+7
1343+8
1344+9
1345+10
1346+11
1347+12
1348+13
1349+14
1350+15
1351+16
1352+17
1353+18
1354+19
1355+20
1356+21
1357+22
1358+23
1359+24
1360+
7781361 producing, processing or preparing controlled
7791362 dangerous substances,
780-
7811363 c. isomerization devices used, intended for use, or
7821364 fashioned specifically for use in increasing the
7831365 potency of any species of plant which is a controlled
7841366 dangerous substance,
785-
7861367 d. testing equipment used, intended for use, or fashioned
7871368 specifically for use in identify ing, or in analyzing
7881369 the strength, effectiveness or purity of controlled
7891370 dangerous substances,
790-
7911371 e. scales and balances used, intended for use, or
7921372 fashioned specifically for use in weighing or
7931373 measuring controlled dangerous substances,
794-
7951374 f. diluents and adulterants, such as quinine
7961375 hydrochloride, mannitol, mannite, dextrose and
7971376 lactose, used, intended for use, or fashioned
7981377 specifically for use in cutting controlled dangerous
7991378 substances,
800-
8011379 g. separation gins and sifters used, intended for use, or
8021380 fashioned specifically for use in removing twigs and
8031381 seeds from, or in otherwise cleaning or refining,
804-marijuana, ENR. H. B. NO. 3567 Page 19
1382+marijuana,
1383+
1384+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 28 1
1385+2
1386+3
1387+4
1388+5
1389+6
1390+7
1391+8
1392+9
1393+10
1394+11
1395+12
1396+13
1397+14
1398+15
1399+16
1400+17
1401+18
1402+19
1403+20
1404+21
1405+22
1406+23
1407+24
8051408
8061409 h. blenders, bowls, containers, spoons and mixing devices
8071410 used, intended for use, or fashioned specifically for
8081411 use in compounding controlled dangerous substan ces,
809-
8101412 i. capsules, balloons, envelopes and other containers
8111413 used, intended for use, or fashioned specifically for
8121414 use in packaging small quantities of controlled
8131415 dangerous substances,
814-
8151416 j. containers and other objects used, intended for use,
8161417 or fashioned specifically for use in parenterally
8171418 injecting controlled dangerous substances into the
8181419 human body,
819-
8201420 k. hypodermic syringes, needles and other objects used,
8211421 intended for use, or fashioned specifically for use in
8221422 parenterally injecting controlled dangerous subst ances
8231423 into the human body,
824-
8251424 l. objects used, intended for use, or fashioned
8261425 specifically for use in ingesting, inhaling or
8271426 otherwise introducing marijuana, cocaine, hashish or
8281427 hashish oil into the human body, such as:
829-
8301428 (1) metal, wooden, acrylic, glass, ston e, plastic or
8311429 ceramic pipes with or without screens, permanent
8321430 screens, hashish heads or punctured metal bowls,
833-
8341431 (2) water pipes,
835-
8361432 (3) carburetion tubes and devices,
8371433
1434+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 29 1
1435+2
1436+3
1437+4
1438+5
1439+6
1440+7
1441+8
1442+9
1443+10
1444+11
1445+12
1446+13
1447+14
1448+15
1449+16
1450+17
1451+18
1452+19
1453+20
1454+21
1455+22
1456+23
1457+24
1458+
8381459 (4) smoking and carburetion masks,
839-
8401460 (5) roach clips, meaning objects used to hold burning
8411461 material, such as a marijuana cigarette, that has
8421462 become too small or too short to be held in the
8431463 hand,
844-
8451464 (6) miniature cocaine spoons and cocaine vials,
846-
8471465 (7) chamber pipes,
848-
849-(8) carburetor pipes, ENR. H. B. NO. 3567 Page 20
850-
1466+(8) carburetor pipes,
8511467 (9) electric pipes,
852-
8531468 (10) air-driven pipes,
854-
8551469 (11) chillums,
856-
8571470 (12) bongs, or
858-
8591471 (13) ice pipes or chillers,
860-
8611472 m. all hidden or novelty pipes, and
862-
8631473 n. any pipe that has a tobacco bowl or chamber of less
8641474 than one-half (1/2) inch in diameter in which there is
8651475 any detectable residue of any controlled dangerous
8661476 substance as defined in this section or any other
8671477 substances not legal for possession or use;
868-
8691478 provided, however, the term drug paraphernalia shall not include
8701479 separation gins intended for use in preparing tea or spice, clamps
8711480 used for constructing electrical equipment, water pipe s designed for
8721481 ornamentation in which no detectable amount of an illegal substance
8731482 is found or pipes designed and used solely for smoking tobacco,
1483+
1484+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 30 1
1485+2
1486+3
1487+4
1488+5
1489+6
1490+7
1491+8
1492+9
1493+10
1494+11
1495+12
1496+13
1497+14
1498+15
1499+16
1500+17
1501+18
1502+19
1503+20
1504+21
1505+22
1506+23
1507+24
1508+
8741509 traditional pipes of an American Indian tribal religious ceremony,
8751510 antique pipes that are thirty (30) years o f age or older, or drug
8761511 testing strips possessed by a person for purposes of determining the
8771512 presence of fentanyl or a fentanyl -related compound;
878-
8791513 37. a. “Synthetic controlled substance” means a substance:
880-
8811514 (1) the chemical structure of which is substantiall y
8821515 similar to the chemical structure of a controlled
8831516 dangerous substance in Schedule I or II,
884-
8851517 (2) which has a stimulant, depressant, or
8861518 hallucinogenic effect on the central nervous
8871519 system that is substantially similar to or
8881520 greater than the stimulant, depre ssant or
8891521 hallucinogenic effect on the central nervous
8901522 system of a controlled dangerous substance in
8911523 Schedule I or II, or
892-
8931524 (3) with respect to a particular person, which such
894-person represents or intends to have a stimulant, ENR. H. B. NO. 3567 Page 21
1525+person represents or intends to have a stimulant,
8951526 depressant, or hallucinogenic eff ect on the
8961527 central nervous system that is substantially
8971528 similar to or greater than the stimulant,
8981529 depressant, or hallucinogenic effect on the
8991530 central nervous system of a controlled dangerous
9001531 substance in Schedule I or II.
9011532
1533+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 31 1
1534+2
1535+3
1536+4
1537+5
1538+6
1539+7
1540+8
1541+9
1542+10
1543+11
1544+12
1545+13
1546+14
1547+15
1548+16
1549+17
1550+18
1551+19
1552+20
1553+21
1554+22
1555+23
1556+24
1557+
9021558 b. The designation of gamma butyro lactone or any other
9031559 chemical as a precursor, pursuant to Section 2 -322 of
9041560 this title, does not preclude a finding pursuant to
9051561 subparagraph a of this paragraph that the chemical is
9061562 a synthetic controlled substance.
907-
9081563 c. “Synthetic controlled substance” does not include:
909-
9101564 (1) a controlled dangerous substance,
911-
9121565 (2) any substance for which there is an approved new
9131566 drug application,
914-
9151567 (3) with respect to a particular person any
9161568 substance, if an exemption is in effect for
9171569 investigational use, for that person under the
9181570 provisions of Section 505 of the Federal Food,
9191571 Drug and Cosmetic Act, Title 21 of the United
9201572 States Code, Section 355, to the extent conduct
9211573 with respect to such substance is pursuant to
9221574 such exemption, or
923-
9241575 (4) any substance to the extent not intended for
9251576 human consumption before such an exemption takes
9261577 effect with respect to that substance.
927-
9281578 d. Prima facie evidence that a substance containing
9291579 salvia divinorum has been enhanced, concentrated or
9301580 chemically or physically altered shall give rise to a
1581+
1582+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 32 1
1583+2
1584+3
1585+4
1586+5
1587+6
1588+7
1589+8
1590+9
1591+10
1592+11
1593+12
1594+13
1595+14
1596+15
1597+16
1598+17
1599+18
1600+19
1601+20
1602+21
1603+22
1604+23
1605+24
1606+
9311607 rebuttable presumption that the substance is a
9321608 synthetic controlled substance;
933-
9341609 38. “Tetrahydrocannabinols” means all substances that have been
9351610 chemically synthesized to emulate the tetrahydrocannabinols of
9361611 marijuana, specifically including any tetrahydrocannabinols derived
9371612 from industrial hemp;
938- ENR. H. B. NO. 3567 Page 22
9391613 39. “Isomer” means the optical isomer, except as used in
9401614 subsections C and F of Section 2 -204 of this title and paragraph 4
9411615 of subsection A of Section 2 -206 of this title. As used in
9421616 subsections C and F of Section 2 -204 of this title, isomer means the
9431617 optical, positional or geometric isomer. As used in paragraph 4 of
9441618 subsection A of Section 2 -206 of this title, the term isomer means
9451619 the optical or geometric isomer;
946-
9471620 40. “Hazardous materials” means materials, whether solid,
9481621 liquid or gas, which are toxic to human, animal, aquatic or plant
9491622 life, and the disposal of which materials is controlled by state or
9501623 federal guidelines;
951-
9521624 41. “Anhydrous ammonia” means any substance that exhibits
9531625 cryogenic evaporative behavior and tests po sitive for ammonia;
954-
9551626 42. “Acute pain” means pain, whether resulting from disease,
9561627 accidental or intentional trauma or other cause, that the
9571628 practitioner reasonably expects to last only a short period of time.
9581629 Acute pain does not include chronic pain, pain being treated as part
1630+
1631+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 33 1
1632+2
1633+3
1634+4
1635+5
1636+6
1637+7
1638+8
1639+9
1640+10
1641+11
1642+12
1643+13
1644+14
1645+15
1646+16
1647+17
1648+18
1649+19
1650+20
1651+21
1652+22
1653+23
1654+24
1655+
9591656 of cancer care, hospice or other end -of-life care, or pain being
9601657 treated as part of palliative care;
961-
9621658 43. “Chronic pain” means pain that persists beyond the usual
9631659 course of an acute disease or healing of an injury. Chronic pain
9641660 may or may not be associated with an acute or chronic pathologic
9651661 process that causes continuous or intermittent pain over months or
9661662 years;
967-
9681663 44. “Initial prescription” means a prescription issued to a
9691664 patient who:
970-
9711665 a. has never previously been issued a prescript ion for
9721666 the drug or its pharmaceutical equivalent in the past
9731667 year, or
974-
9751668 b. requires a prescription for the drug or its
9761669 pharmaceutical equivalent due to a surgical procedure
9771670 or new acute event and has previously had a
9781671 prescription for the drug or its pharmac eutical
9791672 equivalent within the past year.
980-
9811673 When determining whether a patient was previously issued a
982-prescription for a drug or its pharmaceutical equivalent, the ENR. H. B. NO. 3567 Page 23
1674+prescription for a drug or its pharmaceutical equivalent, the
9831675 practitioner shall consult with the patient and review the medical
9841676 record and prescription mon itoring information of the patient;
985-
9861677 45. “Patient-provider agreement” means a written contract or
9871678 agreement that is executed between a practitioner and a patient,
1679+
1680+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 34 1
1681+2
1682+3
1683+4
1684+5
1685+6
1686+7
1687+8
1688+9
1689+10
1690+11
1691+12
1692+13
1693+14
1694+15
1695+16
1696+17
1697+18
1698+19
1699+20
1700+21
1701+22
1702+23
1703+24
1704+
9881705 prior to the commencement of treatment for chronic pain using an
9891706 opioid drug as a means to:
990-
9911707 a. explain the possible risk of development of physical
9921708 or psychological dependence in the patient and prevent
9931709 the possible development of addiction,
994-
9951710 b. document the understanding of both the practitioner
9961711 and the patient regarding the patient -provider
9971712 agreement of the patient,
998-
9991713 c. establish the rights of the patient in association
10001714 with treatment and the obligations of the patient in
10011715 relation to the responsible use, discontinuation of
10021716 use, and storage of opioid drugs, including any
10031717 restrictions on the refill o f prescriptions or the
10041718 acceptance of opioid prescriptions from practitioners,
1005-
10061719 d. identify the specific medications and other modes of
10071720 treatment, including physical therapy or exercise,
10081721 relaxation or psychological counseling, that are
10091722 included as a part of the patient-provider agreement,
1010-
10111723 e. specify the measures the practitioner may employ to
10121724 monitor the compliance of the patient including, but
10131725 not limited to, random specimen screens and pill
10141726 counts, and
1015-
10161727 f. delineate the process for terminating the agreement,
10171728 including the consequences if the practitioner has
1729+
1730+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 35 1
1731+2
1732+3
1733+4
1734+5
1735+6
1736+7
1737+8
1738+9
1739+10
1740+11
1741+12
1742+13
1743+14
1744+15
1745+16
1746+17
1747+18
1748+19
1749+20
1750+21
1751+22
1752+23
1753+24
1754+
10181755 reason to believe that the patient is not complying
10191756 with the terms of the agreement. Compliance with the
10201757 “consent items” shall constitute a valid, informed
10211758 consent for opioid therapy. The practitioner s hall be
10221759 held harmless from civil litigation for failure to
10231760 treat pain if the event occurs because of nonadherence
10241761 by the patient with any of the provisions of the
10251762 patient-provider agreement;
1026- ENR. H. B. NO. 3567 Page 24
10271763 46. “Serious illness” means a medical illness or physical
10281764 injury or condition that substantially affects quality of life for
10291765 more than a short period of time. Serious illness includes, but is
10301766 not limited to, Alzheimer’s disease or related dementias, lung
10311767 disease, cancer, heart failure, renal failure, liver failure or
10321768 chronic, unremitting or intractable pain such as neuropathic pain;
10331769 and
1034-
10351770 47. “Surgical procedure” means a procedure that is performed
10361771 for the purpose of structurally altering the human body by incision
10371772 or destruction of tissues as part of the practice of me dicine. This
10381773 term includes the diagnostic or therapeutic treatment of conditions
10391774 or disease processes by use of instruments such as lasers,
10401775 ultrasound, ionizing, radiation, scalpels, probes or needles that
10411776 cause localized alteration or transportation of l ive human tissue by
10421777 cutting, burning, vaporizing, freezing, suturing, probing or
10431778 manipulating by closed reduction for major dislocations or
1779+
1780+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 36 1
1781+2
1782+3
1783+4
1784+5
1785+6
1786+7
1787+8
1788+9
1789+10
1790+11
1791+12
1792+13
1793+14
1794+15
1795+16
1796+17
1797+18
1798+19
1799+20
1800+21
1801+22
1802+23
1803+24
1804+
10441805 fractures, or otherwise altering by any mechanical, thermal, light -
10451806 based, electromagnetic or chemical means .
1046-
10471807 SECTION 2. AMENDATORY 63 O.S. 2021, Section 2 -106.2, is
10481808 amended to read as follows:
1049-
1050-Section 2-106.2 A. The Oklahoma State Bureau of Narcotics and
1809+Section 2-106.2. A. The Oklahoma State Bureau of Narcotics and
10511810 Dangerous Drugs Control , pursuant to rules promulgated by the
10521811 Oklahoma State Bureau of N arcotics and Dangerous Drugs Control
10531812 Commission, is hereby authorized to:
1054-
10551813 1. Make available for sale used vehicles, used equipment and
10561814 forfeited property to any federal, state, county, or municipal
10571815 agency, trust authority or public school district;
1058-
10591816 2. Sell at public auction any used vehicles, used equipment and
10601817 any property forfeited to the Bureau; and
1061-
10621818 3. Donate or transfer title to any surplus property as defined
10631819 in Section 62.2 of Title 74 of the Oklahoma Statutes, or property
10641820 forfeited to the Bureau, to any law enforcement agency of any
10651821 political subdivision of the State of Oklahoma. The use of such
10661822 donated equipment shall be limited to valid and authorized law
10671823 enforcement efforts by the receiving agency.
1068-
10691824 B. Any property subject to this section shall be exempted from
10701825 the provisions set forth in Section 62.3 of Title 74 of the Oklahoma
1071-Statutes. ENR. H. B. NO. 3567 Page 25
1826+Statutes.
1827+
1828+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 37 1
1829+2
1830+3
1831+4
1832+5
1833+6
1834+7
1835+8
1836+9
1837+10
1838+11
1839+12
1840+13
1841+14
1842+15
1843+16
1844+17
1845+18
1846+19
1847+20
1848+21
1849+22
1850+23
1851+24
10721852
10731853 SECTION 3. AMENDATORY 63 O.S. 2021, Section 2 -204, as
10741854 last amended by Section 1, Chapter 120, O.S.L. 2023 (63 O.S. Supp.
10751855 2023, Section 2-204), is amended to read as follows:
1076-
10771856 Section 2-204. The controlled substances listed in this section
10781857 are included in Schedule I and include any material, compound,
10791858 mixture or preparation that contains any quantity of the following
10801859 hallucinogenic subst ances, their salts, isomers and salts of
10811860 isomers, unless specifically excepted, when the existence of these
10821861 salts, isomers and salts of isomers is possible within the specific
10831862 chemical designation.
1084-
10851863 A. Any of the following opiates including their isomers,
10861864 esters, ethers, salts, and salts of isomers, esters, and ethers,
10871865 unless specifically excepted, when the existence of these isomers,
10881866 esters, ethers, and salts is possible within the specific chemical
10891867 designation:
1090-
10911868 1. Acetylmethadol;
1092-
10931869 2. Allylprodine;
1094-
10951870 3. Alphacetylmethadol;
1096-
10971871 4. Alphameprodine;
1098-
10991872 5. Alphamethadol;
1100-
11011873 6. Benzethidine;
1102-
11031874 7. Betacetylmethadol;
1104-
11051875 8. Betameprodine;
1106-
11071876 9. Betamethadol;
11081877
1878+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 38 1
1879+2
1880+3
1881+4
1882+5
1883+6
1884+7
1885+8
1886+9
1887+10
1888+11
1889+12
1890+13
1891+14
1892+15
1893+16
1894+17
1895+18
1896+19
1897+20
1898+21
1899+22
1900+23
1901+24
1902+
11091903 10. Betaprodine;
1110-
11111904 11. Clonitazene;
1112-
11131905 12. Dextromoramide;
1114-
11151906 13. Dextrorphan (except its methyl ether);
1116- ENR. H. B. NO. 3567 Page 26
11171907 14. Diampromide;
1118-
11191908 15. Diethylthiambutene;
1120-
11211909 16. Dimenoxadol;
1122-
11231910 17. Dimepheptanol;
1124-
11251911 18. Dimethylthiambutene;
1126-
11271912 19. Dioxaphetyl butyrate;
1128-
11291913 20. Dipipanone;
1130-
11311914 21. Ethylmethylthiambutene;
1132-
11331915 22. Etonitazene;
1134-
11351916 23. Etoxeridine;
1136-
11371917 24. Furethidine;
1138-
11391918 25. Hydroxypethidine;
1140-
11411919 26. Isotonitazene;
1142-
11431920 27. Ketobemidone;
1144-
11451921 28. Levomoramide;
1146-
11471922 29. Levophenacylmorphan;
1148-
11491923 30. Metonitazene;
1150-
11511924 31. Morpheridine;
1152-
11531925 32. N-desethyl isotonitazene;
1154-
11551926 33. N-pyrrolidino protonitazene;
11561927
1928+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 39 1
1929+2
1930+3
1931+4
1932+5
1933+6
1934+7
1935+8
1936+9
1937+10
1938+11
1939+12
1940+13
1941+14
1942+15
1943+16
1944+17
1945+18
1946+19
1947+20
1948+21
1949+22
1950+23
1951+24
1952+
11571953 34. Noracymethadol;
1158-
11591954 34. 35. Norlevorphanol;
1160-
1161-35. 36. Normethadone; ENR. H. B. NO. 3567 Page 27
1162-
1955+35. 36. Normethadone;
11631956 36. 37. Norpipanone;
1164-
11651957 37. 38. Phenadoxone;
1166-
11671958 38. 39. Phenampromide;
1168-
11691959 39. 40. Phenomorphan;
1170-
11711960 40. 41. Phenoperidine;
1172-
11731961 41. 42. Piritramide;
1174-
11751962 42. 43. Proheptazine;
1176-
11771963 43. 44. Properidine;
1178-
11791964 44. 45. Protonitazene;
1180-
11811965 45. 46. Racemoramide; or
1182-
11831966 46. 47. Trimeperidine.
1184-
11851967 B. Any of the following opium derivatives, their salts,
11861968 isomers, and salts of isomers, unless specifically excepted, when
11871969 the existence of these salts, isomers, and salts of isomers is
11881970 possible within the specific chemical designation:
1189-
11901971 1. Acetorphine;
1191-
11921972 2. Acetyldihydrocode ine;
1193-
11941973 3. Benzylmorphine;
1195-
11961974 4. Codeine methylbromide;
1197-
11981975 5. Codeine-N-Oxide;
1199-
12001976 6. Cyprenorphine;
12011977
1978+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 40 1
1979+2
1980+3
1981+4
1982+5
1983+6
1984+7
1985+8
1986+9
1987+10
1988+11
1989+12
1990+13
1991+14
1992+15
1993+16
1994+17
1995+18
1996+19
1997+20
1998+21
1999+22
2000+23
2001+24
2002+
12022003 7. Desomorphine;
1203-
12042004 8. Dihydromorphine;
1205-
1206-9. Etorphine; ENR. H. B. NO. 3567 Page 28
1207-
2005+9. Etorphine;
12082006 10. Heroin;
1209-
12102007 11. Hydromorphinol;
1211-
12122008 12. Methyldesorphine;
1213-
12142009 13. Methylhydromorphine;
1215-
12162010 14. Morphine methylbromide ;
1217-
12182011 15. Morphine methylsulfonate;
1219-
12202012 16. Morphine-N-Oxide;
1221-
12222013 17. Myrophine;
1223-
12242014 18. Nicocodeine;
1225-
12262015 19. Nicomorphine;
1227-
12282016 20. Normorphine;
1229-
12302017 21. Phoclodine;
1231-
12322018 22. Thebacon;
1233-
12342019 23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
12352020 (Acetyl fentanyl);
1236-
12372021 24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
12382022 (Crotonyl fentanyl);
1239-
12402023 25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
12412024 furancarboxamide (Furanyl fentanyl);
1242-
12432025 26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
2026+
2027+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 41 1
2028+2
2029+3
2030+4
2031+5
2032+6
2033+7
2034+8
2035+9
2036+10
2037+11
2038+12
2039+13
2040+14
2041+15
2042+16
2043+17
2044+18
2045+19
2046+20
2047+21
2048+22
2049+23
2050+24
12442051
12452052 27. N-(1-phenethylpiperidin-4-yl)-N-
12462053 phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
1247-
12482054 28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
12492055 (Butyrl fentanyl).
1250- ENR. H. B. NO. 3567 Page 29
12512056 C. Any material, compound, mixture, or preparation which
12522057 contains any quantity of the following hallucinogenic substances,
12532058 their salts, isomers, and salts of isomers, unless specifically
12542059 excepted, when the existence of these salts, isomers, and salts of
12552060 isomers is possible within the specific chemical designation:
1256-
12572061 1. Methcathinone;
1258-
12592062 2. 3, 4-methylenedioxy amphetamine;
1260-
12612063 3. 3, 4-methylenedioxy methamphetamine;
1262-
12632064 4. 5-methoxy-3, 4-methylenedioxy amphetamine;
1264-
12652065 5. 3, 4, 5-trimethoxy amphetamine;
1266-
12672066 6. Bufotenine;
1268-
12692067 7. Diethyltryptamine;
1270-
12712068 8. Dimethyltryptamine;
1272-
12732069 9. 4-methyl-2, 5-dimethoxyamphetamine;
1274-
12752070 10. Ibogaine;
1276-
12772071 11. Lysergic acid diet hylamide;
1278-
12792072 12. Marijuana;
1280-
12812073 13. Mescaline;
1282-
12832074 14. N-benzylpiperazine;
1284-
12852075 15. N-ethyl-3-piperidyl benzilate;
12862076
2077+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 42 1
2078+2
2079+3
2080+4
2081+5
2082+6
2083+7
2084+8
2085+9
2086+10
2087+11
2088+12
2089+13
2090+14
2091+15
2092+16
2093+17
2094+18
2095+19
2096+20
2097+21
2098+22
2099+23
2100+24
2101+
12872102 16. N-methyl-3-piperidyl benzilate;
1288-
12892103 17. Psilocybin;
1290-
12912104 18. Psilocyn;
1292-
12932105 19. 2, 5 dimethoxyamphetamine;
1294-
1295-20. 4 Bromo-2, 5-dimethoxyamphetamine; ENR. H. B. NO. 3567 Page 30
1296-
2106+20. 4 Bromo-2, 5-dimethoxyamphetamine;
12972107 21. 4 methoxyamphetamine;
1298-
12992108 22. Cyclohexamine;
1300-
13012109 23. Salvia Divinorum;
1302-
13032110 24. Salvinorin A;
1304-
13052111 25. Thiophene Analog of Phencyclidine. Also known as: 1 -(1-(2-
13062112 thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phencyclidine;
13072113 TPCP, TCP;
1308-
13092114 26. Phencyclidine (PCP);
1310-
13112115 27. Pyrrolidine Analog for Phencyclidine. Also known as 1 -(1-
13122116 Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
1313-
13142117 28. 1-(3-trifluoromethylphenyl) piperazine;
1315-
13162118 29. Flunitrazepam;
1317-
13182119 30. B-hydroxy-amphetamine;
1319-
13202120 31. B-ketoamphetamine;
1321-
13222121 32. 2,5-dimethoxy-4-nitroamphetamine;
1323-
13242122 33. 2,5-dimethoxy-4-bromophenethylamine;
1325-
13262123 34. 2,5-dimethoxy-4-chlorophenethylamine;
1327-
13282124 35. 2,5-dimethoxy-4-iodoamphetamine;
1329-
13302125 36. 2,5-dimethoxy-4-iodophenethylamine;
13312126
2127+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 43 1
2128+2
2129+3
2130+4
2131+5
2132+6
2133+7
2134+8
2135+9
2136+10
2137+11
2138+12
2139+13
2140+14
2141+15
2142+16
2143+17
2144+18
2145+19
2146+20
2147+21
2148+22
2149+23
2150+24
2151+
13322152 37. 2,5-dimethoxy-4-methylphenethylamine;
1333-
13342153 38. 2,5-dimethoxy-4-ethylphenethylamine;
1335-
13362154 39. 2,5-dimethoxy-4-fluorophenethylamine;
1337-
13382155 40. 2,5-dimethoxy-4-nitrophenethylamine;
1339-
1340-41. 2,5-dimethoxy-4-ethylthio-phenethylamine; ENR. H. B. NO. 3567 Page 31
1341-
2156+41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
13422157 42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
1343-
13442158 43. 2,5-dimethoxy-4-propylthio-phenethylamine;
1345-
13462159 44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine;
1347-
13482160 45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
1349-
13502161 46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
1351-
13522162 47. 5-methoxy-N, N-dimethyltryptamine;
1353-
13542163 48. N-methyltryptamine;
1355-
13562164 49. A-ethyltryptamine;
1357-
13582165 50. A-methyltryptamine;
1359-
13602166 51. N, N-diethyltryptamine;
1361-
13622167 52. N, N-diisopropyltryptamine;
1363-
13642168 53. N, N-dipropyltryptamine;
1365-
13662169 54. 5-methoxy-a-methyltryptamine;
1367-
13682170 55. 4-hydroxy-N, N-diethyltryptamine;
1369-
13702171 56. 4-hydroxy-N, N-diisopropyltryptamine;
1371-
13722172 57. 5-methoxy-N, N-diisopropyltryptamine;
1373-
13742173 58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
1375-
13762174 59. 3,4-Methylenedioxymethcathinone (Methylone);
1377-
13782175 60. 3,4-Methylenedioxypyrovalerone (MDPV);
13792176
2177+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 44 1
2178+2
2179+3
2180+4
2181+5
2182+6
2183+7
2184+8
2185+9
2186+10
2187+11
2188+12
2189+13
2190+14
2191+15
2192+16
2193+17
2194+18
2195+19
2196+20
2197+21
2198+22
2199+23
2200+24
2201+
13802202 61. 3-Methylmethcathinone (Metaphedrone);
1381-
13822203 62. 4-Methylmethcathinone (Mephedrone);
1383-
13842204 62. 63. 4-methoxymethcathinone;
1385- ENR. H. B. NO. 3567 Page 32
13862205 63. 64. 4-Fluoromethcathinone;
1387-
13882206 64. 65. 3-Fluoromethcathinone;
1389-
13902207 65. 66. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-
13912208 aminopropane;
1392-
13932209 66. 67. 2,5-Dimethoxy-4-chloroamphetamine;
1394-
13952210 67. 68. 4-Methylethcathinone;
1396-
13972211 68. 69. Pyrovalerone;
1398-
13992212 69. 70. N,N-diallyl-5-methoxytryptamine;
1400-
14012213 70. 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
1402-
14032214 71. 72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone);
1404-
14052215 72. 73. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
1406-
14072216 73. 74. Alpha-Pyrrolidinopentiophenone;
1408-
14092217 74. 75. 4-Fluoroamphetamine;
1410-
14112218 75. 76. Pentedrone;
1412-
14132219 76. 77. 4’-Methyl-a-pyrrolidinohexaphenone;
1414-
14152220 77. 78. 2,5-dimethoxy-4-(n)-propylphenethylamine;
1416-
14172221 78. 79. 2,5-dimethoxyphenethylamine;
1418-
14192222 79. 80. 1,4-Dibenzylpiperazine;
1420-
14212223 80. 81. N,N-Dimethylamphetamine;
1422-
14232224 81. 82. 4-Fluoromethamphetamine;
2225+
2226+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 45 1
2227+2
2228+3
2229+4
2230+5
2231+6
2232+7
2233+8
2234+9
2235+10
2236+11
2237+12
2238+13
2239+14
2240+15
2241+16
2242+17
2243+18
2244+19
2245+20
2246+21
2247+22
2248+23
2249+24
14242250
14252251 82. 83. 4-Chloro-2,5-dimethoxy-N-(2-
14262252 methoxybenzyl)phenethylamine (25C -NBOMe);
1427-
14282253 83. 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
14292254 (25I-NBOMe);
1430- ENR. H. B. NO. 3567 Page 33
14312255 84. 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
14322256 (25B-NBOMe);
1433-
14342257 85. 86. 1-(4-Fluorophenyl)piperazine;
1435-
14362258 86. 87. Methoxetamine;
1437-
14382259 87. 88. 3,4-dichloro-N[2-dimethylamino)cyclohexyl] -N-
14392260 methylbenzamide;
1440-
14412261 88. 89. N-ethyl hexadrone;
1442-
14432262 89. 90. Isopropyl-U-47700;
1444-
14452263 90. 91. Para-fluorobutyrl fentanyl;
1446-
14472264 92. Para-fluorofentanyl (pFF);
1448-
14492265 91. 93. Fluoro isobutryrl fentanyl;
1450-
14512266 92. 94. 3-Hydroxy Phencyclidine (PCP);
1452-
14532267 93. 95. 3-methoxy Phencyclidine (PCP);
1454-
14552268 94. 96. Flualprazolam; or
1456-
14572269 95. 97. Flubromazolam.
1458-
14592270 D. Unless specifically excepted or unless listed in a different
14602271 schedule, any material, compound, mixture, or preparation which
14612272 contains any quantity of the following substances having stimulant
14622273 or depressant effect on the central nervous system:
1463-
14642274 1. Fenethylline;
14652275
2276+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 46 1
2277+2
2278+3
2279+4
2280+5
2281+6
2282+7
2283+8
2284+9
2285+10
2286+11
2287+12
2288+13
2289+14
2290+15
2291+16
2292+17
2293+18
2294+19
2295+20
2296+21
2297+22
2298+23
2299+24
2300+
14662301 2. Mecloqualone;
1467-
14682302 3. N-ethylamphetamine;
1469-
14702303 4. Methaqualone;
1471-
14722304 5. Gamma-Hydroxybutyric Acid, also known as GHB, gamma-
14732305 hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
14742306 oxybate, and sodium oxybutyrate;
1475- ENR. H. B. NO. 3567 Page 34
14762307 6. Gamma-Butyrolactone (GBL) as packaged, marketed,
14772308 manufactured or promoted for human consumption, with the exception
14782309 of legitimate food ad ditive and manufacturing purposes;
1479-
14802310 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or
14812311 manufactured for human consumption, with the exception of legitimate
14822312 food additive and manufacturing purposes;
1483-
14842313 8. Gamma Valerolactone (GVL) as packaged, marketed, or
14852314 manufactured for human consumption, with the exception of legitimate
14862315 food additive and manufacturing purposes;
1487-
14882316 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed,
14892317 manufactured, or promoted for human consumption with the exception
14902318 of legitimate manufacturing purposes; or
1491-
14922319 10. N-ethylpentylone.
1493-
14942320 E. 1. The following industrial uses of Gamma -Butyrolactone,
14952321 Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are
14962322 excluded from all schedules of controlled substances under this
14972323 title:
1498-
14992324 a. pesticides,
15002325
2326+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 47 1
2327+2
2328+3
2329+4
2330+5
2331+6
2332+7
2333+8
2334+9
2335+10
2336+11
2337+12
2338+13
2339+14
2340+15
2341+16
2342+17
2343+18
2344+19
2345+20
2346+21
2347+22
2348+23
2349+24
2350+
15012351 b. photochemical etching,
1502-
15032352 c. electrolytes of small batteries or capacitors,
1504-
15052353 d. viscosity modifiers in polyurethane,
1506-
15072354 e. surface etching of metal coated plastics,
1508-
15092355 f. organic paint disbursements for water soluble inks,
1510-
15112356 g. pH regulators in the dyeing of wool and polyamide
15122357 fibers,
1513-
15142358 h. foundry chemistry as a catalyst during curing,
1515-
15162359 i. curing agents in many coating systems based on
15172360 urethanes and amides,
1518-
15192361 j. additives and flavoring agents in food, confectionary,
1520-and beverage products, ENR. H. B. NO. 3567 Page 35
1521-
2362+and beverage products,
15222363 k. synthetic fiber and clo thing production,
1523-
15242364 l. tetrahydrofuran production,
1525-
15262365 m. gamma butyrolactone production,
1527-
15282366 n. polybutylene terephthalate resin production,
1529-
15302367 o. polyester raw materials for polyurethane elastomers
15312368 and foams,
1532-
15332369 p. coating resin raw material, and
1534-
15352370 q. as an intermediate i n the manufacture of other
15362371 chemicals and pharmaceuticals.
1537-
15382372 2. At the request of any person, the Director of the Oklahoma
15392373 State Bureau of Narcotics and Dangerous Drugs Control may exempt any
15402374 other product containing Gamma -Butyrolactone, Gamma Hydroxyvalerat e,
2375+
2376+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 48 1
2377+2
2378+3
2379+4
2380+5
2381+6
2382+7
2383+8
2384+9
2385+10
2386+11
2387+12
2388+13
2389+14
2390+15
2391+16
2392+17
2393+18
2394+19
2395+20
2396+21
2397+22
2398+23
2399+24
2400+
15412401 Gamma Valerolactone, or 1,4 Butanediol from being included as a
15422402 Schedule I controlled substance if such product is labeled,
15432403 marketed, manufactured and distributed for legitimate industrial use
15442404 in a manner that reduces or eliminates the likelihood of abu se.
1545-
15462405 3. In making a determination regarding an industrial product,
15472406 the Director, after notice and hearing, shall consider the
15482407 following:
1549-
15502408 a. the history and current pattern of abuse,
1551-
15522409 b. the name and labeling of the product,
1553-
15542410 c. the intended manner of distrib ution, advertising and
15552411 promotion of the product, and
1556-
15572412 d. other factors as may be relevant to and consistent
15582413 with the public health and safety.
1559-
15602414 4. The hearing shall be held in accordance with the procedures
15612415 of the Administrative Procedures Act.
1562-
15632416 F. Any material, compound, mixture, or preparation, whether
15642417 produced directly or indirectly from a substance of vegetable origin
1565-or independently by means of chemical synthesis, or by a combination ENR. H. B. NO. 3567 Page 36
2418+or independently by means of chemical synthesis, or by a combination
15662419 of extraction and chemical synthesis, that contains any quantity of
15672420 the following substances, or that contains any of their salts,
15682421 isomers, and salts of isomers when the existence of these salts,
15692422 isomers, and salts of isomers is possible within the specific
15702423 chemical designation:
1571-
15722424 1. JWH-004;
15732425
2426+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 49 1
2427+2
2428+3
2429+4
2430+5
2431+6
2432+7
2433+8
2434+9
2435+10
2436+11
2437+12
2438+13
2439+14
2440+15
2441+16
2442+17
2443+18
2444+19
2445+20
2446+21
2447+22
2448+23
2449+24
2450+
15742451 2. JWH-007;
1575-
15762452 3. JWH-009;
1577-
15782453 4. JWH-015;
1579-
15802454 5. JWH-016;
1581-
15822455 6. JWH-018;
1583-
15842456 7. JWH-019;
1585-
15862457 8. JWH-020;
1587-
15882458 9. JWH-030;
1589-
15902459 10. JWH-046;
1591-
15922460 11. JWH-047;
1593-
15942461 12. JWH-048;
1595-
15962462 13. JWH-049;
1597-
15982463 14. JWH-050;
1599-
16002464 15. JWH-070;
1601-
16022465 16. JWH-071;
1603-
16042466 17. JWH-072;
1605-
16062467 18. JWH-073;
1607-
16082468 19. JWH-076;
1609-
1610-20. JWH-079; ENR. H. B. NO. 3567 Page 37
1611-
2469+20. JWH-079;
16122470 21. JWH-080;
1613-
16142471 22. JWH-081;
1615-
16162472 23. JWH-082;
1617-
16182473 24. JWH-094;
1619-
16202474 25. JWH-096;
16212475
2476+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 50 1
2477+2
2478+3
2479+4
2480+5
2481+6
2482+7
2483+8
2484+9
2485+10
2486+11
2487+12
2488+13
2489+14
2490+15
2491+16
2492+17
2493+18
2494+19
2495+20
2496+21
2497+22
2498+23
2499+24
2500+
16222501 26. JWH-098;
1623-
16242502 27. JWH-116;
1625-
16262503 28. JWH-120;
1627-
16282504 29. JWH-122;
1629-
16302505 30. JWH-145;
1631-
16322506 31. JWH-146;
1633-
16342507 32. JWH-147;
1635-
16362508 33. JWH-148;
1637-
16382509 34. JWH-149;
1639-
16402510 35. JWH-150;
1641-
16422511 36. JWH-156;
1643-
16442512 37. JWH-167;
1645-
16462513 38. JWH-175;
1647-
16482514 39. JWH-180;
1649-
16502515 40. JWH-181;
1651-
16522516 41. JWH-182;
1653-
16542517 42. JWH-184;
1655- ENR. H. B. NO. 3567 Page 38
16562518 43. JWH-185;
1657-
16582519 44. JWH-189;
1659-
16602520 45. JWH-192;
1661-
16622521 46. JWH-193;
1663-
16642522 47. JWH-194;
1665-
16662523 48. JWH-195;
1667-
16682524 49. JWH-196;
16692525
2526+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 51 1
2527+2
2528+3
2529+4
2530+5
2531+6
2532+7
2533+8
2534+9
2535+10
2536+11
2537+12
2538+13
2539+14
2540+15
2541+16
2542+17
2543+18
2544+19
2545+20
2546+21
2547+22
2548+23
2549+24
2550+
16702551 50. JWH-197;
1671-
16722552 51. JWH-198;
1673-
16742553 52. JWH-199;
1675-
16762554 53. JWH-200;
1677-
16782555 54. JWH-201;
1679-
16802556 55. JWH-202;
1681-
16822557 56. JWH-203;
1683-
16842558 57. JWH-204;
1685-
16862559 58. JWH-205;
1687-
16882560 59. JWH-206;
1689-
16902561 60. JWH-207;
1691-
16922562 61. JWH-208;
1693-
16942563 62. JWH-209;
1695-
16962564 63. JWH-210;
1697-
16982565 64. JWH-211;
1699-
1700-65. JWH-212; ENR. H. B. NO. 3567 Page 39
1701-
2566+65. JWH-212;
17022567 66. JWH-213;
1703-
17042568 67. JWH-234;
1705-
17062569 68. JWH-235;
1707-
17082570 69. JWH-236;
1709-
17102571 70. JWH-237;
1711-
17122572 71. JWH-239;
1713-
17142573 72. JWH-240;
1715-
17162574 73. JWH-241;
17172575
2576+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 52 1
2577+2
2578+3
2579+4
2580+5
2581+6
2582+7
2583+8
2584+9
2585+10
2586+11
2587+12
2588+13
2589+14
2590+15
2591+16
2592+17
2593+18
2594+19
2595+20
2596+21
2597+22
2598+23
2599+24
2600+
17182601 74. JWH-242;
1719-
17202602 75. JWH-243;
1721-
17222603 76. JWH-244;
1723-
17242604 77. JWH-245;
1725-
17262605 78. JWH-246;
1727-
17282606 79. JWH-248;
1729-
17302607 80. JWH-249;
1731-
17322608 81. JWH-250;
1733-
17342609 82. JWH-251;
1735-
17362610 83. JWH-252;
1737-
17382611 84. JWH-253;
1739-
17402612 85. JWH-262;
1741-
17422613 86. JWH-292;
1743-
17442614 87. JWH-293;
1745- ENR. H. B. NO. 3567 Page 40
17462615 88. JWH-302;
1747-
17482616 89. JWH-303;
1749-
17502617 90. JWH-304;
1751-
17522618 91. JWH-305;
1753-
17542619 92. JWH-306;
1755-
17562620 93. JWH-307;
1757-
17582621 94. JWH-308;
1759-
17602622 95. JWH-311;
1761-
17622623 96. JWH-312;
1763-
17642624 97. JWH-313;
17652625
2626+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 53 1
2627+2
2628+3
2629+4
2630+5
2631+6
2632+7
2633+8
2634+9
2635+10
2636+11
2637+12
2638+13
2639+14
2640+15
2641+16
2642+17
2643+18
2644+19
2645+20
2646+21
2647+22
2648+23
2649+24
2650+
17662651 98. JWH-314;
1767-
17682652 99. JWH-315;
1769-
17702653 100. JWH-316;
1771-
17722654 101. JWH-346;
1773-
17742655 102. JWH-348;
1775-
17762656 103. JWH-363;
1777-
17782657 104. JWH-364;
1779-
17802658 105. JWH-365;
1781-
17822659 106. JWH-367;
1783-
17842660 107. JWH-368;
1785-
17862661 108. JWH-369;
1787-
17882662 109. JWH-370;
1789-
1790-110. JWH-371; ENR. H. B. NO. 3567 Page 41
1791-
2663+110. JWH-371;
17922664 111. JWH-373;
1793-
17942665 112. JWH-386;
1795-
17962666 113. JWH-387;
1797-
17982667 114. JWH-392;
1799-
18002668 115. JWH-394;
1801-
18022669 116. JWH-395;
1803-
18042670 117. JWH-397;
1805-
18062671 118. JWH-398;
1807-
18082672 119. JWH-399;
1809-
18102673 120. JWH-400;
1811-
18122674 121. JWH-412;
18132675
2676+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 54 1
2677+2
2678+3
2679+4
2680+5
2681+6
2682+7
2683+8
2684+9
2685+10
2686+11
2687+12
2688+13
2689+14
2690+15
2691+16
2692+17
2693+18
2694+19
2695+20
2696+21
2697+22
2698+23
2699+24
2700+
18142701 122. JWH-413;
1815-
18162702 123. JWH-414;
1817-
18182703 124. JWH-415;
1819-
18202704 125. CP-55, 940;
1821-
18222705 126. CP-47, 497;
1823-
18242706 127. HU-210;
1825-
18262707 128. HU-211;
1827-
18282708 129. WIN-55, 212-2;
1829-
18302709 130. AM-2201;
1831-
18322710 131. AM-2233;
1833-
18342711 132. JWH-018 adamantyl-carboxamide;
1835- ENR. H. B. NO. 3567 Page 42
18362712 133. AKB48;
1837-
18382713 134. JWH-122 N-(4-pentenyl)analog;
1839-
18402714 135. MAM2201;
1841-
18422715 136. URB597;
1843-
18442716 137. URB602;
1845-
18462717 138. URB754;
1847-
18482718 139. UR144;
1849-
18502719 140. XLR11;
1851-
18522720 141. A-796,260;
1853-
18542721 142. STS-135;
1855-
18562722 143. AB-FUBINACA;
1857-
18582723 144. AB-PINACA;
1859-
18602724 145. PB-22;
18612725
2726+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 55 1
2727+2
2728+3
2729+4
2730+5
2731+6
2732+7
2733+8
2734+9
2735+10
2736+11
2737+12
2738+13
2739+14
2740+15
2741+16
2742+17
2743+18
2744+19
2745+20
2746+21
2747+22
2748+23
2749+24
2750+
18622751 146. AKB48 N-5-Fluorpentyl;
1863-
18642752 147. AM1248;
1865-
18662753 148. FUB-PB-22;
1867-
18682754 149. ADB-FUBINACA;
1869-
18702755 150. BB-22;
1871-
18722756 151. 5-Fluoro PB-22; or
1873-
18742757 152. 5-Fluoro AKB-48.
1875-
18762758 G. In addition to those substances listed in subsection F of
18772759 this section, unless specific ally excepted or unless listed in
18782760 another schedule, any material, compound, mixture, or preparation
18792761 which contains any quantity of a synthetic cannabinoid found to be
1880-in any of the following chemical groups: ENR. H. B. NO. 3567 Page 43
1881-
2762+in any of the following chemical groups:
18822763 1. Naphthoylindoles: any compound containing a 3-(1-
18832764 naphthoyl)indole structure with or without substitution at the
18842765 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
18852766 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
18862767 (N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-
18872768 2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
18882769 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
18892770 halophenyl group, whether or not further substituted on the indole
18902771 ring to any extent, and whether or not substituted on the naphthyl
18912772 ring to any extent. Naphthoylindoles include, but are not limited
18922773 to:
18932774
2775+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 56 1
2776+2
2777+3
2778+4
2779+5
2780+6
2781+7
2782+8
2783+9
2784+10
2785+11
2786+12
2787+13
2788+14
2789+15
2790+16
2791+17
2792+18
2793+19
2794+20
2795+21
2796+22
2797+23
2798+24
2799+
18942800 a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH -
18952801 200),
1896-
18972802 b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
1898-
18992803 c. 1-pentyl-3-(1-naphthoyl)indole (JWH -018),
1900-
19012804 d. 1-butyl-3-(1-naphthoyl)indole (JWH -073),
1902-
19032805 e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH -081),
1904-
19052806 f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH -015),
1906-
19072807 g. 1-hexyl-3-(1-naphthoyl)indole (JWH -019),
1908-
19092808 h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH -122),
1910-
19112809 i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH -210),
1912-
19132810 j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH -398),
1914-
19152811 k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH -007),
1916-
19172812 l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH -164),
1918-
19192813 m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
19202814 (JWH-098),
1921-
19222815 n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH -412),
1923-
19242816 o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
1925-naphthoyl)indole (AM-1220), ENR. H. B. NO. 3567 Page 44
1926-
2817+naphthoyl)indole (AM -1220),
19272818 p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
19282819 (MAM-2201), or
1929-
19302820 q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM -2232);
1931-
19322821 2. Naphthylmethylindoles: any compound containing a 1H -indol-3-
19332822 yl-(1-naphthyl)methane structure with or without substitution at the
19342823 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
2824+
2825+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 57 1
2826+2
2827+3
2828+4
2829+5
2830+6
2831+7
2832+8
2833+9
2834+10
2835+11
2836+12
2837+13
2838+14
2839+15
2840+16
2841+17
2842+18
2843+19
2844+20
2845+21
2846+22
2847+23
2848+24
2849+
19352850 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halo benzyl, 1-
19362851 (N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
19372852 2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
19382853 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
19392854 halophenyl group, whether or not further substituted on the i ndole
19402855 ring to any extent, and whether or not substituted on the naphthyl
19412856 ring to any extent. Naphthylmethylindoles include, but are not
19422857 limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH -175);
1943-
19442858 3. Naphthoylpyrroles: any compound containing a 3 -(1-
19452859 naphthoyl)pyrrole structure with or without substitution at the
19462860 nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
19472861 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
19482862 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
19492863 morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
19502864 morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
19512865 phenyl, or halophenyl group, whether or not further substituted on
19522866 the pyrrole ring to any extent, and whether or not substituted on
19532867 the naphthyl group to any extent. Naphthoylpyrroles include, but
19542868 are not limited to:
1955-
19562869 a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH -147),
1957-
19582870 b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
19592871 (JWH-370),
1960-
19612872 c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH -030), or
1962-
19632873 d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH -147);
2874+
2875+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 58 1
2876+2
2877+3
2878+4
2879+5
2880+6
2881+7
2882+8
2883+9
2884+10
2885+11
2886+12
2887+13
2888+14
2889+15
2890+16
2891+17
2892+18
2893+19
2894+20
2895+21
2896+22
2897+23
2898+24
19642899
19652900 4. Naphthylideneindenes: any compound containing a 1 -(1-
19662901 naphthylmethylene)indene structure with or without substitution at
19672902 the 3-position of the indene ring by an alkyl, haloalkyl,
19682903 cyanoalkyl, alkenyl, cycloalky lmethyl, cycloalkylethyl, benzyl,
19692904 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
1970-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3- ENR. H. B. NO. 3567 Page 45
2905+morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
19712906 morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
19722907 phenyl, or halophenyl group, whethe r or not further substituted on
19732908 the indene group to any extent, and whether or not substituted on
19742909 the naphthyl group to any extent. Naphthylmethylindenes include,
19752910 but are not limited to, (1 -[(3-pentyl)-1H-inden-1-
19762911 ylidene)methyl]naphthalene (JWH -176);
1977-
19782912 5. Phenylacetylindoles: any compound containing a 3 -
19792913 phenylacetylindole structure with or without substitution at the
19802914 nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
19812915 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
19822916 (N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
19832917 2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
19842918 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
19852919 halophenyl group, whether or not further substituted on the indole
19862920 ring to any extent, and whether or not substituted on the phenyl
19872921 ring to any extent. Phenylacetylindoles include, but are not
19882922 limited to:
1989-
19902923 a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250),
2924+
2925+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 59 1
2926+2
2927+3
2928+4
2929+5
2930+6
2931+7
2932+8
2933+9
2934+10
2935+11
2936+12
2937+13
2938+14
2939+15
2940+16
2941+17
2942+18
2943+19
2944+20
2945+21
2946+22
2947+23
2948+24
19912949
19922950 b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
19932951 (RCS-8),
1994-
19952952 c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH -203),
1996-
19972953 d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH -251),
1998-
19992954 e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH -201), or
2000-
20012955 f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
2002-
20032956 6. Cyclohexylphenols: any compound containin g a 2-(3-
20042957 hydroxycyclohexyl)phenol structure with or without substitution at
20052958 the 5-position of the phenolic ring by an alkyl, haloalkyl,
20062959 cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
20072960 halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
20082961 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
20092962 morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
20102963 phenyl, or halophenyl group, and whether or not further substituted
20112964 on the cyclohexyl ring to any extent. Cyclohexylphenols include,
20122965 but are not limited to:
2013-
20142966 a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
2015-hydroxycyclohexyl]-phenol (CP-47,497), ENR. H. B. NO. 3567 Page 46
2016-
2967+hydroxycyclohexyl]-phenol (CP-47,497),
20172968 b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
20182969 phenol (cannabicyclohexanol; CP -47,497 C8 homologue),
20192970 or
2020-
20212971 c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
20222972 hydroxypropyl)cyclohexyl] -phenol (CP 55, 940);
2973+
2974+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 60 1
2975+2
2976+3
2977+4
2978+5
2979+6
2980+7
2981+8
2982+9
2983+10
2984+11
2985+12
2986+13
2987+14
2988+15
2989+16
2990+17
2991+18
2992+19
2993+20
2994+21
2995+22
2996+23
2997+24
20232998
20242999 7. Benzoylindoles: any compound containing a 3 -(benzoyl)indole
20253000 structure with or without substitution at the nitrogen atom of the
20263001 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
20273002 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
20283003 2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
20293004 pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
20303005 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
20313006 halophenyl group, whether or not further substituted on the indole
20323007 ring to any extent, and whether or not substituted on the phenyl
20333008 group to any extent. Benzoylindoles include, but are not limited
20343009 to:
2035-
20363010 a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS -4),
2037-
20383011 b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
20393012 methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
2040-
20413013 c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM -694),
2042-
20433014 d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or
2044-
20453015 e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
20463016 iodobenzoyl)indole (AM -2233);
2047-
20483017 8. Cyclopropoylindoles: Any compound containing a 3 -
20493018 (cyclopropoyl)indole structure with substitution at the nitrogen
20503019 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
20513020 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
20523021 2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
20533022 pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
3023+
3024+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 61 1
3025+2
3026+3
3027+4
3028+5
3029+6
3030+7
3031+8
3032+9
3033+10
3034+11
3035+12
3036+13
3037+14
3038+15
3039+16
3040+17
3041+18
3042+19
3043+20
3044+21
3045+22
3046+23
3047+24
3048+
20543049 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
20553050 halophenyl group, whether or not further substituted in the indole
20563051 ring to any extent and whether or not substituted in the
20573052 cyclopropoyl ring to any extent. Cyclopropoylindoles include, but
20583053 are not limited to:
2059- ENR. H. B. NO. 3567 Page 47
20603054 a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
20613055 (UR-144),
2062-
20633056 b. 1-(5-chloropentyl)-3-(2,2,3,3-
20643057 tetramethylcyclopropoyl)indole (5Cl-UR-144), or
2065-
20663058 c. 1-(5-fluoropentyl)-3-(2,2,3,3-
20673059 tetramethylcyclopropoyl)indole (XLR11);
2068-
20693060 9. Indole Amides: Any compound containing a 1H -Indole-3-
20703061 carboxamide structure with or without substitution at the nitrogen
20713062 atom of the indole ring by an alkyl, hal oalkyl, cyanoalkyl, alkenyl,
20723063 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
20733064 2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
20743065 pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
20753066 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
20763067 halophenyl group, whether or not substituted at the carboxamide
20773068 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
20783069 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
20793070 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
20803071 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
20813072 further substituted in the indole, adamantyl, naphthyl, phenyl,
3073+
3074+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 62 1
3075+2
3076+3
3077+4
3078+5
3079+6
3080+7
3081+8
3082+9
3083+10
3084+11
3085+12
3086+13
3087+14
3088+15
3089+16
3090+17
3091+18
3092+19
3093+20
3094+21
3095+22
3096+23
3097+24
3098+
20823099 pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole
20833100 Amides include, but are not limited to:
2084-
20853101 a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
20863102 (2NE1),
2087-
20883103 b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
20893104 carboxamide (STS-135),
2090-
20913105 c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
20923106 indole-3-carboxamide (ADBICA),
2093-
20943107 d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
20953108 fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
2096-
20973109 e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
20983110 (NNE1),
2099-
21003111 f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
21013112 carboxamide (5F-NNE1),
2102-
21033113 g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
2104-or ENR. H. B. NO. 3567 Page 48
2105-
3114+or
21063115 h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
21073116 (5F-SDB-006);
2108-
21093117 10. Indole Esters: Any compound containing a 1H -Indole-3-
21103118 carboxylate structure with or without substitution at the nitrogen
21113119 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
21123120 cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
21133121 2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
21143122 pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
3123+
3124+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 63 1
3125+2
3126+3
3127+4
3128+5
3129+6
3130+7
3131+8
3132+9
3133+10
3134+11
3135+12
3136+13
3137+14
3138+15
3139+16
3140+17
3141+18
3142+19
3143+20
3144+21
3145+22
3146+23
3147+24
3148+
21153149 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
21163150 halophenyl group, whether or not substituted at the carboxylate
21173151 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
21183152 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
21193153 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
21203154 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
21213155 further substituted in the indole, adamantyl, naphthyl, phenyl,
21223156 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Indole
21233157 Esters include, but are not limited to:
2124-
21253158 a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
21263159 22),
2127-
21283160 b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
21293161 carboxylate (5F-PB-22),
2130-
21313162 c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
21323163 carboxylate (BB-22),
2133-
21343164 d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
21353165 carboxylate (FDU-PB-22), or
2136-
21373166 e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
21383167 carboxylate (NM2201);
2139-
21403168 11. Adamantanoylindoles: Any compound containing an
21413169 adamantanyl-(1H-indol-3-yl)methanone structure with or without
21423170 substitution at the nitrogen atom of the indole ring by an alkyl,
21433171 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
21443172 benzyl, halobenzyl, 1 -(N-methyl-2-piperidinyl)methyl, 2 -(4-
3173+
3174+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 64 1
3175+2
3176+3
3177+4
3178+5
3179+6
3180+7
3181+8
3182+9
3183+10
3184+11
3185+12
3186+13
3187+14
3188+15
3189+16
3190+17
3191+18
3192+19
3193+20
3194+21
3195+22
3196+23
3197+24
3198+
21453199 morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
21463200 morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
21473201 phenyl, or halophenyl group, whether or not further substituted in
2148-the indole ring to any extent and whether or not substituted in the ENR. H. B. NO. 3567 Page 49
3202+the indole ring to any extent and whether or not substituted in the
21493203 adamantyl ring to any extent. Adamantanoylindoles include, but are
21503204 not limited to:
2151-
21523205 a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
21533206 indol-3-yl]methanone (AM1248), or
2154-
21553207 b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
21563208 001);
2157-
21583209 12. Carbazole Ketone: Any compound containing (9H -carbazole-3-
21593210 yl) methanone structure with or without substitution at the nitrogen
21603211 atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl,
21613212 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
21623213 (N-methyl-2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-
21633214 2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
21643215 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
21653216 halophenyl group, with substitution at the carbon of the methanone
21663217 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
21673218 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
21683219 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
21693220 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
21703221 further substituted at the carbazole, adamantyl, naphthyl, phenyl,
21713222 pyrrole, quinolinyl, or cycloalkyl rings to any extent. Carbazole
3223+
3224+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 65 1
3225+2
3226+3
3227+4
3228+5
3229+6
3230+7
3231+8
3232+9
3233+10
3234+11
3235+12
3236+13
3237+14
3238+15
3239+16
3240+17
3241+18
3242+19
3243+20
3244+21
3245+22
3246+23
3247+24
3248+
21723249 Ketones include, but are not limited to, naphthalen -1-yl(9-pentyl-
21733250 9H-carbazol-3-yl)methanone (EG-018);
2174-
21753251 13. Benzimidazole Ketone: Any compound containing
21763252 (benzimidazole-2-yl) methanone structure with or without
21773253 substitution at either nitrogen atom of the benz imidazole ring by an
21783254 alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
21793255 cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
21803256 piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
21813257 pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
21823258 (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
21833259 halophenyl group, with substitution at the carbon of the methanone
21843260 group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
21853261 cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
21863262 1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
21873263 dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
21883264 further substituted in the benzimidazole, adamantyl, naphthyl,
21893265 phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent.
21903266 Benzimidazole Ketones include, but are not limited to:
2191-
21923267 a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
2193-l)methanone (JWH-018 benzimidazole analog), or ENR. H. B. NO. 3567 Page 50
2194-
3268+l)methanone (JWH-018 benzimidazole analog), or
21953269 b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
21963270 yl)(naphthalen-1-yl)methanone (FUBIMINA); and
3271+
3272+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 66 1
3273+2
3274+3
3275+4
3276+5
3277+6
3278+7
3279+8
3280+9
3281+10
3282+11
3283+12
3284+13
3285+14
3286+15
3287+16
3288+17
3289+18
3290+19
3291+20
3292+21
3293+22
3294+23
3295+24
21973296
21983297 14. Modified by Replacement : any compound defined in this
21993298 subsection that is modified by replacement of a carbon with nitrogen
22003299 in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
2201-
22023300 H. Any prescription drug approved by the federal Food and Drug
22033301 Administration under the provisions of Section 505 of the Federal
22043302 Food, Drug and Cosmetic Act, Title 21 of the United States Code,
22053303 Section 355, that is designated, rescheduled or deleted as a
22063304 controlled substance under federal law by the United States Drug
22073305 Enforcement Administrat ion shall be excluded from Schedule I and
22083306 shall be prescribed, distributed, dispensed or used in accordance
22093307 with federal law upon the issuance of a notice, final rule or
22103308 interim final rule by the United States Drug Enforcement
22113309 Administration designating, r escheduling or deleting as a controlled
22123310 substance such a drug product under federal law, unless and until
22133311 the State Board of Pharmacy takes action pursuant to Section 2 -201
22143312 of this title. If the Board of Pharmacy does not take action
22153313 pursuant to Section 2 -201 of this title, the drug product shall be
22163314 deemed to be designated, rescheduled or deleted as a controlled
22173315 substance in accordance with federal law and in compliance with the
22183316 Uniform Controlled Dangerous Substances Act.
2219-
22203317 SECTION 4. AMENDATORY 63 O.S. 2021, Section 2 -304, as
22213318 last amended by Section 3, Chapter 375, O.S.L. 2023 (63 O.S. Supp.
22223319 2023, Section 2-304), is amended to read as follows:
3320+
3321+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 67 1
3322+2
3323+3
3324+4
3325+5
3326+6
3327+7
3328+8
3329+9
3330+10
3331+11
3332+12
3333+13
3334+14
3335+15
3336+16
3337+17
3338+18
3339+19
3340+20
3341+21
3342+22
3343+23
3344+24
22233345
22243346 Section 2-304. A. A registration, pursuant to Section 2 -303 of
22253347 this title, to manufactu re, distribute, dispense, prescribe,
22263348 administer or use for scientific purposes a controlled dangerous
22273349 substance shall be limited, conditioned, denied, suspended,
22283350 annulled, or revoked by the Director of the Oklahoma State Bureau of
22293351 Narcotics and Dangerous D rugs Control upon a finding that the
22303352 registrant or applicant:
2231-
22323353 1. Has materially falsified any application filed pursuant to
22333354 the Uniform Controlled Dangerous Substances Act or required by the
22343355 Uniform Controlled Dangerous Substances Act. It shall be unlawf ul
22353356 to knowingly and willfully or intentionally:
2236-
22373357 a. make false statements, include false data or omit
2238-material information on an application for a ENR. H. B. NO. 3567 Page 51
3358+material information on an application for a
22393359 registration with the Oklahoma State Bureau of
22403360 Narcotics and Dangerous Drugs Control, or
2241-
22423361 b. provide false data or omit material information in any
22433362 records or reports required by rule or law to be
22443363 created, maintained or submitted to the Bureau .
2245-
22463364 Any registrant or applicant for a registration or any official,
22473365 agent or employee of any registrant or applicant for a reg istration
22483366 who violates the provisions of this paragraph shall be guilty of a
22493367 misdemeanor and additionally subject to administrative action ;
2250-
22513368 2. Has been found guilty of, entered a plea of guilty or
22523369 entered a plea of nolo contendere to a misdemeanor relatin g to any
3370+
3371+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 68 1
3372+2
3373+3
3374+4
3375+5
3376+6
3377+7
3378+8
3379+9
3380+10
3381+11
3382+12
3383+13
3384+14
3385+15
3386+16
3387+17
3388+18
3389+19
3390+20
3391+21
3392+22
3393+23
3394+24
3395+
22533396 substance defined herein as a controlled dangerous substance or any
22543397 felony under the laws of any state or the United States;
2255-
22563398 3. Has had his or her federal registration retired, suspended
22573399 or revoked by a competent federal authority and is no longe r
22583400 authorized by federal law to manufacture, distribute, dispense,
22593401 prescribe, administer or use for scientific purposes controlled
22603402 dangerous substances;
2261-
22623403 4. Has failed to maintain effective controls against the
22633404 diversion of controlled dangerous substances t o unauthorized persons
22643405 or entities;
2265-
22663406 5. Has prescribed, dispensed or administered a controlled
22673407 dangerous substance from schedules other than those specified in his
22683408 or her state or federal registration;
2269-
22703409 6. Has had a restriction, suspension, revocation, lim itation,
22713410 condition or probation placed on his or her professional license or
22723411 certificate or practice as a result of a proceeding pursuant to the
22733412 general statutes;
2274-
22753413 7. Is abusing or, within the past five (5) years, has abused or
22763414 excessively used drugs or co ntrolled dangerous substances;
2277-
22783415 8. Has prescribed, sold, administered or ordered any controlled
22793416 dangerous substance for an immediate family member, himself or
22803417 herself; provided that this shall not apply to a medical emergency
22813418 when no other doctor is availa ble to respond to the emergency;
2282- ENR. H. B. NO. 3567 Page 52
3419+
3420+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 69 1
3421+2
3422+3
3423+4
3424+5
3425+6
3426+7
3427+8
3428+9
3429+10
3430+11
3431+12
3432+13
3433+14
3434+15
3435+16
3436+17
3437+18
3438+19
3439+20
3440+21
3441+22
3442+23
3443+24
3444+
22833445 9. Has possessed, used, prescribed, dispensed or administered
22843446 drugs or controlled dangerous substances for other than legitimate
22853447 medical or scientific purposes or for purposes outside the normal
22863448 course of his or her profes sional practice;
2287-
22883449 10. Has been under the influence of alcohol or another
22893450 intoxicating substance which adversely affected the central nervous
22903451 system, vision, hearing or other sensory or motor functioning to
22913452 such degree the person was impaired during the per formance of his or
22923453 her job; or
2293-
22943454 11. Has violated any federal law relating to any controlled
22953455 dangerous substances, any provision of the Uniform Controlled
22963456 Dangerous Substances Act or any rules of the Oklahoma State Bureau
22973457 of Narcotics and Dangerous Drugs Co ntrol.
2298-
22993458 B. In the event the Director suspends or revokes a registration
23003459 granted under Section 2 -303 of this title, all controlled dangerous
23013460 substances owned or possessed by the registrant pursuant to such
3461+registration at the time of revocation or suspensio n or the
3462+effective date of the revocation order, as the case may be, may in
3463+the discretion of the Director be impounded and preserved. All
3464+controlled dangerous substances not impounded or preserved by the
3465+Director shall be maintained by the registrant. No Upon issuance of
3466+a revocation order, no disposition, purchase, distribution, sale, or
3467+transfer may be made of controlled dangerous substances until the
3468+time for taking an appeal has elapsed or until all appeals have been
3469+
3470+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 70 1
3471+2
3472+3
3473+4
3474+5
3475+6
3476+7
3477+8
3478+9
3479+10
3480+11
3481+12
3482+13
3483+14
3484+15
3485+16
3486+17
3487+18
3488+19
3489+20
3490+21
3491+22
3492+23
3493+24
3494+
3495+concluded unless a court, upon ap plication therefor, orders the sale
3496+of perishable substances and the deposit of the proceeds of the sale
3497+with the court to be distributed to the prevailing party . Upon a
3498+revocation order becoming final, all such controlled dangerous
3499+substances shall be fo rfeited to the state or otherwise considered
3500+waste and submitted to a licensed waste disposal service for
3501+destruction pursuant to Section 430 of this title in accordance with
3502+applicable law and by order of the Director .
3503+C. The Drug Enforcement Administrat ion shall promptly be
3504+notified of all orders suspending or revoking registration and all
3505+forfeitures of controlled dangerous substances.
3506+SECTION 5. AMENDATORY 63 O.S. 2021, Section 2 -305, as
3507+last amended by Section 4, Chapter 375, O.S.L. 2023 (63 O.S. Supp.
3508+2023, Section 2-305), is amended to read as follows:
3509+Section 2-305. A. In addition to any other remedies provided
3510+for by law, the Director shall issue a written order to be served on
3511+the parties before annulling, conditioning, suspending or revoking
3512+any registration that the Director has reason to believe is
3513+operating inconsistent with any provision of Section 2 -303 of this
3514+title, pursuant to Section 2 -304 of this title or otherwise where
3515+there has been a violation of any feder al law, any rule or
3516+regulation of the Drug Enforcement Administration, any provision of
3517+the Uniform Controlled Dangerous Substances Act, or any rules or
3518+
3519+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 71 1
3520+2
3521+3
3522+4
3523+5
3524+6
3525+7
3526+8
3527+9
3528+10
3529+11
3530+12
3531+13
3532+14
3533+15
3534+16
3535+17
3536+18
3537+19
3538+20
3539+21
3540+22
3541+23
3542+24
3543+
3544+regulations of the Oklahoma State Bureau of Narcotics and Dangerous
3545+Drugs Control.
3546+B. The written orde r shall state with specificity the nature of
3547+the violation or basis for the action. The Director may impose any
3548+disciplinary action authorized by the Uniform Controlled Dangerous
3549+Substances Act or rules of the Oklahoma State Bureau of Narcotics
3550+and Dangerous Drugs Control including, but not limited to, the
3551+assessment of monetary penalties.
3552+C. Any written order issued pursuant to the provisions of this
3553+section shall become a final order unless the registrant requests an
3554+administrative hearing in accordance with the rules and regulations
3555+promulgated by the Director within thirty (30) days of issuance.
3556+Upon such request, the Director shall promptly initiate
3557+administrative proceedings and serve formal notice of the
3558+proceedings pursuant to Section 309 of Title 75 of the Oklahoma
3559+Statutes. Nothing in this section shall be construed so as to
3560+require an individual proceeding for the denial of a new application
3561+for registration.
3562+D. The Director may authorize the Deputy Director or the
3563+General Counsel of the Oklah oma State Bureau of Narcotics and
3564+Dangerous Drugs Control to initiate any individual proceedings under
3565+this title. Nothing in this section shall be construed so as to
3566+delegate the authority of the Director to issue a final agency order
3567+of an individual proceeding adverse to a party. If a party fails to
3568+
3569+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 72 1
3570+2
3571+3
3572+4
3573+5
3574+6
3575+7
3576+8
3577+9
3578+10
3579+11
3580+12
3581+13
3582+14
3583+15
3584+16
3585+17
3586+18
3587+19
3588+20
3589+21
3590+22
3591+23
3592+24
3593+
3594+request an administrative hearing in a timely manner, the written
3595+order as issued shall be deemed adopted by the Director as the final
3596+agency order concerning the matter without further action by the
3597+Director.
3598+E. All proceedings shall be conducted in accordance with the
3599+Administrative Procedures Act and the rules and regulations of the
3600+Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
3601+without regard to any criminal prosecution or other proceedi ng.
3602+1. Proceedings to refuse renewal, revoke, or suspend a
3603+registration shall not abate the existing registration which shall
3604+remain in effect pending the outcome of those administrative
3605+proceedings; provided, the registrant submits timely and sufficient
3606+renewal applications annually . This abatement shall not apply when
3607+the Director finds there is an imminent danger to the public health
3608+or safety requiring an immediate suspension.
3609+2. The Director may delegate to an administrative hearing
3610+officer the authority to conduct hearings and recommend action for
3611+final agency orders in accordance with the rules and regulations of
3612+the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control.
3613+F. The Director may issue an order immediately suspending a
3614+registration, without notice or a hearing, when he or she finds
3615+there is imminent danger to the public health or safety which
3616+warrants this action. The suspension shall continue in effect until
3617+the conclusion of any administrative proceedings, including judicial
3618+
3619+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 73 1
3620+2
3621+3
3622+4
3623+5
3624+6
3625+7
3626+8
3627+9
3628+10
3629+11
3630+12
3631+13
3632+14
3633+15
3634+16
3635+17
3636+18
3637+19
3638+20
3639+21
3640+22
3641+23
3642+24
3643+
3644+review thereof, unless sooner withdrawn by the Director or dissolved
3645+by a court of competent jurisdiction. The order shall state the
3646+existence of an emergency requiring action be taken that the
3647+Director deems necessary to meet the emergency. Such action may
3648+include, but is not limited to, ordering the registrant to
3649+immediately cease and desist operations. The order shall be
3650+effective immediately upon issuance. Any person to whom the order
3651+is directed shall comply immediately with the provisions of the
3652+order. The Director may assess a penalty not to exceed Ten Thousand
3653+Dollars ($10,000.00) per day of noncompliance with the order. In
3654+assessing such a penalty, the Director shall consider the
3655+seriousness of the violation and any efforts to comply with
3656+applicable requirements. Upon application to the Director, the
3657+registrant shall be offered a hearing within thirty (30) days of the
3658+issuance of the order.
3659+G. In lieu of or in addition to any other remedies available to
3660+the Director, if a finding is made that a registrant has committed
3661+any act in violation of federal law relating to any controlled
3662+substance, any provision of the Uniform Controlled Dangerous
3663+Substances Act or any rules of the Oklahoma State Bureau of
3664+Narcotics and Dangerous Drugs Control, the D irector is hereby
3665+authorized to assess an administrative penalty not to exceed Five
3666+Thousand Dollars ($5,000.00) per day for each such act. The
3667+provisions of this subsection shall not apply to violations of
3668+
3669+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 74 1
3670+2
3671+3
3672+4
3673+5
3674+6
3675+7
3676+8
3677+9
3678+10
3679+11
3680+12
3681+13
3682+14
3683+15
3684+16
3685+17
3686+18
3687+19
3688+20
3689+21
3690+22
3691+23
3692+24
3693+
3694+subsection G of Section 2 -309D of this title. N othing in this
3695+section shall be construed so as to permit the Director of the
3696+Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to
3697+assess administrative fines for violations of the provisions of
3698+subsection G of Section 2 -309D of this title.
3699+H. If a judge of competent jurisdiction finds probable cause
3700+that a registrant has possessed, transferred, sold, or offered for
3701+sale any controlled dangerous substance in violation of this act,
3702+all controlled dangerous substances in Schedule I of Section 2 -204
3703+of this title and all controlled dangerous substances in Schedules
3704+II, III, IV, and V that are not in properly labeled containers in
3705+accordance with this act then in the possession of the registrant
3706+shall be deemed contraband and shall be seized and su mmarily
3707+forfeited pursuant to Section 2 -505 of this title. Samples shall be
3708+retained of all controlled dangerous substances seized in accordance
3709+with Section 2-508 of this title as required. The Director is
3710+authorized to assess an eradication or destruct ion fine not to
3711+exceed Fifty Thousand Dollars ($50,000.00) against the registrant.
3712+H. I. Upon an annulment, revocation, or denial of a
3713+registration the Director may prohibit the registrant or applicant
3714+from reapplying for registration for a period up to f ive (5) years
3715+following the date of the final order. The length of any
3716+prohibition shall not be used as grounds to contest the validity of
3717+the annulment, revocation, or denial of a registration.
3718+
3719+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 75 1
3720+2
3721+3
3722+4
3723+5
3724+6
3725+7
3726+8
3727+9
3728+10
3729+11
3730+12
3731+13
3732+14
3733+15
3734+16
3735+17
3736+18
3737+19
3738+20
3739+21
3740+22
3741+23
3742+24
3743+
3744+SECTION 6. AMENDATORY 63 O.S. 2021 , Section 2-309, as
3745+amended by Section 2, Chapter 304, O.S.L. 2023 (63 O.S. Supp. 2023,
3746+Section 2-309), is amended to read as follows:
3747+Section 2-309. A. 1. Except for dosages medically required
3748+for a period not to exceed forty -eight (48) hours which are
3749+administered by or on direction of a practitioner, other than a
3750+pharmacist, or medication dispensed directly by a practitioner,
3751+other than a pharmacist, to an ultimate user, no controlled
3752+dangerous substance included in Schedule II, which is a prescriptio n
3753+drug as determined under regulation promulgated by the Board of
3754+Pharmacy, shall be dispensed without an electronic prescription of a
3755+practitioner; provided, that in emergency situations, as prescribed
3756+by the Board of Pharmacy by regulation, such drug may be dispensed
3757+upon oral prescription reduced promptly to writing and filed by the
3758+pharmacist in a manner to be prescribed by rules and regulations of
3759+the Director of the Oklahoma State Bureau of Narcotics and Dangerous
3760+Drugs Control.
3761+2. Electronic prescri bing shall be utilized for Schedules II,
3762+III, IV and V, subject to the requirements set forth in 21 CFR,
3763+Section 1311 et seq.
3764+3. An electronic prescription with electronic signature may
3765+serve as an original prescription, subject to the requirements set
3766+forth in 21 CFR, Section 1311 et seq.
3767+
3768+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 76 1
3769+2
3770+3
3771+4
3772+5
3773+6
3774+7
3775+8
3776+9
3777+10
3778+11
3779+12
3780+13
3781+14
3782+15
3783+16
3784+17
3785+18
3786+19
3787+20
3788+21
3789+22
3790+23
3791+24
3792+
3793+4. Prescriptions shall be retained in conformity with the
3794+requirements of this section and Section 2 -307 of this title. No
3795+prescription for a Schedule II substance may be refilled.
3796+5. The electronic prescription requi rement provided for in this
3797+section shall not apply to prescriptions for controlled dangerous
3798+substances issued by any of the following:
3799+a. a person licensed to practice veterinary medicine,
3800+b. a practitioner who experiences temporary technological
3801+or electrical failure or other extenuating
3802+circumstance that prevents the prescription from being
3803+transmitted electronically; provided, however, that
3804+the practitioner documents the reason for this
3805+exception in the medical record of the patient,
3806+c. a practitioner, other than a pharmacist, who dispenses
3807+directly to an ultimate user,
3808+d. a practitioner who orders a controlled dangerous
3809+substance to be administered through an on -site
3810+pharmacy in:
3811+(1) a hospital as defined in Section 1 -701 of this
3812+title,
3813+(2) a nursing facility as defined in Section 1 -1902
3814+of this title,
3815+(3) a hospice inpatient facility as defined in
3816+Section 1-860.2 of this title,
3817+
3818+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 77 1
3819+2
3820+3
3821+4
3822+5
3823+6
3824+7
3825+8
3826+9
3827+10
3828+11
3829+12
3830+13
3831+14
3832+15
3833+16
3834+17
3835+18
3836+19
3837+20
3838+21
3839+22
3840+23
3841+24
3842+
3843+(4) an outpatient dialysis facility,
3844+(5) a continuum of care facility as defined in
3845+Section 1-890.2 of this title, or
3846+(6) a penal institution listed in Section 509 of
3847+Title 57 of the Oklahoma Statutes,
3848+e. a practitioner who orders a controlled dangerous
3849+substance to be administered through a hospice program
3850+including but not limited to a hospice program that
3851+provides hospice serv ices in the private residence of
3852+a patient or in a long -term care facility where the
3853+patient resides. As used in this subparagraph,
3854+“hospice program” has the same meaning as provided by
3855+Section 1-860.2 of this title,
3856+f. a practitioner who writes a prescri ption to be
3857+dispensed by a pharmacy located on federal property,
3858+provided the practitioner documents the reason for
3859+this exception in the medical record of the patient,
3860+or
3861+g. a practitioner that has received a waiver or extension
3862+from his or her licensing board,
3863+h. a practitioner who prescribes a controlled dangerous
3864+substance for a supply that when taken as prescribed
3865+would be consumed within seventy -two (72) hours, or
3866+
3867+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 78 1
3868+2
3869+3
3870+4
3871+5
3872+6
3873+7
3874+8
3875+9
3876+10
3877+11
3878+12
3879+13
3880+14
3881+15
3882+16
3883+17
3884+18
3885+19
3886+20
3887+21
3888+22
3889+23
3890+24
3891+
3892+i. a practitioner who determines that an electronic
3893+prescription cannot be issued in a t imely manner and
3894+the condition of the patient is at risk .
3895+6. Electronic prescriptions shall not may be utilized under the
3896+following circumstances:
3897+a. compound compounded prescriptions containing two or
3898+more commercially available products or two or more
3899+active pharmaceutical ingredients ,
3900+b. compounded infusion prescriptions containing two or
3901+more commercially available products or two or more
3902+active pharmaceutical ingredients , or
3903+c. prescriptions issued under approved research
3904+protocols, or
3905+d. if the practitioner determines that an electronic
3906+prescription cannot be issued in a timely manner and
3907+the condition of the patient is at risk .
3908+7. A pharmacist who receives a written, oral or facsimile
3909+prescription shall not be required to verify that the prescriptio n
3910+falls under one of the exceptions provided for in paragraph 6 of
3911+this subsection. Pharmacists may continue to dispense medications
3912+from otherwise valid written, oral or facsimile prescriptions that
3913+are consistent with the provisions of this section.
3914+
3915+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 79 1
3916+2
3917+3
3918+4
3919+5
3920+6
3921+7
3922+8
3923+9
3924+10
3925+11
3926+12
3927+13
3928+14
3929+15
3930+16
3931+17
3932+18
3933+19
3934+20
3935+21
3936+22
3937+23
3938+24
3939+
3940+8. Practitioners shall indicate in the health record of a
3941+patient that an exception to the electronic prescription requirement
3942+was utilized.
3943+9. All prescriptions issued pursuant to paragraphs paragraph 5
3944+and subparagraph c of paragraph 6 of this subsection shall be issued
3945+on an official prescription form provided approved by the Oklahoma
3946+State Bureau of Narcotics and Dangerous Drugs Control if not issued
3947+electronically.
3948+10. a. Effective January 1, 2020, practitioners Practitioners
3949+shall register be registered with the Oklahoma State
3950+Bureau of Narcotics and Dangerous Drugs Control in
3951+order to be issued purchase official prescription
3952+forms. Such registration shall include, but not be
3953+limited to, the primary address and the address of
3954+each place of business to be imprinted on official
3955+prescription forms. Any change to a registered
3956+practitioner’s registered address shall be promptly
3957+reported to the practitioner’s licensing board and the
3958+Bureau by the practitioner in a manner approved by the
3959+Bureau.
3960+b. A practitioner’s registration shall be without fee and
3961+subject to approval by the Bureau. Such registration
3962+shall be valid for a period of two (2) years and may
3963+be denied, suspended or revoked by the Bureau upon a
3964+
3965+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 80 1
3966+2
3967+3
3968+4
3969+5
3970+6
3971+7
3972+8
3973+9
3974+10
3975+11
3976+12
3977+13
3978+14
3979+15
3980+16
3981+17
3982+18
3983+19
3984+20
3985+21
3986+22
3987+23
3988+24
3989+
3990+finding by the Bureau or licensing board that the
3991+registered practitioner has had any license to
3992+practice a medical profession revoked or suspended by
3993+any state or federal agency.
3994+c. Where the Bureau has revoked the registration of a
3995+registered practitioner, the Bureau may revoke or
3996+cancel any official pre scription forms in the
3997+possession of the registered practitioner. Any
3998+revocation or any suspension shall require the
3999+registered practitioner to return all unused official
4000+prescription forms to the Bureau within fifteen (15)
4001+calendar days after the date of the written
4002+notification.
4003+d.
4004+c. A practitioner that has had any license to practice
4005+terminated, revoked or suspended by a state or federal
4006+agency may, upon restoration of such license or
4007+certificate, register to be issued official
4008+prescription forms with the Bureau.
4009+11. a. Except as provided in subparagraph f of this
4010+paragraph, the Bureau shall issue official Official
4011+prescription forms free of charge only to registered
4012+practitioners in this state. Such forms shall not be
4013+transferable. The number of offi cial prescription
4014+
4015+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 81 1
4016+2
4017+3
4018+4
4019+5
4020+6
4021+7
4022+8
4023+9
4024+10
4025+11
4026+12
4027+13
4028+14
4029+15
4030+16
4031+17
4032+18
4033+19
4034+20
4035+21
4036+22
4037+23
4038+24
4039+
4040+forms issued to a registered shall be purchased at the
4041+expense of the practitioner at any time shall be at
4042+the discretion of or the employer of the practitioner
4043+from a list of vendors approved by the Bureau.
4044+b. Official prescription forms issued to a registered
4045+practitioner shall be imprinted only with the primary
4046+address and may include other addresses listed on the
4047+registration of the practitioner to identify the place
4048+of origin. Such prescriptions shall be sent only to
4049+the primary address of the registered practitioner.
4050+c. Official prescription forms issued to of a registered
4051+practitioner shall be used only by the practitioner to
4052+whom they are issued designated on the official
4053+prescription form.
4054+d. The Bureau may revoke or cancel offici al prescription
4055+forms in possession of registered practitioners when
4056+the license of such practitioner is suspended,
4057+terminated or revoked.
4058+e. Official prescription forms of registered
4059+practitioners who are deceased or who no longer
4060+prescribe shall be retur ned to the Bureau at a
4061+designated address. If the registered practitioner is
4062+deceased, it is the responsibility of the registered
4063+
4064+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 82 1
4065+2
4066+3
4067+4
4068+5
4069+6
4070+7
4071+8
4072+9
4073+10
4074+11
4075+12
4076+13
4077+14
4078+15
4079+16
4080+17
4081+18
4082+19
4083+20
4084+21
4085+22
4086+23
4087+24
4088+
4089+practitioner’s estate or lawful designee to return
4090+such forms.
4091+f. The Bureau may issue official prescription forms to
4092+employees or agents of the Bureau and other government
4093+agencies for the purpose of preventing, identifying,
4094+investigating and prosecuting unacceptable or illegal
4095+practices by providers and other persons and assisting
4096+in the recovery of overpayments under any prog ram
4097+operated by the state or paid for with state funds.
4098+Such prescription forms shall be issued for this
4099+purpose only to individuals who are authorized to
4100+conduct investigations on behalf of the Bureau or
4101+other government agencies as part of their officia l
4102+duties. Individuals and agencies receiving such
4103+prescription forms for this purpose shall provide
4104+appropriate assurances to the Bureau that adequate
4105+safeguards and security measures are in place to
4106+prevent the use of such prescription forms for
4107+anything other than official government purposes.
4108+12. a. Adequate safeguards and security measures shall be
4109+undertaken by registered practitioners holding
4110+official prescription forms to assure against the
4111+loss, destruction, theft or unauthorized use of the
4112+forms. Registered practitioners shall maintain a
4113+
4114+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 83 1
4115+2
4116+3
4117+4
4118+5
4119+6
4120+7
4121+8
4122+9
4123+10
4124+11
4125+12
4126+13
4127+14
4128+15
4129+16
4130+17
4131+18
4132+19
4133+20
4134+21
4135+22
4136+23
4137+24
4138+
4139+sufficient but not excessive supply of such forms in
4140+reserve.
4141+b. Registered practitioners shall immediately notify the
4142+Bureau, in a manner designated by the Bureau, upon
4143+their knowledge of the loss, destruction, t heft or
4144+unauthorized use of any official prescription forms
4145+issued to them, as well as the failure to receive
4146+official prescription forms within a reasonable time
4147+after ordering them from the Bureau.
4148+c. Registered practitioners shall immediately notify the
4149+Bureau upon their knowledge of any diversion or
4150+suspected diversion of drugs pursuant to the loss,
4151+theft or unauthorized use of prescriptions.
4152+B. 1. Except for dosages medically required for a period not
4153+to exceed seventy-two (72) hours which are admini stered by or on
4154+direction of a practitioner , other than a pharmacist , or medication
4155+dispensed directly by a practitioner , other than a pharmacist, to an
4156+ultimate user, or the circumstances provided for in paragraphs 5 and
4157+6 of subsection A of this section , no controlled dangerous substance
4158+included in Schedule III or IV, which is a prescription drug as
4159+determined under regulation promulgated by the Board of Pharmacy,
4160+shall be dispensed without an electronic prescription.
4161+2. Any prescription for a controlle d dangerous substance in
4162+Schedule III, IV or V may not be filled or refilled more than six
4163+
4164+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 84 1
4165+2
4166+3
4167+4
4168+5
4169+6
4170+7
4171+8
4172+9
4173+10
4174+11
4175+12
4176+13
4177+14
4178+15
4179+16
4180+17
4181+18
4182+19
4183+20
4184+21
4185+22
4186+23
4187+24
4188+
4189+(6) months after the date thereof or be refilled more than five
4190+times after the date of the prescription, unless renewed by the
4191+practitioner.
4192+C. Whenever it appears to the Director of the Oklahoma State
4193+Bureau of Narcotics and Dangerous Drugs Control that a drug not
4194+considered to be a prescription drug under existing state law or
4195+regulation of the Board of Pharmacy should be so considered because
4196+of its abuse potenti al, the Director shall so advise the Board of
4197+Pharmacy and furnish to the Board all available data relevant
4198+thereto.
4199+D. 1. “Prescription”, as used in this section, means a
4200+written, oral or electronic order by a practitioner to a pharmacist
4201+for a controlled dangerous substance for a particular patient, which
4202+specifies the date of its issue, and the full name and address of
4203+the patient and, if the controlled dangerous substance is prescribed
4204+for an animal, the species of the animal, the name and quantity of
4205+the controlled dangerous substance prescribed, the directions for
4206+use, the name and address of the owner of the animal and, if
4207+written, the signature of the practitioner. When electronically
4208+prescribed, the full name of the patient may include the name a nd
4209+species of the animal.
4210+2. “Registered practitioner”, as used in this section, means a
4211+licensed practitioner duly registered with the Oklahoma State Bureau
4212+
4213+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 85 1
4214+2
4215+3
4216+4
4217+5
4218+6
4219+7
4220+8
4221+9
4222+10
4223+11
4224+12
4225+13
4226+14
4227+15
4228+16
4229+17
4230+18
4231+19
4232+20
4233+21
4234+22
4235+23
4236+24
4237+
4238+of Narcotics and Dangerous Drugs Control authorized to be issued
4239+purchase official prescription f orms.
4240+E. No person shall solicit, dispense, receive or deliver any
4241+controlled dangerous substance through the mail, unless the ultimate
4242+user is personally known to the practitioner and circumstances
4243+clearly indicate such method of delivery is in the best interest of
4244+the health and welfare of the ultimate user.
4245+SECTION 7. AMENDATORY 63 O.S. 2021, Section 2 -406, as
4246+amended by Section 2, Chapter 235, O.S.L. 2023 (63 O.S. Supp. 2023,
4247+Section 2-406), is amended to read as follows:
4248+Section 2-406. A. It shall be unlawful for any registrant or
4249+person applying for registration to knowingly or intentionally:
4250+1. To distribute Distribute, other than by dispensing or as
4251+otherwise authorized by the Uniform Controlled Dangerous Substances
4252+Act, a controlled dangerous substance classified in Schedules I or
4253+II, in the course of his or her legitimate business, except pursuant
4254+to an order form as required by Section 2 -308 of this title;
4255+2. To use Use in the course of the manufacture or distribution
4256+of a controlled dangerous substance a registration number which is
4257+fictitious, revoked, suspended or issued to another person;
4258+3. To acquire Acquire or obtain possession of a controlled
4259+dangerous substance by misrepresentation, fraud, forgery, deception
4260+or subterfuge;
4261+
4262+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 86 1
4263+2
4264+3
4265+4
4266+5
4267+6
4268+7
4269+8
4270+9
4271+10
4272+11
4273+12
4274+13
4275+14
4276+15
4277+16
4278+17
4279+18
4280+19
4281+20
4282+21
4283+22
4284+23
4285+24
4286+
4287+4. To furnish Furnish false or fraudulent material information
4288+in, or omit any material information from, any application, report,
4289+or other document required to be kept or filed under the Uniform
4290+Controlled Dangerous Substances Act, or any record required to be
4291+kept by the Uniform Controlled Dangerous Substances Act;
4292+5. To make Make, distribute, or possess any punch, die, plate,
4293+stone, or other thing designed to print, imprint, or reproduce the
4294+trademark, trade name, or other identifying ma rk, imprint, or device
4295+of another or any likeness of any of the foregoing upon any drug or
4296+container or labeling thereof so as to render such drug a
4297+counterfeit controlled dangerous substance; and
4298+6. To purchase Purchase, or attempt, endeavor, or conspire to
4299+obtain or purchase, any license or registration required to
4300+distribute, possess, prescribe, or manufacture any controlled
4301+dangerous substance on behalf of, or at the request or demand of,
4302+any other person through the use of a straw person or straw part y.
4303+B. Any person who violates this section is guilty of a felony
4304+punishable by imprisonment for not more than twenty (20) years or a
4305+fine not more than Two Hundred Fifty Thousand Dollars ($250,000.00),
4306+or both.
4307+C. Any person convicted of a second or subs equent violation of
4308+this section is punishable by a term of imprisonment twice that
4309+otherwise authorized and by twice the fine otherwise authorized.
4310+Convictions for second or subsequent violations of this section
4311+
4312+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 87 1
4313+2
4314+3
4315+4
4316+5
4317+6
4318+7
4319+8
4320+9
4321+10
4322+11
4323+12
4324+13
4325+14
4326+15
4327+16
4328+17
4329+18
4330+19
4331+20
4332+21
4333+22
4334+23
4335+24
4336+
4337+shall not be subject to statutory provisio ns for suspended
4338+sentences, deferred sentences, or probation.
4339+D. Any person convicted of any offense described in this
4340+section shall, in addition to any fine imposed, pay a special
4341+assessment trauma-care fee of One Hundred Dollars ($100.00) to be
4342+deposited into the Trauma Care Assistance Revolving Fund created in
4343+Section 1-2530.9 of this title.
4344+SECTION 8. REPEALER 63 O.S. 2021, Sections 2 -101, as
4345+amended by Section 10, Chapter 91, O.S.L. 2019, as last amended by
4346+Section 1, Chapter 235, O.S.L. 2023, and as last amended by Section
4347+1, Chapter 304, O.S.L. 2023, 2 -304, as amended by Section 1, Chapter
4348+176, O.S.L. 2023, 2-305, as amended by Section 2, Chapter 176,
4349+O.S.L. 2023, 2-309, as amended by Section 1, Chapter 333, O.S.L.
4350+2021, 2-402, as amended by Section 1, Chapter 220, O.S.L 2016 , and
4351+2-406, as last amended by Section 7, Chapter 375, O.S.L. 2023 (63
4352+O.S. Supp. 2023, Sections 2 -101, 2-304, 2-305, 2-309, 2-402, and 2-
4353+406), are hereby repealed.
4354+SECTION 9. It being immediately necessary for the preservation
4355+of the public peace, health or safety, an emergency is hereby
4356+declared to exist, by reason whereof this act shall take effect and
4357+be in full force from and after its passage and approval. ”
4358+
4359+
4360+ENGR. S. A. TO ENGR. H. B. NO. 3567 Page 88 1
4361+2
4362+3
4363+4
4364+5
4365+6
4366+7
4367+8
4368+9
4369+10
4370+11
4371+12
4372+13
4373+14
4374+15
4375+16
4376+17
4377+18
4378+19
4379+20
4380+21
4381+22
4382+23
4383+24
4384+
4385+Passed the Senate the 24t h day of April, 2024.
4386+
4387+
4388+
4389+ Presiding Officer of the Senate
4390+
4391+
4392+Passed the House of Representatives the ____ day of __________,
4393+2024.
4394+
4395+
4396+
4397+ Presiding Officer of the House
4398+ of Representatives
4399+
4400+ENGR. H. B. NO. 3567 Page 1 1
4401+2
4402+3
4403+4
4404+5
4405+6
4406+7
4407+8
4408+9
4409+10
4410+11
4411+12
4412+13
4413+14
4414+15
4415+16
4416+17
4417+18
4418+19
4419+20
4420+21
4421+22
4422+23
4423+24
4424+
4425+ENGROSSED HOUSE
4426+BILL NO. 3567 By: Manger of the House
4427+
4428+ and
4429+
4430+ Paxton of the Senate
4431+
4432+
4433+
4434+
4435+
4436+
4437+An Act relating to controlled dangerous drugs;
4438+amending 63 O.S. 2021, Sections 2-101, as last
4439+amended by Section 1, Chapter 375, O.S.L. 2023 , 2-
4440+106.2, 2-304, as amended by Section 3, Chapter 375,
4441+O.S.L. 2023, 2-305, as amended by Section 4, Chapter
4442+375, O.S.L. 2023, 2-309, as amended by Section 2,
4443+Chapter 304, O.S.L. 2023 and 2-406, as amended by
4444+Section 2, Chapter 235, O.S.L. 2023 (63 O.S. Supp.
4445+2023, Sections 2-101, 2-304, 2-305, 2-309 and 2-406),
4446+which relate to the Uniform Controlled Dangerous
4447+Substances Act; adding and alphabetizing definitions;
4448+deleting reference to promulgated rules ; clarifying
4449+circumstances that provide fo r the revocation or
4450+suspension of registrations; deleting certain penalty
4451+provision; updating manner by wh ich controlled
4452+dangerous substances are forf eited; deeming written
4453+order as final under certain circumstances; allowing
4454+registrations to remain in effect under certain
4455+circumstances; authorizing the utilization of
4456+electronic prescriptions under certain circumstances;
4457+requiring practitioners to purchase official
4458+prescription forms; providing r estrictions on use of
4459+official prescription forms; modifying scope of
4460+certain prohibited act; repealing
4461+63 O.S. 2021, Sections 2-101, as last amended by
4462+Section 10, Chapter 91, O.S.L. 2019, Section 1,
4463+Chapter 235, O.S.L. 2023, Section 1, Chapter 304,
4464+O.S.L. 2023, 2-304, as last amended by Section 1 ,
4465+Chapter 176, O.S.L. 2023, 2-305, as amended by
4466+Section 2, Chapter 176, O.S.L. 2023, 2-309 as last
4467+amended by Section 1, Chapter 333, O.S.L. 2021, 2-
4468+402, as last amended by Section 1, Chapter 220,
4469+O.S.L. 2016 and 2-406, as last amended by Section 7,
4470+Chapter 375, O.S.L. 2023 (63 O.S. Supp. 2023,
4471+Sections 2-101, 2-304, 2-305, 2-309, 2-402 and 2-
4472+
4473+ENGR. H. B. NO. 3567 Page 2 1
4474+2
4475+3
4476+4
4477+5
4478+6
4479+7
4480+8
4481+9
4482+10
4483+11
4484+12
4485+13
4486+14
4487+15
4488+16
4489+17
4490+18
4491+19
4492+20
4493+21
4494+22
4495+23
4496+24
4497+
4498+406), which relate to the Uniform Controlled
4499+Dangerous Substance Act; and declaring an emergency.
4500+
4501+
4502+
4503+
4504+
4505+
4506+
4507+
4508+BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
4509+SECTION 10. AMENDATORY 63 O.S. 2021, Section 2-101, as
4510+last amended by Sect ion 1, Chapter 375, O.S.L. 2023 (63 O.S. Supp.
4511+2023, Section 2-101), is amended to read as follows:
4512+Section 2-101. As used in the Uniform Controlled Dangerous
4513+Substances Act:
4514+1. "Acute pain" means pain, whether resulting from disease,
4515+accidental trauma or intentional trauma or other cause that the
4516+practitioner reasonably expects to last only a short period of time.
4517+Acute pain does not include chronic pain, pain being treated as part
4518+of cancer care, hospice or other end-of-life care, or pain being
4519+treated as part of palliative care;
4520+2. "Administer" means the direct application of a controlled
4521+dangerous substance, whether by injection, inhalation, ingestion or
4522+any other means, to the body of a patient, animal or research
4523+subject by:
4524+a. a practitioner (or, in the presence of the
4525+practitioner, by the authorized agent of the
4526+practitioner), or
4527+
4528+ENGR. H. B. NO. 3567 Page 3 1
4529+2
4530+3
4531+4
4532+5
4533+6
4534+7
4535+8
4536+9
4537+10
4538+11
4539+12
4540+13
4541+14
4542+15
4543+16
4544+17
4545+18
4546+19
4547+20
4548+21
4549+22
4550+23
4551+24
4552+
4553+b. the patient or research subject at the direction and
4554+in the presence of the practitioner;
4555+2. 3. "Agent" means a peace officer appointed by and who acts
4556+on behalf of the Director of the Oklahoma State Bureau of Narcotics
4557+and Dangerous Drugs Control or an authorized person who acts on
4558+behalf of or at the direction of a person who manufactures,
4559+distributes, dispenses, prescribes, administers or uses for
4560+scientific purposes controlled dangerous substances but does not
4561+include a common or contract carrier, public warehouser or employee
4562+thereof, or a person required to register under the Uniform
4563+Controlled Dangerous Substances Act;
4564+4. "Anhydrous ammonia" means any substance that exhibits
4565+cryogenic evaporative behavior and tests positive for ammonia;
4566+3. 5. "Board" means the Advisory Board to the Director of the
4567+Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
4568+4. 6. "Bureau" means the Oklahoma State Bureau of Narcotics and
4569+Dangerous Drugs Control;
4570+7. "Chronic pain" means pain that persists beyond the usual
4571+course of an acute disease or healing of an injury. Chronic pain
4572+may or may not be associated with an acute or chronic pathologic
4573+process that causes continuous or intermittent pain over months or
4574+years;
4575+5. 8. "Coca leaves" includes cocaine and any compound,
4576+manufacture, salt, derivative, mixture or preparation of coca
4577+
4578+ENGR. H. B. NO. 3567 Page 4 1
4579+2
4580+3
4581+4
4582+5
4583+6
4584+7
4585+8
4586+9
4587+10
4588+11
4589+12
4590+13
4591+14
4592+15
4593+16
4594+17
4595+18
4596+19
4597+20
4598+21
4599+22
4600+23
4601+24
4602+
4603+leaves, except derivatives of coca leaves which do not contain
4604+cocaine or ecgonine;
4605+6. 9. "Commissioner" or "Director" means the Director of the
4606+Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
4607+7. 10. "Control" means to add, remove or change the placement
4608+of a drug, substance or immediate precursor under the Uniform
4609+Controlled Dangerous Substances Act;
4610+8. 11. "Controlled dangerous substance" means a drug, substance
4611+or immediate precursor in Schedules I through V of the Uniform
4612+Controlled Dangerous Substances Act or any drug, substance or
4613+immediate precursor listed either temporarily or permanently as a
4614+federally controlled substance. Any conflict between state and
4615+federal law with regard to the particular schedule in which a
4616+substance is listed shall be resolved in favor of state law;
4617+9. 12. "Counterfeit substance" means a controlled substance
4618+which, or the container or labeling of which without authorization,
4619+bears the trademark, trade name or other identifying marks, imprint,
4620+number or device or any likeness thereof of a manufacturer,
4621+distributor or dispenser other than the person who in fact
4622+manufactured, distributed or dispensed the substance;
4623+10. 13. "Deliver" or "delivery" means the actual, constructive
4624+or attempted transfer from one person to another of a controlled
4625+dangerous substance or drug paraphernalia, whether or not there is
4626+an agency relationship;
4627+
4628+ENGR. H. B. NO. 3567 Page 5 1
4629+2
4630+3
4631+4
4632+5
4633+6
4634+7
4635+8
4636+9
4637+10
4638+11
4639+12
4640+13
4641+14
4642+15
4643+16
4644+17
4645+18
4646+19
4647+20
4648+21
4649+22
4650+23
4651+24
4652+
4653+11. 14. "Dispense" means to deliver a controlled dangerous
4654+substance to an ultimate user or human research subject by or
4655+pursuant to the lawful order of a practitioner, including the
4656+prescribing, administering, packaging, labeling or compounding
4657+necessary to prepare the substance for such distribution.
4658+"Dispenser" is a practitioner who delivers a controlled dangerous
4659+substance to an ultimate user or human research subject;
4660+12. 15. "Distribute" means to deliver other than by
4661+administering or dispensing a controlled dangerous substance;
4662+13. 16. "Distributor" means a commercial entity engaged in the
4663+distribution or reverse distribution of narcotics and dangerous
4664+drugs and who complies with all regulations promulgated by the
4665+federal Drug Enforcement Administration and the Oklahoma State
4666+Bureau of Narcotics and Dangerous Drugs Control;
4667+14. 17. "Drug" means articles:
4668+a. recognized in the official United States Pharmacopeia,
4669+official Homeopathic Pharmacopoeia of the United
4670+States, or official National Formulary, or any
4671+supplement to any of them,
4672+b. intended for use in the diagnosis, cure, mitigation,
4673+treatment or prevention of disease in man or other
4674+animals,
4675+c. other than food, intended to affect the structure or
4676+any function of the body of man or other animals, and
4677+
4678+ENGR. H. B. NO. 3567 Page 6 1
4679+2
4680+3
4681+4
4682+5
4683+6
4684+7
4685+8
4686+9
4687+10
4688+11
4689+12
4690+13
4691+14
4692+15
4693+16
4694+17
4695+18
4696+19
4697+20
4698+21
4699+22
4700+23
4701+24
4702+
4703+d. intended for use as a component of any article
4704+specified in this paragraph;
4705+provided, however, the term drug does not include devices or their
4706+components, parts or accessories;
4707+18. "Drug paraphernalia" means all equipment, products, and
4708+materials of any kind which are used, intended for use, or fashioned
4709+specifically for use in planting, propagating, cultivating, growing,
4710+harvesting, manufacturing, comp ounding, converting, producing,
4711+processing, preparing, testing, analyzing, packaging, repackaging,
4712+storing, containing, concealing, injecting, ingesting, inhaling, or
4713+otherwise introducing into the human body, a controlled dangerous
4714+substance in violation o f the Uniform Controlled Dangerous
4715+Substances Act including, but not limited to:
4716+a. kits used, intended for use, or fashioned specifically
4717+for use in planting, propagating, cultivating, growing
4718+or harvesting of any species of plant which is a
4719+controlled dangerous substance or from which a
4720+controlled dangerous substance can be derived,
4721+b. kits used, intended for use, or fashioned specifically
4722+for use in manufacturing, compounding, converting,
4723+producing, processing, or preparing controlled
4724+dangerous substances ,
4725+c. isomerization devices used, intended for use, or
4726+fashioned specifically for use in increasing the
4727+
4728+ENGR. H. B. NO. 3567 Page 7 1
4729+2
4730+3
4731+4
4732+5
4733+6
4734+7
4735+8
4736+9
4737+10
4738+11
4739+12
4740+13
4741+14
4742+15
4743+16
4744+17
4745+18
4746+19
4747+20
4748+21
4749+22
4750+23
4751+24
4752+
4753+potency of any species of plant which is a controlled
4754+dangerous substance,
4755+d. testing equipment used, intended for use, or fashioned
4756+specifically for use in identifying, or in analyzing
4757+the strength, effectiveness, or purity of controlled
4758+dangerous substances,
4759+e. scales and balances used, intended for use, or
4760+fashioned specifically for use in weighing or
4761+measuring controlled dangerous substances,
4762+f. diluents and adulterants, such as quinine
4763+hydrochloride, mannitol, mannite, dextrose and
4764+lactose, used, intended for use, or fashioned
4765+specifically for use in cutting controlled dangerous
4766+substances,
4767+g. separation gins and sifters used, intended for use, or
4768+fashioned specifically for use in removing twigs and
4769+seeds from, or in otherwise cleaning or refining,
4770+marijuana,
4771+h. blenders, bowls, containers, spoons, and mixing
4772+devices used, intended for use, or fashioned
4773+specifically for use in compounding controlled
4774+dangerous substances,
4775+i. capsules, balloons, envelopes, and other containers
4776+used, intended for use, or fashioned specifically for
4777+
4778+ENGR. H. B. NO. 3567 Page 8 1
4779+2
4780+3
4781+4
4782+5
4783+6
4784+7
4785+8
4786+9
4787+10
4788+11
4789+12
4790+13
4791+14
4792+15
4793+16
4794+17
4795+18
4796+19
4797+20
4798+21
4799+22
4800+23
4801+24
4802+
4803+use in packaging small quantities of controlled
4804+dangerous substances,
4805+j. containers and other objects used, intended for use,
4806+or fashioned specifically for use in parenterally
4807+injecting controlled dangerous substances into the
4808+human body,
4809+k. hypodermic syringes, needles, and other objects used,
4810+intended for use, or fashioned specifically for use in
4811+parenterally injecting controlled dan gerous substances
4812+into the human body, except as authorized by Section
4813+2-1101 of this title,
4814+l. objects used, intended for use, or fashioned
4815+specifically for use in ingesting, inhaling, or
4816+otherwise introducing marijuana, cocaine, hashish, or
4817+hashish oil into the human body, such as:
4818+(1) metal, wooden, acrylic, glass, stone, plastic, or
4819+ceramic pipes with or without screens, permanent
4820+screens, hashish heads, or punctured metal bowls,
4821+(2) water pipes,
4822+(3) carburetion tubes and devices,
4823+(4) smoking and carburetion masks,
4824+(5) roach clips, meaning objects used to hold burning
4825+material, such as a marijuana cigarette, that has
4826+
4827+ENGR. H. B. NO. 3567 Page 9 1
4828+2
4829+3
4830+4
4831+5
4832+6
4833+7
4834+8
4835+9
4836+10
4837+11
4838+12
4839+13
4840+14
4841+15
4842+16
4843+17
4844+18
4845+19
4846+20
4847+21
4848+22
4849+23
4850+24
4851+
4852+become too small or too short to be held in the
4853+hand,
4854+(6) miniature cocaine spoons and cocaine vials,
4855+(7) chamber pipes,
4856+(8) carburetor pipes,
4857+(9) electric pipes,
4858+(10) air-driven pipes,
4859+(11) chillums,
4860+(12) bongs, or
4861+(13) ice pipes or chillers,
4862+m. all hidden or novelty pipes, and
4863+n. any pipe that has a tobacco bowl or chamber of less
4864+than one-half (1/2) inch in diameter in which there is
4865+any detectable residue of any controlled dangerous
4866+substance as defined in this section or any other
4867+substances not legal for possession or use;
4868+provided, however, the term drug paraphernalia shall not include
4869+separation gins intended for use in preparing tea or spice, clamps
4870+used for constructing electrical equipment, water pipes designed for
4871+ornamentation in which no detectable amount of an illegal substance
4872+is found or pipes designed and used solely for smoking tobacco,
4873+traditional pipes of an American Indian tribal religious ceremony,
4874+antique pipes that are thirty (30) years of age or older, or drug
4875+
4876+ENGR. H. B. NO. 3567 Page 10 1
4877+2
4878+3
4879+4
4880+5
4881+6
4882+7
4883+8
4884+9
4885+10
4886+11
4887+12
4888+13
4889+14
4890+15
4891+16
4892+17
4893+18
4894+19
4895+20
4896+21
4897+22
4898+23
4899+24
4900+
4901+testing strips possessed by a person for purposes of determining the
4902+presence of fentanyl or a fentanyl-related compound;
4903+15. 19. "Drug-dependent person" means a person who is using a
4904+controlled dangerous substance and who is in a state of psychic or
4905+physical dependence, or both, arising from administration of that
4906+controlled dangerous substance on a continuous basis. Drug
4907+dependence is characterized by behavioral and other responses which
4908+include a strong compulsion to take the substance on a continuous
4909+basis in order to experience its psychic effects, or to avoid the
4910+discomfort of its absence;
4911+20. "Harm-reduction services" means programs established to:
4912+a. reduce the spread of infectious diseases r elated to
4913+injection drug use,
4914+b. reduce drug dependency, overdose deaths and associated
4915+complications, and
4916+c. increase safe recovery and disposal of us ed syringes
4917+and sharp waste;
4918+21. "Hazardous materials" means materials, whether solid,
4919+liquid or gas, which are toxic to human, animal, aquatic, or plant
4920+life, and the disposal of which materials is controlled by state or
4921+federal guidelines;
4922+16. 22. "Home care agency" means any sole proprietorship,
4923+partnership, association, corporation, or other organization which
4924+administers, offers, or provides home care services, for a fee or
4925+
4926+ENGR. H. B. NO. 3567 Page 11 1
4927+2
4928+3
4929+4
4930+5
4931+6
4932+7
4933+8
4934+9
4935+10
4936+11
4937+12
4938+13
4939+14
4940+15
4941+16
4942+17
4943+18
4944+19
4945+20
4946+21
4947+22
4948+23
4949+24
4950+
4951+pursuant to a contract for such services, to clients in their place
4952+of residence;
4953+17. 23. "Home care services" means skilled or personal care
4954+services provided to clients in their place of residence for a fee;
4955+18. 24. "Hospice" means a centrally administered, nonprofit or
4956+for-profit, medically directed, nurse-coordinated program which
4957+provides a continuum of home and inpatient care for the terminally
4958+ill patient and the patient's family. Such term shall also include
4959+a centrally administered, nonprofit or for-profit, medically
4960+directed, nurse-coordinated program if such program is licensed
4961+pursuant to the provisions of the Uniform Controlled Dangerous
4962+Substances Act. A hospice program offers palliative and supportive
4963+care to meet the special needs arising out of the physical,
4964+emotional and spiritual stresses which are experienced during the
4965+final stages of illness and during dying and bereavement. This care
4966+is available twenty-four (24) hours a day, seven (7) days a week,
4967+and is provided on the basis of need, regardless of ability to pay.
4968+"Class A" Hospice refers to Medicare-certified hospices. "Class B"
4969+refers to all other providers of hospice services;
4970+19. 25. "Imitation controlled substance" means a substance that
4971+is not a controlled dangerous substance, which by dosage unit
4972+appearance, color, shape, size, markings or by representations made,
4973+would lead a reasonable person to believe that the substance is a
4974+controlled dangerous substance, or is an agricultural drug that is
4975+
4976+ENGR. H. B. NO. 3567 Page 12 1
4977+2
4978+3
4979+4
4980+5
4981+6
4982+7
4983+8
4984+9
4985+10
4986+11
4987+12
4988+13
4989+14
4990+15
4991+16
4992+17
4993+18
4994+19
4995+20
4996+21
4997+22
4998+23
4999+24
5000+
5001+not a controlled dangerous substance being used outside of the scope
5002+of practice or normal course of busi ness, as defined by the Oklahoma
5003+Veterinary Board, or is a federal Food and Drug Administration-
5004+approved drug that is not a controlled dangerous substance being
5005+used outside the scope of approval for illicit purposes such as
5006+adulterating or lacing other co ntrolled dangerous substances. In
5007+the event the appearance of the dosage unit or use is not reasonably
5008+sufficient to establish that the substance is an imitation
5009+controlled substance, the court or authority concerned should
5010+consider, in addition to all ot her factors, the following factors as
5011+related to "representations made" in determining whether the
5012+substance is an imitation controlled substance:
5013+a. statements made by an owner or by any other person in
5014+control of the substance concerning the nature of the
5015+substance, or its use or effect,
5016+b. statements made to the recipient that the substance
5017+may be resold for inordinate profit,
5018+c. whether the substance is packaged in a manner normally
5019+used for illicit controlled substances,
5020+d. evasive tactics or actions utilized by the owner or
5021+person in control of the substance to avoid detection
5022+by law enforcement authorities,
5023+e. prior convictions, if any, of an owner, or any other
5024+person in control of the object, under state or
5025+
5026+ENGR. H. B. NO. 3567 Page 13 1
5027+2
5028+3
5029+4
5030+5
5031+6
5032+7
5033+8
5034+9
5035+10
5036+11
5037+12
5038+13
5039+14
5040+15
5041+16
5042+17
5043+18
5044+19
5045+20
5046+21
5047+22
5048+23
5049+24
5050+
5051+federal law related to controlled substances or fraud,
5052+and
5053+f. the proximity of the substances to controlled
5054+dangerous substances;
5055+20. 26. "Immediate precursor" means a substance which the
5056+Director has found to be and by regulation designates as being the
5057+principal compound commonly used or produced primarily for use, and
5058+which is an immediate chemical intermediary used, or likely to be
5059+used, in the manufacture of a controlled dangerous substance, the
5060+control of which is necessary to prevent, curtail or limit such
5061+manufacture;
5062+27. "Initial prescription" means a prescription issued to a
5063+patient who:
5064+a. has never previously been issued a prescription for
5065+the drug or its pharmaceutical equivalent in the past
5066+year, or
5067+b. requires a prescription for the drug or its
5068+pharmaceutical equivalent due to a surgical procedure
5069+or new acute event and has previously had a
5070+prescription for the drug or its pharmaceutical
5071+equivalent within the past year.
5072+When determining whether a patient was previously issued a
5073+prescription for a drug or its pharmaceutical equivalent, the
5074+
5075+ENGR. H. B. NO. 3567 Page 14 1
5076+2
5077+3
5078+4
5079+5
5080+6
5081+7
5082+8
5083+9
5084+10
5085+11
5086+12
5087+13
5088+14
5089+15
5090+16
5091+17
5092+18
5093+19
5094+20
5095+21
5096+22
5097+23
5098+24
5099+
5100+practitioner shall consult with the patient and review the medical
5101+record and prescription monitoring information of the patient;
5102+28. "Isomer" means the optical isomer, except as used in
5103+subsections C and F of Section 2-204 of this title and paragraph 4
5104+of subsection A of Section 2-206 of this title. As used in
5105+subsections C and F of Section 2-204 of this title, isomer means the
5106+optical, positional, or geometric isomer. As used in paragraph 4 of
5107+subsection A of Section 2-206 of this title, the term isomer means
5108+the optical or geometric isomer;
5109+21. 29. "Laboratory" means a laboratory approved by the
5110+Director as proper to be entrusted with the custody of controlled
5111+dangerous substances and the use of controlled dangerous substances
5112+for scientific and medical purposes and for purposes of instruction;
5113+22. 30. "Manufacture" means the production, preparation,
5114+propagation, compounding or processing of a controlled dangerous
5115+substance, either directly or indirectly by extraction from
5116+substances of natural or synthetic origin, or independently by means
5117+of chemical synthesis or by a combination of extraction and chemical
5118+synthesis. "Manufacturer" includes any person who packages,
5119+repackages or labels any container of any controlled dangerous
5120+substance, except practitioners who dispense or compound
5121+prescription orders for delivery to the ultimate consumer;
5122+23. 31. "Marijuana" means all parts of the plant Cannabis
5123+sativa L., whether growing or not; the seeds thereof; the resin
5124+
5125+ENGR. H. B. NO. 3567 Page 15 1
5126+2
5127+3
5128+4
5129+5
5130+6
5131+7
5132+8
5133+9
5134+10
5135+11
5136+12
5137+13
5138+14
5139+15
5140+16
5141+17
5142+18
5143+19
5144+20
5145+21
5146+22
5147+23
5148+24
5149+
5150+extracted from any part of such plant; and every compound,
5151+manufacture, salt, derivative, mixture or preparation of such plant,
5152+its seeds or resin, but shall not include:
5153+a. the mature stalks of such plant or fiber produced from
5154+such stalks,
5155+b. oil or cake made from the seeds of such plant,
5156+including cannabidiol derived from the seeds of the
5157+marijuana plant,
5158+c. any other compound, manufacture, salt, derivative,
5159+mixture or preparation of such mature stalks (except
5160+the resin extracted therefrom), including cannabidiol
5161+derived from mature stalks, fiber, oil or cake,
5162+d. the sterilized seed of such plant which is incapable
5163+of germination,
5164+e. for any person participating in a clinical trial to
5165+administer cannabidiol for the treatment of severe
5166+forms of epilepsy pursuant to Section 2-802 of this
5167+title, a drug or substance approved by the federal
5168+Food and Drug Administration for use by those
5169+participants,
5170+f. for any person or the parents, legal guardians or
5171+caretakers of the person who have received a written
5172+certification from a physician licensed in this state
5173+that the person has been diagnosed by a physician as
5174+
5175+ENGR. H. B. NO. 3567 Page 16 1
5176+2
5177+3
5178+4
5179+5
5180+6
5181+7
5182+8
5183+9
5184+10
5185+11
5186+12
5187+13
5188+14
5189+15
5190+16
5191+17
5192+18
5193+19
5194+20
5195+21
5196+22
5197+23
5198+24
5199+
5200+having Lennox-Gastaut syndrome, Dravet syndrome, also
5201+known as severe myoclonic epilepsy of infancy, or any
5202+other severe form of epilepsy that is not adequately
5203+treated by traditional medical therapies, spasticity
5204+due to multiple sclerosis or due to paraplegia,
5205+intractable nausea and vomiting, appetite stimulation
5206+with chronic wasting diseases, the substance
5207+cannabidiol, a nonpsychoactive cannabinoid, found in
5208+the plant Cannabis sativa L. or any other preparation
5209+thereof, that has a tetrahydrocannabinol concentration
5210+not more than three-tenths of one percent (0.3%) and
5211+that is delivered to the patient in the form of a
5212+liquid,
5213+g. any federal Food-and-Drug-Administration Food and Drug
5214+Administration-approved drug or substance, or
5215+h. industrial hemp, from the plant Cannabis sativa L. and
5216+any part of such plant, whether growing or not, with a
5217+delta-9 tetrahydrocannabinol concentration not more
5218+than three-tenths of one percent (0.3%) on a dry-
5219+weight basis which shall only be grown pursuant to the
5220+Oklahoma Industrial Hemp Program and may be shipped
5221+intrastate and interstate;
5222+24. 32. "Medical purpose" means an intention to utilize a
5223+controlled dangerous substance for physical or mental treatment, for
5224+
5225+ENGR. H. B. NO. 3567 Page 17 1
5226+2
5227+3
5228+4
5229+5
5230+6
5231+7
5232+8
5233+9
5234+10
5235+11
5236+12
5237+13
5238+14
5239+15
5240+16
5241+17
5242+18
5243+19
5244+20
5245+21
5246+22
5247+23
5248+24
5249+
5250+diagnosis, or for the prevention of a disease condition not in
5251+violation of any state or federal law and not for the purpose of
5252+satisfying physiological or psychological dependence or other abuse;
5253+25. 33. "Mid-level practitioner" means an Advanced Practice
5254+Registered Nurse as defined and within parameters specified in
5255+Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
5256+animal euthanasia technician as defined in Section 698.2 of Title 59
5257+of the Oklahoma Statutes, or an animal control officer registered by
5258+the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
5259+under subsection B of Section 2-301 of this title within the
5260+parameters of such officer's duties under Sections 501 through 508
5261+of Title 4 of the Oklahoma Statutes;
5262+26. 34. "Narcotic drug" means any of the following, whether
5263+produced directly or indirectly by extraction from substances of
5264+vegetable origin, or independently by means of chemical synthesis,
5265+or by a combination of extraction and chemical synthesis:
5266+a. opium, coca leaves and opiates,
5267+b. a compound, manufacture, salt, derivative or
5268+preparation of opium, coca leaves or opiates,
5269+c. cocaine, its salts, optical and geometric isomers, and
5270+salts of isomers,
5271+d. ecgonine, its derivatives, their salts, isomers and
5272+salts of isomers, and
5273+
5274+ENGR. H. B. NO. 3567 Page 18 1
5275+2
5276+3
5277+4
5278+5
5279+6
5280+7
5281+8
5282+9
5283+10
5284+11
5285+12
5286+13
5287+14
5288+15
5289+16
5290+17
5291+18
5292+19
5293+20
5294+21
5295+22
5296+23
5297+24
5298+
5299+e. a substance, and any compound, manufacture, salt,
5300+derivative or preparation thereof, which is chemically
5301+identical with any of the substances referred to in
5302+subparagraphs a through d of this paragraph, except
5303+that the words narcotic drug as used in Section 2-101
5304+et seq. of this title shall not include decocainized
5305+coca leaves or extracts of coca leaves, which extracts
5306+do not contain cocaine or ecgonine;
5307+27. 35. "Opiate" or "opioid" means any Schedule II, III, IV or
5308+V substance having an addiction-forming or addiction-sustaining
5309+liability similar to morphine or being capable of conversion into a
5310+drug having such addiction-forming or addiction-sustaining
5311+liability. The terms do not include, unless specifically designated
5312+as controlled under the Uniform Controlled Dangerous Substances Act,
5313+the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its
5314+salts (dextromethorphan). The terms do include the racemic and
5315+levorotatory forms;
5316+28. 36. "Opium poppy" means the plant of the species Papaver
5317+somniferum L., except the seeds thereof;
5318+37. "Palliative care" means a specialized medical service for
5319+people of any age and at any stage of a serious illness or life-
5320+altering medical event that focuses on na vigating complex medical
5321+decisions while providing patient autonomy and access to
5322+information. Utilizing a holistic and interdisciplinary team
5323+
5324+ENGR. H. B. NO. 3567 Page 19 1
5325+2
5326+3
5327+4
5328+5
5329+6
5330+7
5331+8
5332+9
5333+10
5334+11
5335+12
5336+13
5337+14
5338+15
5339+16
5340+17
5341+18
5342+19
5343+20
5344+21
5345+22
5346+23
5347+24
5348+
5349+approach, palliative care addresses physical, int ellectual,
5350+emotional, social, and spiritual needs. Palliative care may be
5351+provided in the inpatient, outp atient, or home care setting and
5352+strives to improve quality of lif e for both the patient and the
5353+family;
5354+38. "Patient-provider agreement" means a written contract or
5355+agreement that is executed between a practitioner and a patient
5356+prior to the commencement of treatment for chronic pain using an
5357+opioid drug as a means to:
5358+a. explain the possible risk of development of physical
5359+or psychological dependence in the patient and prevent
5360+the possible development of addiction,
5361+b. document the understanding of both the practitioner
5362+and the patient regarding the patient-provider
5363+agreement of the patient,
5364+c. establish the rights of the patient in association
5365+with treatment and the obligations of the patient in
5366+relation to the responsible use, discontinuation of
5367+use, and storage of opioid drugs, including any
5368+restrictions on the refill of prescriptions or the
5369+acceptance of opioid prescriptions from practitioners,
5370+d. identify the specific medications and other modes of
5371+treatment, including physical therapy or exercise,
5372+
5373+ENGR. H. B. NO. 3567 Page 20 1
5374+2
5375+3
5376+4
5377+5
5378+6
5379+7
5380+8
5381+9
5382+10
5383+11
5384+12
5385+13
5386+14
5387+15
5388+16
5389+17
5390+18
5391+19
5392+20
5393+21
5394+22
5395+23
5396+24
5397+
5398+relaxation, or psychological counseling, that are
5399+included as a part of the patient-provider agreement,
5400+e. specify the measures the practitioner may employ to
5401+monitor the compliance of the patient including, but
5402+not limited to, random specimen screens and pill
5403+counts, and
5404+f. delineate the process for terminating the agreement,
5405+including the consequences if the practitioner has
5406+reason to believe that the patient is not complying
5407+with the terms of the agreement. Compliance with the
5408+"consent items" shall constitute a valid, informed
5409+consent for opioid therapy. The practitioner shall be
5410+held harmless from civil litigation for failure to
5411+treat pain if the event occurs because of nonadherence
5412+by the patient with any of the provisions of the
5413+patient-provider agreement;
5414+29. 39. "Peace officer" means a police officer, sheriff, deputy
5415+sheriff, district attorney's investigator, investigator from the
5416+Office of the Attorney General, or any other person elected or
5417+appointed by law to enforce any of the criminal laws of this state
5418+or of the United States;
5419+30. 40. "Person" means an individual, corporation, government
5420+or governmental subdivision or agency, business trust, estate,
5421+trust, partnership or association, or any other legal entity;
5422+
5423+ENGR. H. B. NO. 3567 Page 21 1
5424+2
5425+3
5426+4
5427+5
5428+6
5429+7
5430+8
5431+9
5432+10
5433+11
5434+12
5435+13
5436+14
5437+15
5438+16
5439+17
5440+18
5441+19
5442+20
5443+21
5444+22
5445+23
5446+24
5447+
5448+31. 41. "Poppy straw" means all parts, except the seeds, of the
5449+opium poppy, after mowing;
5450+32. 42. "Practitioner" means:
5451+a. (1) a medical doctor or osteopathic physician,
5452+(2) a dentist,
5453+(3) a podiatrist,
5454+(4) an optometrist,
5455+(5) a veterinarian,
5456+(6) a physician assistant or Advanced Practice
5457+Registered Nurse under the supervision of a
5458+licensed medical doctor or osteopathic physician,
5459+(7) a scientific investigator, or
5460+(8) any other person,
5461+licensed, registered or otherwise permitted to
5462+prescribe, distribute, dispense, conduct research with
5463+respect to, use for scientific purposes or administer
5464+a controlled dangerous substance in the course of
5465+professional practice or research in this state, or
5466+b. a pharmacy, hospital, laboratory or other institution
5467+licensed, registered or otherwise permitted to
5468+distribute, dispense, conduct research with respect
5469+to, use for scientific purposes or administer a
5470+controlled dangerous substance in the course of
5471+professional practice or research in this state;
5472+
5473+ENGR. H. B. NO. 3567 Page 22 1
5474+2
5475+3
5476+4
5477+5
5478+6
5479+7
5480+8
5481+9
5482+10
5483+11
5484+12
5485+13
5486+14
5487+15
5488+16
5489+17
5490+18
5491+19
5492+20
5493+21
5494+22
5495+23
5496+24
5497+
5498+33. 43. "Production" includes the manufacture, planting,
5499+cultivation, growing or harvesting of a controlled dangerous
5500+substance;
5501+44. "Serious illness" means a medical illness or physical
5502+injury or condition that substantially affects quality of life for
5503+more than a short period of time. Serious illness includes, but is
5504+not limited to, Alzheimer's disease or related dementias, lung
5505+disease, cancer, heart failure, renal failure, liver failure, or
5506+chronic, unremitting, or intractable pain such as neuropathic pain;
5507+34. 45. "State" means the State of Oklahoma or any other state
5508+of the United States;
5509+46. "Straw person" or "straw party", also known as a "front",
5510+means a third party who:
5511+a. is put up in name only to take part in a transaction
5512+or otherwise is a nominal party to a transaction with
5513+no actual control,
5514+b. acts on behalf of another person to obtain title to
5515+property and executes documents and instruments the
5516+principal may direct respecting property, or
5517+c. purchases property for anot her for the purpose of
5518+concealing the identity of the real purchaser or to
5519+accomplish some purpose otherw ise in violation of
5520+Oklahoma Statutes;
5521+
5522+ENGR. H. B. NO. 3567 Page 23 1
5523+2
5524+3
5525+4
5526+5
5527+6
5528+7
5529+8
5530+9
5531+10
5532+11
5533+12
5534+13
5535+14
5536+15
5537+16
5538+17
5539+18
5540+19
5541+20
5542+21
5543+22
5544+23
5545+24
5546+
5547+47. "Surgical procedure" means a procedure that is performed
5548+for the purpose of structurally altering the human body by incision
5549+or destruction of tissues as part of the practice of medicine. This
5550+term includes the diagnostic or therapeutic treatment of conditions
5551+or disease processes by use of instruments such as lasers,
5552+ultrasound, ionizing, radiation, scalpels, probes, or needles that
5553+cause localized alteration or transportation of live human tissue by
5554+cutting, burning, vaporizing, freezing, suturing, probing, or
5555+manipulating by closed reduction for major dislocations or
5556+fractures, or otherwise altering by any mechanical, thermal, light-
5557+based, electromagnetic, or chemical means;
5558+48. a. "Synthetic controlled substance" means a substance:
5559+(1) the chemical structure of which is substantially
5560+similar to the chemical structure of a controlled
5561+dangerous substance in Schedule I or II,
5562+(2) which has a stimulant, depressant, or
5563+hallucinogenic effect on the central nervous
5564+system that is substantially similar to or
5565+greater than the stimulant, depressant, or
5566+hallucinogenic effect on the central nervous
5567+system of a controlled dangerous substance in
5568+Schedule I or II, or
5569+(3) with respect to a particular person, which such
5570+person represents or intends to have a stimulant,
5571+
5572+ENGR. H. B. NO. 3567 Page 24 1
5573+2
5574+3
5575+4
5576+5
5577+6
5578+7
5579+8
5580+9
5581+10
5582+11
5583+12
5584+13
5585+14
5586+15
5587+16
5588+17
5589+18
5590+19
5591+20
5592+21
5593+22
5594+23
5595+24
5596+
5597+depressant, or hallucinogenic effect on the
5598+central nervous system that is substantially
5599+similar to or greater than the stimulant,
5600+depressant, or hallucinogenic effect on the
5601+central nervous system of a controlled dangerous
5602+substance in Schedule I or II.
5603+b. The designation of gamma butyrolactone or any other
5604+chemical as a precursor, pursuant to Section 2-322 of
5605+this title, does not preclude a finding pursuant to
5606+subparagraph a of this paragraph that the chemical is
5607+a synthetic controlled substance.
5608+c. "Synthetic controlled substance" does not include:
5609+(1) a controlled dangerous substance,
5610+(2) any substance for which there is an approved new
5611+drug application,
5612+(3) with respect to a particular person any
5613+substance, if an exemption is in effect for
5614+investigational use, for that person under the
5615+provisions of Section 505 of the Federal Food,
5616+Drug and Cosmetic Act, Title 21 of the United
5617+States Code, Section 355, to the extent conduct
5618+with respect to such substance is pursuant to
5619+such exemption, or
5620+
5621+ENGR. H. B. NO. 3567 Page 25 1
5622+2
5623+3
5624+4
5625+5
5626+6
5627+7
5628+8
5629+9
5630+10
5631+11
5632+12
5633+13
5634+14
5635+15
5636+16
5637+17
5638+18
5639+19
5640+20
5641+21
5642+22
5643+23
5644+24
5645+
5646+(4) any substance to the extent not intended for
5647+human consumption before such an exemption takes
5648+effect with respect to that substance.
5649+d. Prima facie evidence that a substance containing
5650+salvia divinorum has been enhanced, concentrated, or
5651+chemically or physically altered shall give rise to a
5652+rebuttable presumption that the substance is a
5653+synthetic controlled substance;
5654+49. "Tetrahydrocannabinols" means all substances that have been
5655+chemically synthesized to emulate the tetrahyd rocannabinols of
5656+marijuana, specificall y including any tetrahydrocannabinols derived
5657+from industrial hemp; and
5658+35. 50. "Ultimate user" means a person who lawfully possesses a
5659+controlled dangerous substance for the person's own use or for the
5660+use of a member of the person's household or for administration to
5661+an animal owned by the person or by a member of the person's
5662+household;
5663+36. "Drug paraphernalia" means all equipment, products and
5664+materials of any kind which are used, intended for use, or fashioned
5665+specifically for use in planting, propagating, cultivating, growing,
5666+harvesting, manufacturing, comp ounding, converting, producing,
5667+processing, preparing, testing, analyzing, packaging, repackaging,
5668+storing, containing, concealing, injecting, ingesting, inhaling or
5669+otherwise introducing into the human body, a controlled dangerous
5670+
5671+ENGR. H. B. NO. 3567 Page 26 1
5672+2
5673+3
5674+4
5675+5
5676+6
5677+7
5678+8
5679+9
5680+10
5681+11
5682+12
5683+13
5684+14
5685+15
5686+16
5687+17
5688+18
5689+19
5690+20
5691+21
5692+22
5693+23
5694+24
5695+
5696+substance in violation o f the Uniform Controlled Dangerous
5697+Substances Act including, but not limited to:
5698+a. kits used, intended for use, or fashioned specifically
5699+for use in planting, propagating, cultivating, growing
5700+or harvesting of any species of plant which is a
5701+controlled dangerous substance or from which a
5702+controlled dangerous substance can be derived,
5703+b. kits used, intended for use, or fashioned specifically
5704+for use in manufacturing, compounding, converting,
5705+producing, processing or preparing controlled
5706+dangerous substances ,
5707+c. isomerization devices used, intended for use, or
5708+fashioned specifically for use in increasing the
5709+potency of any species of plant which is a controlled
5710+dangerous substance,
5711+d. testing equipment used, intended for use, or fashioned
5712+specifically for use in identifying, or in analyzing
5713+the strength, effectiveness or purity of controlled
5714+dangerous substances,
5715+e. scales and balances used, intended for use, or
5716+fashioned specifically for use in weighing or
5717+measuring controlled dangerous substances,
5718+f. diluents and adulterants, such as quinine
5719+hydrochloride, mannitol, mannite, dextrose and
5720+
5721+ENGR. H. B. NO. 3567 Page 27 1
5722+2
5723+3
5724+4
5725+5
5726+6
5727+7
5728+8
5729+9
5730+10
5731+11
5732+12
5733+13
5734+14
5735+15
5736+16
5737+17
5738+18
5739+19
5740+20
5741+21
5742+22
5743+23
5744+24
5745+
5746+lactose, used, intended for use, or fashioned
5747+specifically for use in cutting controlled dangerous
5748+substances,
5749+g. separation gins and sifters used, intended for use, or
5750+fashioned specifically for use in removing twigs and
5751+seeds from, or in otherwise cleaning or refining,
5752+marijuana,
5753+h. blenders, bowls, containers, spoons and mixing devices
5754+used, intended for use, or fashioned specifically for
5755+use in compounding controlled dange rous substances,
5756+i. capsules, balloons, envelopes and other containers
5757+used, intended for use, or fashioned specifically for
5758+use in packaging small quantities of controlled
5759+dangerous substances,
5760+j. containers and other objects used, intended for use,
5761+or fashioned specifically for use in parenterally
5762+injecting controlled dangerous substances into the
5763+human body,
5764+k. hypodermic syringes, needles and other objects used,
5765+intended for use, or fashioned specifically for use in
5766+parenterally injecting controlled dan gerous substances
5767+into the human body,
5768+l. objects used, intended for use, or fashioned
5769+specifically for use in ingesting, inhaling or
5770+
5771+ENGR. H. B. NO. 3567 Page 28 1
5772+2
5773+3
5774+4
5775+5
5776+6
5777+7
5778+8
5779+9
5780+10
5781+11
5782+12
5783+13
5784+14
5785+15
5786+16
5787+17
5788+18
5789+19
5790+20
5791+21
5792+22
5793+23
5794+24
5795+
5796+otherwise introducing marijuana, cocaine, hashish or
5797+hashish oil into the human body, such as:
5798+(1) metal, wooden, acrylic, glass, stone, plastic or
5799+ceramic pipes with or without screens, permanent
5800+screens, hashish heads or punctured metal bowls,
5801+(2) water pipes,
5802+(3) carburetion tubes and devices,
5803+(4) smoking and carburetion masks,
5804+(5) roach clips, meaning objects used to hold burning
5805+material, such as a marijuana cigarette, that has
5806+become too small or too short to be held in the
5807+hand,
5808+(6) miniature cocaine spoons and cocaine vials,
5809+(7) chamber pipes,
5810+(8) carburetor pipes,
5811+(9) electric pipes,
5812+(10) air-driven pipes,
5813+(11) chillums,
5814+(12) bongs, or
5815+(13) ice pipes or chillers,
5816+m. all hidden or novelty pipes, and
5817+n. any pipe that has a tobacco bowl or chamber of less
5818+than one-half (1/2) inch in diameter in which there is
5819+any detectable residue of any controlled dangerous
5820+
5821+ENGR. H. B. NO. 3567 Page 29 1
5822+2
5823+3
5824+4
5825+5
5826+6
5827+7
5828+8
5829+9
5830+10
5831+11
5832+12
5833+13
5834+14
5835+15
5836+16
5837+17
5838+18
5839+19
5840+20
5841+21
5842+22
5843+23
5844+24
5845+
5846+substance as defined in this section or any other
5847+substances not legal for possession or use;
5848+provided, however, the term drug paraphernalia shall not include
5849+separation gins intended for use in preparing tea or spice, clamps
5850+used for constructing electrical equ ipment, water pipes designed for
5851+ornamentation in which no detectable amount of an illegal substance
5852+is found or pipes designed and used solely for smoking tobacco,
5853+traditional pipes of an American Indian tribal religious ceremony,
5854+antique pipes that ar e thirty (30) years of age or older, or drug
5855+testing strips possessed by a person for purposes of determining the
5856+presence of fentanyl or a fentanyl-related compound;
5857+37. a. "Synthetic controlled substance" means a substance:
5858+(1) the chemical structure of which is substantially
5859+similar to the chemical structure of a controlled
5860+dangerous substance in Schedule I or II,
5861+(2) which has a stimulant, depressant, or
5862+hallucinogenic effect on the cent ral nervous
5863+system that is substantially similar to or
5864+greater than the stimulant, depressant or
5865+hallucinogenic effect on the central nervous
5866+system of a controlled dangerous substance in
5867+Schedule I or II, or
5868+(3) with respect to a particular person, which such
5869+person represents or intends to have a stimulant,
5870+
5871+ENGR. H. B. NO. 3567 Page 30 1
5872+2
5873+3
5874+4
5875+5
5876+6
5877+7
5878+8
5879+9
5880+10
5881+11
5882+12
5883+13
5884+14
5885+15
5886+16
5887+17
5888+18
5889+19
5890+20
5891+21
5892+22
5893+23
5894+24
5895+
5896+depressant, or hallucinogenic effect on the
5897+central nervous system that is substantially
5898+similar to or greater than the stimulant,
5899+depressant, or hallucinogenic effect on the
5900+central nervous system of a controlled dangerous
5901+substance in Schedule I or II.
5902+b. The designation of gamma butyrolactone or any other
5903+chemical as a precursor, pursuant to Section 2-322 of
5904+this title, does not preclude a finding pursuant to
5905+subparagraph a of this paragraph that the chemical is
5906+a synthetic controlled substance.
5907+c. "Synthetic controlled substance" does not include:
5908+(1) a controlled dangerous substance,
5909+(2) any substance for which there is an approved new
5910+drug application,
5911+(3) with respect to a particular person any
5912+substance, if an exemption is in effect for
5913+investigational use, for that person under the
5914+provisions of Section 505 of the Federal Food,
5915+Drug and Cosmetic Act, Title 21 of the United
5916+States Code, Section 355, to the extent conduct
5917+with respect to such subst ance is pursuant to
5918+such exemption, or
5919+
5920+ENGR. H. B. NO. 3567 Page 31 1
5921+2
5922+3
5923+4
5924+5
5925+6
5926+7
5927+8
5928+9
5929+10
5930+11
5931+12
5932+13
5933+14
5934+15
5935+16
5936+17
5937+18
5938+19
5939+20
5940+21
5941+22
5942+23
5943+24
5944+
5945+(4) any substance to the extent not intended for
5946+human consumption before such an exemption takes
5947+effect with respect to that substance.
5948+d. Prima facie evidence that a substance containing
5949+salvia divinorum has been en hanced, concentrated or
5950+chemically or physically altered shall give rise to a
5951+rebuttable presumption that the substance is a
5952+synthetic controlled substance;
5953+38. "Tetrahydrocannabinols" means all substances that have been
5954+chemically synthesized to emulate the tetrahydrocannabinols of
5955+marijuana, specifically including any tetrahydrocannabinols derived
5956+from industrial hemp;
5957+39. "Isomer" means the optical isomer, except as used in
5958+subsections C and F of Section 2-204 of this title and paragraph 4
5959+of subsection A of Section 2-206 of this title. As used in
5960+subsections C and F of Section 2-204 of this title, isomer means the
5961+optical, positional or geometric isomer. As used in paragraph 4 of
5962+subsection A of Section 2-206 of this title, the term isomer means
5963+the optical or geometric isomer;
5964+40. "Hazardous materials" means materials, whether solid,
5965+liquid or gas, which are toxic to human, animal, aquatic or plant
5966+life, and the disposal of which materials is controlled by state or
5967+federal guidelines;
5968+
5969+ENGR. H. B. NO. 3567 Page 32 1
5970+2
5971+3
5972+4
5973+5
5974+6
5975+7
5976+8
5977+9
5978+10
5979+11
5980+12
5981+13
5982+14
5983+15
5984+16
5985+17
5986+18
5987+19
5988+20
5989+21
5990+22
5991+23
5992+24
5993+
5994+41. "Anhydrous ammonia" means any substance that exhibits
5995+cryogenic evaporative behavior and tests positive for ammonia;
5996+42. "Acute pain" means pain, whether resulting from disease,
5997+accidental or intentional trauma or other cause, that the
5998+practitioner reasonably expects to last only a short period of time.
5999+Acute pain does not include chronic pain, pain being treated as part
6000+of cancer care, hospice or other end-of-life care, or pain being
6001+treated as part of palliative care;
6002+43. "Chronic pain" means pain that persists beyond the usual
6003+course of an acute disease or healing of an injury. Chronic pain
6004+may or may not be associated with an acute or chronic pathologic
6005+process that causes continuous or intermittent pain over months or
6006+years;
6007+44. "Initial prescription" means a prescription issued to a
6008+patient who:
6009+a. has never previously been issued a prescription for
6010+the drug or its pharmaceutical equivalent in the past
6011+year, or
6012+b. requires a prescription for the drug or its
6013+pharmaceutical equivalent due to a surgical procedure
6014+or new acute event and has previously had a
6015+prescription for the drug or its pharmaceutical
6016+equivalent within the past year.
6017+
6018+ENGR. H. B. NO. 3567 Page 33 1
6019+2
6020+3
6021+4
6022+5
6023+6
6024+7
6025+8
6026+9
6027+10
6028+11
6029+12
6030+13
6031+14
6032+15
6033+16
6034+17
6035+18
6036+19
6037+20
6038+21
6039+22
6040+23
6041+24
6042+
6043+When determining whether a patient was previously issued a
6044+prescription for a drug or its pharmaceutical equivalent, the
6045+practitioner shall consult with the patient and review the medical
6046+record and prescription monitoring information of the patient;
6047+45. "Patient-provider agreement" means a written contract or
6048+agreement that is executed between a practitioner and a patient,
6049+prior to the commencement of treatment for chronic pain using an
6050+opioid drug as a means to:
6051+a. explain the possible risk of development of physical
6052+or psychological dependence in the patient and prevent
6053+the possible development of addiction,
6054+b. document the understanding of both the practitioner
6055+and the patient regarding the patient-provider
6056+agreement of the patient,
6057+c. establish the rights of the patient in association
6058+with treatment and the obligations of the patient in
6059+relation to the responsible use, discontinuation of
6060+use, and storage of opioid drugs, including any
6061+restrictions on the refill of prescriptions or the
6062+acceptance of opioid prescriptions from practitioners,
6063+d. identify the specific medications and other modes of
6064+treatment, including physical therapy or exercise,
6065+relaxation or psychological counseling, that are
6066+included as a part of the patient-provider agreement,
6067+
6068+ENGR. H. B. NO. 3567 Page 34 1
6069+2
6070+3
6071+4
6072+5
6073+6
6074+7
6075+8
6076+9
6077+10
6078+11
6079+12
6080+13
6081+14
6082+15
6083+16
6084+17
6085+18
6086+19
6087+20
6088+21
6089+22
6090+23
6091+24
6092+
6093+e. specify the measures the practitioner may employ to
6094+monitor the compliance of the patient including, but
6095+not limited to, random specimen screens and pill
6096+counts, and
6097+f. delineate the process for terminating the agreement,
6098+including the consequences if the practitioner has
6099+reason to believe that the patient is not complying
6100+with the terms of the agreement. Compliance with the
6101+"consent items" shall constitute a valid, informed
6102+consent for opioid therapy. The practitioner shall be
6103+held harmless from civil litigation for failure to
6104+treat pain if the event occurs because of nonadherence
6105+by the patient with any of the provisions of the
6106+patient-provider agreement;
6107+46. "Serious illness" means a medical illness or physical
6108+injury or condition that substantially affects quality of life for
6109+more than a short period of time. Serious illness includes, but is
6110+not limited to, Alzheimer's disease or related dementias, lung
6111+disease, cancer, heart failure, renal failure, liver failure or
6112+chronic, unremitting or intractable pain such as neuropathic pain;
6113+and
6114+47. "Surgical procedure" means a procedure that is performed
6115+for the purpose of structurally altering the human body by incision
6116+or destruction of tissues as part of the practice of medicine. This
6117+
6118+ENGR. H. B. NO. 3567 Page 35 1
6119+2
6120+3
6121+4
6122+5
6123+6
6124+7
6125+8
6126+9
6127+10
6128+11
6129+12
6130+13
6131+14
6132+15
6133+16
6134+17
6135+18
6136+19
6137+20
6138+21
6139+22
6140+23
6141+24
6142+
6143+term includes the diagnostic or therapeutic treatment of conditions
6144+or disease processes by use of instruments such as lasers,
6145+ultrasound, ionizing, radiation, scalpels, probes or needles that
6146+cause localized alteration or transportation of live human tissue by
6147+cutting, burning, vaporizing, freezing, suturing, probing or
6148+manipulating by closed reduction for major dislocations or
6149+fractures, or otherwise altering by any mechanical, thermal, light-
6150+based, electromagnetic or chemical means.
6151+SECTION 11. AMENDATORY 63 O.S. 2021, Section 2-106.2, is
6152+amended to read as follows:
6153+Section 2-106.2 A. The Oklahoma State Bu reau of Narcotics and
6154+Dangerous Drugs Control, pursuant to rules promulgated by the
6155+Oklahoma State Bureau of Narcotics an d Dangerous Drugs Control
6156+Commission, is hereby authorized to:
6157+1. Make available for sale used vehicles, used equipment and
6158+forfeited property to any federal, state, county, or municipal
6159+agency, trust authority or public school district;
6160+2. Sell at public auction any used vehicles, used equipment and
6161+any property forfeited to the Bureau; and
6162+3. Donate or transfer title to any surplus p roperty as defined
6163+in Section 62.2 of T itle 74 of the Oklahoma Statutes, or property
6164+forfeited to the Bureau, to any law enforcement agency of any
6165+political subdivision of the State o f Oklahoma. The use of such
6166+
6167+ENGR. H. B. NO. 3567 Page 36 1
6168+2
6169+3
6170+4
6171+5
6172+6
6173+7
6174+8
6175+9
6176+10
6177+11
6178+12
6179+13
6180+14
6181+15
6182+16
6183+17
6184+18
6185+19
6186+20
6187+21
6188+22
6189+23
6190+24
6191+
6192+donated equipment shall be limited to valid and authorized law
6193+enforcement efforts by the receiving agency.
6194+B. Any property subject to this section shall be exempte d from
6195+the provisions set for th in Section 62.3 of Title 74 of the Oklahoma
6196+Statutes.
6197+SECTION 12. AMENDATORY 63 O.S. 2021, Section 2-304, as
6198+amended by Section 3, Chapter 375, O.S.L. 2023 (63 O.S. Supp. 2023,
6199+Section 2-304), is amended to read as follows:
6200+Section 2-304. A. A registration, pursuant to Section 2-303 of
6201+this title, to manufacture, distribute, dispe nse, prescribe,
6202+administer or use for scientific purposes a controlled dangerous
6203+substance shall be limited, conditioned, denied, suspended,
6204+annulled, or revoked by the Director of the Oklahoma State Bureau of
6205+Narcotics and Dangerous Drugs Control upon a finding that the
6206+registrant or applicant:
6207+1. Has materially falsified any applicatio n filed pursuant to
6208+the Uniform Controlled Dangerous Substances Act or requi red by the
6209+Uniform Controlled Dangerous Substances Act. It shall be unlawful
6210+to knowingly and willfully intentionally:
6211+a. make false statements, include false data or omit
6212+material information on an application for a
6213+registration with the Oklahoma State Bureau of
6214+Narcotics and Dangerous Drugs Control, or
6215+
6216+ENGR. H. B. NO. 3567 Page 37 1
6217+2
6218+3
6219+4
6220+5
6221+6
6222+7
6223+8
6224+9
6225+10
6226+11
6227+12
6228+13
6229+14
6230+15
6231+16
6232+17
6233+18
6234+19
6235+20
6236+21
6237+22
6238+23
6239+24
6240+
6241+b. provide false data or omit material information in any
6242+records or reports required by rule or law to be
6243+created, maintained or submitted to the Bureau.
6244+Any registrant or applicant for a registration or any official,
6245+agent or employee of any registrant or applicant for a registration
6246+who violates the provisions of this paragraph shall be guilty of a
6247+misdemeanor and additionally subject to admin istrative action;
6248+2. Has been found guilty of, entered a plea of guilty or
6249+entered a plea of nolo contendere to a misdemeanor relating to any
6250+substance defined herein as a controlled dangerous substance or any
6251+felony under the laws of any state or the Uni ted States;
6252+3. Has had his or her federal registration retired, suspended
6253+or revoked by a competent federal authority and is no longer
6254+authorized by federal law to manufacture, distribute, dispense,
6255+prescribe, administer or use for scientific purposes con trolled
6256+dangerous substances;
6257+4. Has failed to maintain effective controls against the
6258+diversion of controlled dangerous substances to unauthorized persons
6259+or entities;
6260+5. Has prescribed, dispensed or administered a controlled
6261+dangerous substance from sc hedules other than those specified in his
6262+or her state or federal registration;
6263+6. Has had a restriction, suspension, revocation, limitation,
6264+condition or probation placed on his or her professional license or
6265+
6266+ENGR. H. B. NO. 3567 Page 38 1
6267+2
6268+3
6269+4
6270+5
6271+6
6272+7
6273+8
6274+9
6275+10
6276+11
6277+12
6278+13
6279+14
6280+15
6281+16
6282+17
6283+18
6284+19
6285+20
6286+21
6287+22
6288+23
6289+24
6290+
6291+certificate or practice as a result of a proc eeding pursuant to the
6292+general statutes;
6293+7. Is abusing or, within the past five (5) years, has abused or
6294+excessively used drugs or controlled dangerous substances;
6295+8. Has prescribed, sold, administered or ordered any controlled
6296+dangerous substance for an immediate family member, himself or
6297+herself; provided that this shall not apply to a medical emergency
6298+when no other doctor is available to respond to the emergency;
6299+9. Has possessed, used, prescribed, dispensed or administered
6300+drugs or controlled dangerous substa nces for other than legitimate
6301+medical or scientific purposes or for purpos es outside the normal
6302+course of his or her professional practice;
6303+10. Has been under the influence of alcohol or another
6304+intoxicating substance which adversely affected the central nervous
6305+system, vision, hearing or other sensory or motor functioning to
6306+such degree the person was impaired during the performance of his or
6307+her job; or
6308+11. Has violated any federal law relating to any controlled
6309+dangerous substances, any provision of the Uniform Controlled
6310+Dangerous Substances Act or any rules of the Oklahoma State Bureau
6311+of Narcotics and Dangerous Drugs Control.
6312+B. In the event the Director suspends or revokes a registration
6313+granted under Section 2-303 of this title, all controlled dangerous
6314+substances owned or possessed by the registrant pursuant to such
6315+
6316+ENGR. H. B. NO. 3567 Page 39 1
6317+2
6318+3
6319+4
6320+5
6321+6
6322+7
6323+8
6324+9
6325+10
6326+11
6327+12
6328+13
6329+14
6330+15
6331+16
6332+17
6333+18
6334+19
6335+20
6336+21
6337+22
6338+23
6339+24
6340+
23026341 registration at the time of revocation or suspension or the
23036342 effective date of the revocation order, as the case may be, may in
23046343 the discretion of the Director be impounded and preserved . All
23056344 controlled dangerous substances not impounded or preserved by the
23066345 Director shall be maintained by the registran t. No Upon issuance of
23076346 a revocation order, no disposition, purchase, distribution, sale, or
23086347 transfer may be made of controlled dangerous substances until the
23096348 time for taking an appeal has elapsed or until all appeals have been
23106349 concluded unless a court, upon application therefor, orders the sale
23116350 of perishable substances and the deposit of the proceeds of the sale
23126351 with the court to be distributed to the prevailing party. Upon a
23136352 revocation order becoming final, all such controlled dangerous
23146353 substances shall be forfeited to the state or otherwise considered
23156354 waste and submitted to a licensed waste disposal service for
23166355 destruction pursuant to Section 430 of this title in accordance with
23176356 applicable law and by order of the Director.
2318-
23196357 C. The Drug Enforcement Administration shall promptly be
23206358 notified of all orders suspending or revoking registration and all
23216359 forfeitures of controlled dangerous substances.
2322-
2323-SECTION 5. AMENDATORY 63 O.S. 2021, Section 2 -305, as
2324-last amended by Section 4, Chapter 375, O.S.L. 2023 (63 O.S. Supp.
2325-2023, Section 2-305), is amended to read as follows:
2326- ENR. H. B. NO. 3567 Page 53
6360+SECTION 13. AMENDATORY 63 O.S. 2021, Section 2-305, as
6361+amended by Section 4, Chapter 375, O.S.L. 2023 (63 O.S. Supp. 2 023,
6362+Section 2-305), is amended to read as follows:
23276363 Section 2-305. A. In addition to any other remedies provided
23286364 for by law, the Director shall issue a writte n order to be served on
6365+
6366+ENGR. H. B. NO. 3567 Page 40 1
6367+2
6368+3
6369+4
6370+5
6371+6
6372+7
6373+8
6374+9
6375+10
6376+11
6377+12
6378+13
6379+14
6380+15
6381+16
6382+17
6383+18
6384+19
6385+20
6386+21
6387+22
6388+23
6389+24
6390+
23296391 the parties before annulling, conditioning, suspending or revoking
23306392 any registration that the Director has reason to believe is
23316393 operating inconsistent with any provision of Section 2-303 of this
23326394 title, pursuant to Section 2-304 of this title or otherwise where
23336395 there has been a violation of any federal law, any rule or
23346396 regulation of the Drug Enforcement Administration, any provision of
23356397 the Uniform Controlled Dangerous Substances Act, or any rules or
23366398 regulations of the Oklahoma State Bu reau of Narcotics and Dangerous
23376399 Drugs Control.
2338-
23396400 B. The written order shall state with specificit y the nature of
23406401 the violation or basis for the action. The Director may impose any
23416402 disciplinary action authorized by the Uniform Controlled Dangerous
23426403 Substances Act or rules of the Oklahoma State Bureau of Narcotics
23436404 and Dangerous Drugs Control including, but not limited to, the
23446405 assessment of monetary penalties.
2345-
23466406 C. Any written order issued pursuant to the provisions of this
23476407 section shall become a final order unl ess the registrant requests an
23486408 administrative hearing in accordance with the rules and regulatio ns
23496409 promulgated by the Director within thirty (30) days of issuance.
23506410 Upon such request, the Director shall promptly initiate
23516411 administrative proceedings and serv e formal notice of the
23526412 proceedings pursuant to Section 309 of Title 75 of the Oklahoma
23536413 Statutes. Nothing in this section shall be construed so as to
6414+
6415+ENGR. H. B. NO. 3567 Page 41 1
6416+2
6417+3
6418+4
6419+5
6420+6
6421+7
6422+8
6423+9
6424+10
6425+11
6426+12
6427+13
6428+14
6429+15
6430+16
6431+17
6432+18
6433+19
6434+20
6435+21
6436+22
6437+23
6438+24
6439+
23546440 require an individual proceeding for the denial of a new application
23556441 for registration.
2356-
23576442 D. The Director may authorize the Deputy Director or the
23586443 General Counsel of the Oklahoma State Bureau of Narcotics and
23596444 Dangerous Drugs Control to initiate any individual proceedings under
23606445 this title. Nothing in this section shall be construed so as to
23616446 delegate the authorit y of the Director to issue a final agency order
23626447 of an individual proceeding adverse to a party. If a party fails to
23636448 request an administrative hearing in a timely manner, the written
23646449 order as issued shall be deemed ad opted by the Director as the final
23656450 agency order concerning the matter without further action by the
23666451 Director.
2367-
23686452 E. All proceedings shall be conducted in accordance with the
23696453 Administrative Procedures Act and the rules and regulations of the
23706454 Oklahoma State Bureau of Narcotics and Dangerous Drugs C ontrol
2371-without regard to any criminal prosecution or other proceedi ng. ENR. H. B. NO. 3567 Page 54
2372-
6455+without regard to any criminal prosecution or other proceeding.
23736456 1. Proceedings to refuse renewal, revoke, or suspend a
23746457 registration shall not abate the existing registration which shall
23756458 remain in effect pending the outcome of those administrative
23766459 proceedings; provided, the registrant submits timely and sufficient
23776460 renewal applications annually . This abatement shall not apply when
23786461 the Director finds there is an imminent danger to the public health
23796462 or safety requiring an immediate suspension.
23806463
6464+ENGR. H. B. NO. 3567 Page 42 1
6465+2
6466+3
6467+4
6468+5
6469+6
6470+7
6471+8
6472+9
6473+10
6474+11
6475+12
6476+13
6477+14
6478+15
6479+16
6480+17
6481+18
6482+19
6483+20
6484+21
6485+22
6486+23
6487+24
6488+
23816489 2. The Director may delegate to an administrative hearing
23826490 officer the authority to conduct hearings and recommend action for
23836491 final agency orders in accordance with the rules and regulations of
23846492 the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control.
2385-
23866493 F. The Director may issue an order immediately suspending a
23876494 registration, without notice or a hearing, when he or she finds
23886495 there is imminent danger to the public health or safety which
23896496 warrants this action. The suspension shall continue in effect until
23906497 the conclusion of any administrative proceedings, including judicial
23916498 review thereof, unless sooner withdrawn by the Director or dissolved
23926499 by a court of competent jurisdiction. The order shall state the
23936500 existence of an emergency requiring action be taken that the
23946501 Director deems necessary to meet the emergency. Such action may
23956502 include, but is not limited to, ordering the registrant to
23966503 immediately cease and desist operations. The order shall be
23976504 effective immediately upon issuance. Any person to whom the order
23986505 is directed shall comply immediately with the provisions of the
23996506 order. The Director may assess a penalty not to exceed Ten Thousand
24006507 Dollars ($10,000.00) per day of noncompliance with the order. In
24016508 assessing such a penalty, the Director shall consider the
24026509 seriousness of the violation and any efforts to comply with
24036510 applicable requirements. Upon application to the Director, the
24046511 registrant shall be offered a hearing within thirty (30) days of the
24056512 issuance of the order.
24066513
6514+ENGR. H. B. NO. 3567 Page 43 1
6515+2
6516+3
6517+4
6518+5
6519+6
6520+7
6521+8
6522+9
6523+10
6524+11
6525+12
6526+13
6527+14
6528+15
6529+16
6530+17
6531+18
6532+19
6533+20
6534+21
6535+22
6536+23
6537+24
6538+
24076539 G. In lieu of or in addition to any other remedies available to
24086540 the Director, if a finding is made that a registrant has committed
24096541 any act in violation of federal law rela ting to any controlled
24106542 substance, any provision of the Unifor m Controlled Dangerous
24116543 Substances Act or any rules of the Oklahoma State Bureau of
24126544 Narcotics and Dangerous Drugs Control, the Director is hereby
24136545 authorized to assess an administrative penalty not to exceed Five
24146546 Thousand Dollars ($5,000.00) per day for each such act. The
24156547 provisions of this subsection shall not apply to violations of
2416-subsection G of Section 2 -309D of this title. N othing in this ENR. H. B. NO. 3567 Page 55
6548+subsection G of Section 2-309D of this title. Nothing in this
24176549 section shall be construed so as to permit the Direct or of the
24186550 Oklahoma State Bureau of Narcotics and Dangerous Dr ugs Control to
24196551 assess administrative fines for violations of the provisions of
24206552 subsection G of Section 2-309D of this title.
2421-
24226553 H. If a judge of competent jurisdiction finds probable cau se
24236554 that a registrant has possessed, transferred, sold, or offered for
24246555 sale any controlled dangerous substance in violation of this act,
24256556 all controlled dangerous substances in Schedule I of Section 2-204
24266557 of this title and all controlled dangerous substances in Schedu les
24276558 II, III, IV, and V that are not in properly labeled container s in
24286559 accordance with this act then in the possession of the registrant
24296560 shall be deemed contraband and shall be seized and summarily
24306561 forfeited pursuant to Section 2-505 of this title. Samples shall be
24316562 retained of all controlled dangerous substances seized in accordance
6563+
6564+ENGR. H. B. NO. 3567 Page 44 1
6565+2
6566+3
6567+4
6568+5
6569+6
6570+7
6571+8
6572+9
6573+10
6574+11
6575+12
6576+13
6577+14
6578+15
6579+16
6580+17
6581+18
6582+19
6583+20
6584+21
6585+22
6586+23
6587+24
6588+
24326589 with Section 2-508 of this title as required. The Director is
24336590 authorized to assess an eradication or destruction fine not to
24346591 exceed Fifty Thousand Dollars ($50,000.00) against the registrant.
2435-
24366592 H. I. Upon an annulment, revocation, or denial of a
24376593 registration the Director may prohibit the registrant or applicant
24386594 from reapplying for registration for a period up to five (5) years
24396595 following the date of the final order. The length of any
24406596 prohibition shall not be used as grounds to contest the validity o f
24416597 the annulment, revocation, or denial of a registration.
2442-
2443-SECTION 6. AMENDATORY 63 O.S. 202 1, Section 2-309, as
6598+SECTION 14. AMENDATORY 63 O.S. 2021, Section 2-309, as
24446599 amended by Section 2, Chapter 304, O.S.L. 2023 ( 63 O.S. Supp. 2023,
24456600 Section 2-309), is amended to read as f ollows:
2446-
24476601 Section 2-309. A. 1. Except for dosages medically required
24486602 for a period not to exceed forty-eight (48) hours which are
24496603 administered by or on direction of a practitioner, other than a
24506604 pharmacist, or medication dispensed directly by a practitioner,
24516605 other than a pharmac ist, to an ultimate user, no controlled
24526606 dangerous substance included in Sc hedule II, which is a prescription
24536607 drug as determined under regulation promulgated by the Board of
24546608 Pharmacy, shall be dispensed without an electronic prescription of a
24556609 practitioner; provided, that in emergency situations, as prescribed
24566610 by the Board of Phar macy by regulation, such drug may be dispensed
24576611 upon oral prescription reduced promptly to writing and filed by the
24586612 pharmacist in a manner to be prescribed by rules and regulations of
6613+
6614+ENGR. H. B. NO. 3567 Page 45 1
6615+2
6616+3
6617+4
6618+5
6619+6
6620+7
6621+8
6622+9
6623+10
6624+11
6625+12
6626+13
6627+14
6628+15
6629+16
6630+17
6631+18
6632+19
6633+20
6634+21
6635+22
6636+23
6637+24
6638+
24596639 the Director of the Oklahoma State Bureau of Narcotics and Dangerous
24606640 Drugs Control.
2461- ENR. H. B. NO. 3567 Page 56
24626641 2. Electronic prescribing shall be utilized for Schedules II,
24636642 III, IV and V, subject to t he requirements set forth in 21 CFR,
24646643 Section 1311 et seq.
2465-
24666644 3. An electronic presc ription with electronic signature may
24676645 serve as an original prescription, s ubject to the requirements set
24686646 forth in 21 CFR, Section 1311 et seq.
2469-
24706647 4. Prescriptions shall be retai ned in conformity with the
24716648 requirements of this section and Section 2-307 of this title. No
24726649 prescription for a Schedule II substance may be refilled.
2473-
24746650 5. The electronic prescription requirement provided for in this
24756651 section shall not apply to prescriptions for controlled dangerous
24766652 substances issued by any of the following:
2477-
24786653 a. a person licensed to practice veterinary medicine,
2479-
24806654 b. a practitioner who experience s temporary technological
24816655 or electrical failure or other extenuating
24826656 circumstance that prevents the p rescription from being
24836657 transmitted electronically; provided, however, that
24846658 the practitioner documents the reason for this
24856659 exception in the medical record o f the patient,
2486-
24876660 c. a practitioner, other than a pharmacist, who dispenses
24886661 directly to an ultimate user ,
6662+
6663+ENGR. H. B. NO. 3567 Page 46 1
6664+2
6665+3
6666+4
6667+5
6668+6
6669+7
6670+8
6671+9
6672+10
6673+11
6674+12
6675+13
6676+14
6677+15
6678+16
6679+17
6680+18
6681+19
6682+20
6683+21
6684+22
6685+23
6686+24
24896687
24906688 d. a practitioner who orders a controlled dangerous
24916689 substance to be administere d through an on-site
24926690 pharmacy in:
2493-
24946691 (1) a hospital as defined in Section 1 -701 of this
24956692 title,
2496-
24976693 (2) a nursing facility as defined in Section 1-1902
24986694 of this title,
2499-
25006695 (3) a hospice inpatient facility as defined in
25016696 Section 1-860.2 of this title,
2502-
25036697 (4) an outpatient dialysis facility,
2504-
25056698 (5) a continuum of care facility as defined in
2506-Section 1-890.2 of this title, or ENR. H. B. NO. 3567 Page 57
2507-
6699+Section 1-890.2 of this title, or
25086700 (6) a penal institution listed in Section 509 of
25096701 Title 57 of the Oklahoma St atutes,
2510-
25116702 e. a practitioner who orders a controlled dangerous
25126703 substance to be admin istered through a hospice program
25136704 including but not limited to a hospice program that
25146705 provides hospice services in the private residence of
25156706 a patient or in a long-term care facility where the
25166707 patient resides. As used in this subparagraph,
2517-“hospice program” has the same meaning as provided by
6708+"hospice program" has the same meaning as provided by
25186709 Section 1-860.2 of this title,
2519-
25206710 f. a practitioner who writes a prescription to be
25216711 dispensed by a pharmacy located on federal property,
6712+
6713+ENGR. H. B. NO. 3567 Page 47 1
6714+2
6715+3
6716+4
6717+5
6718+6
6719+7
6720+8
6721+9
6722+10
6723+11
6724+12
6725+13
6726+14
6727+15
6728+16
6729+17
6730+18
6731+19
6732+20
6733+21
6734+22
6735+23
6736+24
6737+
25226738 provided the practitioner documents the reason for
25236739 this exception in the medic al record of the patient,
25246740 or
2525-
25266741 g. a practitioner that has received a waiver or extension
25276742 from his or her licensing board,
2528-
25296743 h. a practitioner who prescribes a con trolled dangerous
25306744 substance for a supply that when taken as prescribed
25316745 would be consumed within seventy -two (72) hours, or
2532-
25336746 i. a practitioner who determines that an electronic
25346747 prescription cannot be issued in a timel y manner and
25356748 the condition of the patient is at risk .
2536-
25376749 6. Electronic prescriptions shall not may be utilized under the
25386750 following circumstances:
2539-
25406751 a. compound compounded prescriptions containing two or
25416752 more commercially available products or two or more
25426753 active pharmaceutical ingredients,
2543-
25446754 b. compounded infusion prescriptions containing two or
25456755 more commercially available products or two or mo re
25466756 active pharmaceutical ingredient s, or
2547-
25486757 c. prescriptions issued under approved research
25496758 protocols, or
2550- ENR. H. B. NO. 3567 Page 58
25516759 d. if the practitioner determines that an electronic
25526760 prescription cannot be issued in a timely manner and
25536761 the condition of the patient is at risk .
6762+
6763+ENGR. H. B. NO. 3567 Page 48 1
6764+2
6765+3
6766+4
6767+5
6768+6
6769+7
6770+8
6771+9
6772+10
6773+11
6774+12
6775+13
6776+14
6777+15
6778+16
6779+17
6780+18
6781+19
6782+20
6783+21
6784+22
6785+23
6786+24
25546787
25556788 7. A pharmacist who receives a written, ora l or facsimile
25566789 prescription shall not be required to verify that the prescription
25576790 falls under one of the exceptions provided for in paragraph 6 of
25586791 this subsection. Pharmacists may cont inue to dispense medications
25596792 from otherwise valid written, oral or facs imile prescriptions that
25606793 are consistent with the provisions of this section.
2561-
25626794 8. Practitioners shall indicate in the health record of a
25636795 patient that an exception to the electronic presc ription requirement
25646796 was utilized.
2565-
25666797 9. All prescriptions issued pursuant to paragraphs paragraph 5
25676798 and subparagraph c of paragra ph 6 of this subsection shall be issued
25686799 on an official prescription form provided approved by the Oklahoma
25696800 State Bureau of Narcotics and Dangerous Drugs Control if not issued
25706801 electronically.
2571-
25726802 10. a. Effective January 1, 2020, practitioners Practitioners
25736803 shall register be registered with the Oklahoma State
25746804 Bureau of Narcotics and Dangerous Drugs Control in
25756805 order to be issued purchase official prescription
25766806 forms. Such registration shall include, but not be
25776807 limited to, the primary address and the address of
25786808 each place of business to be imprinted on official
25796809 prescription forms. Any change to a regist ered
2580-practitioner’s registered address shall be promptly
2581-reported to the practitioner’s licensing board and the
6810+practitioner's registered address shall be promptl y
6811+reported to the practitioner's licensing board and the
6812+
6813+ENGR. H. B. NO. 3567 Page 49 1
6814+2
6815+3
6816+4
6817+5
6818+6
6819+7
6820+8
6821+9
6822+10
6823+11
6824+12
6825+13
6826+14
6827+15
6828+16
6829+17
6830+18
6831+19
6832+20
6833+21
6834+22
6835+23
6836+24
6837+
25826838 Bureau by the practitioner in a manner approved by the
25836839 Bureau.
2584-
2585-b. A practitioner’s registration shall be without fee and
6840+b. A practitioner's registration shall be without fee and
25866841 subject to approval by the Bureau. Such registration
25876842 shall be valid for a per iod of two (2) years and may
25886843 be denied, suspended or revoked by the Bu reau upon a
25896844 finding by the Bureau or licensing board that the
25906845 registered practitioner has had any license to
25916846 practice a medical pro fession revoked or suspended by
25926847 any state or federal ag ency.
2593-
25946848 c. Where the Bureau has revoked the registration of a
2595-registered practitioner, the Bureau may r evoke or ENR. H. B. NO. 3567 Page 59
6849+registered practitioner, the Bureau may revoke or
25966850 cancel any official prescription forms in the
25976851 possession of the registered practitioner. A ny
25986852 revocation or any suspension shall require the
25996853 registered practitioner to return all unused official
26006854 prescription forms to the Bureau within fiftee n (15)
26016855 calendar days after the date of the written
26026856 notification.
2603-
26046857 d.
2605-
26066858 c. A practitioner that has had any license to practice
26076859 terminated, revoked or suspended by a sta te or federal
26086860 agency may, upon restoration of such license or
6861+
6862+ENGR. H. B. NO. 3567 Page 50 1
6863+2
6864+3
6865+4
6866+5
6867+6
6868+7
6869+8
6870+9
6871+10
6872+11
6873+12
6874+13
6875+14
6876+15
6877+16
6878+17
6879+18
6880+19
6881+20
6882+21
6883+22
6884+23
6885+24
6886+
26096887 certificate, register to be issued official
26106888 prescription forms with the Bureau.
2611-
26126889 11. a. Except as provided in subparagrap h f of this
26136890 paragraph, the Bureau shall issue official Official
26146891 prescription forms free of charge only to registered
26156892 practitioners in this st ate. Such forms shall not be
26166893 transferable. The number of official prescription
26176894 forms issued to a registered shall be purchased at the
26186895 expense of the practitioner at any time shall be at
26196896 the discretion of or the employer of the practitioner
26206897 from a list of vendors approved by the Bureau.
2621-
26226898 b. Official prescription forms issued to a registered
26236899 practitioner shall be imprinted only with the primary
26246900 address and may include other addresses listed on the
26256901 registration of the practitioner to identify the place
26266902 of origin. Such prescriptions shall be sent only to
26276903 the primary address of the registered practitioner.
2628-
26296904 c. Official prescription forms issued to of a registered
26306905 practitioner shall be used o nly by the practitioner to
26316906 whom they are issued designated on the official
26326907 prescription form.
2633-
26346908 d. The Bureau may revoke or cancel official prescription
26356909 forms in possession of registered practitioners when
6910+
6911+ENGR. H. B. NO. 3567 Page 51 1
6912+2
6913+3
6914+4
6915+5
6916+6
6917+7
6918+8
6919+9
6920+10
6921+11
6922+12
6923+13
6924+14
6925+15
6926+16
6927+17
6928+18
6929+19
6930+20
6931+21
6932+22
6933+23
6934+24
6935+
26366936 the license of such practitioner is suspended,
26376937 terminated or revoked.
2638-
26396938 e. Official prescription forms of registered
2640-practitioners who are deceased or who no longer ENR. H. B. NO. 3567 Page 60
6939+practitioners who are deceased or who no lon ger
26416940 prescribe shall be returned to the Bureau at a
26426941 designated address. If the registered practitioner is
26436942 deceased, it is the responsibility of the registered
2644-practitioner’s estate or lawful designee to return
6943+practitioner's estate or lawful designee to return
26456944 such forms.
2646-
26476945 f. The Bureau may issue official p rescription forms to
26486946 employees or agents of the Bureau and other government
26496947 agencies for the purpose of preventing, identifying,
26506948 investigating and prosecuting unacceptabl e or illegal
26516949 practices by providers and other perso ns and assisting
26526950 in the recovery of overpayments under any program
26536951 operated by the state or paid for with state funds.
26546952 Such prescription forms shall be issued for this
26556953 purpose only to individuals who are authorized to
26566954 conduct investigations on behalf of t he Bureau or
26576955 other government agenc ies as part of their official
26586956 duties. Individuals and agencies receiving such
26596957 prescription forms for this purpose shall provide
26606958 appropriate assurances to the Bureau that adequate
26616959 safeguards and security measures are in p lace to
6960+
6961+ENGR. H. B. NO. 3567 Page 52 1
6962+2
6963+3
6964+4
6965+5
6966+6
6967+7
6968+8
6969+9
6970+10
6971+11
6972+12
6973+13
6974+14
6975+15
6976+16
6977+17
6978+18
6979+19
6980+20
6981+21
6982+22
6983+23
6984+24
6985+
26626986 prevent the use of such pre scription forms for
26636987 anything other than official government purposes.
2664-
26656988 12. a. Adequate safeguards and security measures shall be
26666989 undertaken by registered practitioners hol ding
26676990 official prescription forms to assure against the
26686991 loss, destruction, theft or un authorized use of the
26696992 forms. Registered practitioners shall maintain a
26706993 sufficient but not excessive supply of such forms in
26716994 reserve.
2672-
26736995 b. Registered practitioners shall imm ediately notify the
26746996 Bureau, in a manner designated by the Bureau, upon
26756997 their knowledge of the loss, destruction, theft or
26766998 unauthorized use of any official prescription forms
26776999 issued to them, as well as the failure to receive
26787000 official prescription forms with in a reasonable time
26797001 after ordering them from the B ureau.
2680-
26817002 c. Registered practitioners shall immediately notify the
26827003 Bureau upon their knowledge of any diversion or
26837004 suspected diversion of drugs pursuant to the loss,
26847005 theft or unauthorized use of prescriptions .
2685- ENR. H. B. NO. 3567 Page 61
26867006 B. 1. Except for dosages medically required for a period not
26877007 to exceed seventy-two (72) hours which are administered by or on
26887008 direction of a practitioner, other than a pharmacist, or medication
26897009 dispensed directly by a practiti oner, other than a pharmac ist, to an
2690-ultimate user, or the circumstances provided for in paragra phs 5 and
7010+
7011+ENGR. H. B. NO. 3567 Page 53 1
7012+2
7013+3
7014+4
7015+5
7016+6
7017+7
7018+8
7019+9
7020+10
7021+11
7022+12
7023+13
7024+14
7025+15
7026+16
7027+17
7028+18
7029+19
7030+20
7031+21
7032+22
7033+23
7034+24
7035+
7036+ultimate user or the circumstances provi ded for in paragraphs 5 and
26917037 6 of subsection A of this secti on, no controlled dangerous substance
26927038 included in Schedule III or IV, which is a prescription drug as
26937039 determined under regulation promulgated by the Board of Pharmacy,
26947040 shall be dispensed w ithout an electronic prescription.
2695-
26967041 2. Any prescription for a controlled dangerous substance in
26977042 Schedule III, IV or V may not be fi lled or refilled more than six
26987043 (6) months after the date thereof or be refilled more than five
26997044 times after the date of the prescription, unless renewed by the
27007045 practitioner.
2701-
27027046 C. Whenever it appears to the Director of the Oklahoma State
27037047 Bureau of Narcotics a nd Dangerous Drugs Control that a drug not
27047048 considered to be a prescription drug under existing state law or
27057049 regulation of the Board of Pharmacy should be so considered bec ause
27067050 of its abuse potential, the Director shall so advise the Board of
27077051 Pharmacy and furnish to the Board all available data relevant
27087052 thereto.
2709-
2710-D. 1. “Prescription”, as used in this section, means a
7053+D. 1. "Prescription", as used in this section, means a
27117054 written, oral or electronic order by a practitioner to a pharmacist
27127055 for a controlled dangerous substance for a particular patient, which
27137056 specifies the date of its issue, and the full name and address of
27147057 the patient and, if the controlled dangerous substance is prescribed
27157058 for an animal, the species of the animal, the name and quantity of
27167059 the controlled dangerous substance prescribed, the directio ns for
7060+
7061+ENGR. H. B. NO. 3567 Page 54 1
7062+2
7063+3
7064+4
7065+5
7066+6
7067+7
7068+8
7069+9
7070+10
7071+11
7072+12
7073+13
7074+14
7075+15
7076+16
7077+17
7078+18
7079+19
7080+20
7081+21
7082+22
7083+23
7084+24
7085+
27177086 use, the name and address of the owner of the animal and, if
27187087 written, the signature of the practitioner. When electronically
27197088 prescribed, the full name of the patient may include the name and
27207089 species of the animal.
2721-
2722-2. “Registered practitioner”, as used in this section, means a
7090+2. "Registered practitioner", as used in this section, means a
27237091 licensed practitioner duly registered with the Oklahoma State Bureau
27247092 of Narcotics and Dangerous Drugs Control authorized to be issued
27257093 purchase official prescription forms.
2726-
27277094 E. No person shall solicit, dispense, receive or deliver any
27287095 controlled dangerous substance throug h the mail, unless the ultimate
2729-user is personally known to the practitioner and circumstances ENR. H. B. NO. 3567 Page 62
7096+user is personally known to the practitioner and circ umstances
27307097 clearly indicate such method of delivery is in the best interest of
27317098 the health and welfare of the ultimate user.
2732-
2733-SECTION 7. AMENDATORY 63 O.S. 2021, Section 2 -406, as
7099+SECTION 15. AMENDATORY 63 O.S. 2021, Section 2-406, as
27347100 amended by Section 2, Chapter 235, O.S.L. 2023 (63 O.S. S upp. 2023,
27357101 Section 2-406), is amended to read as follows:
2736-
27377102 Section 2-406. A. It shall be unlawful for any registrant or
27387103 person applying for registration to knowingly or intentio nally:
2739-
27407104 1. To distribute Distribute, other than by dispensing or as
27417105 otherwise authorized by the Uniform Controlled Dangerous Substances
27427106 Act, a controlled dangerous substance classified in Schedules I or
27437107 II, in the course of his or her legitimate business, except pursuant
27447108 to an order form as required by Section 2 -308 of this title;
27457109
7110+ENGR. H. B. NO. 3567 Page 55 1
7111+2
7112+3
7113+4
7114+5
7115+6
7116+7
7117+8
7118+9
7119+10
7120+11
7121+12
7122+13
7123+14
7124+15
7125+16
7126+17
7127+18
7128+19
7129+20
7130+21
7131+22
7132+23
7133+24
7134+
27467135 2. To use Use in the course of the manufacture or distribution
27477136 of a controlled dangerous substance a registration number which is
27487137 fictitious, revoked, suspended or issued to another person;
2749-
27507138 3. To acquire Acquire or obtain possession of a controlled
27517139 dangerous substance by misrepresentation, fra ud, forgery, deception
27527140 or subterfuge;
2753-
27547141 4. To furnish Furnish false or fraudulent material information
27557142 in, or omit any material information from, any application, report,
27567143 or other document required to be kept or filed under the Uniform
27577144 Controlled Dangerous Substances Act, or any record required to be
27587145 kept by the Uniform Controlled Dangerous Substances Act;
2759-
27607146 5. To make Make, distribute, or possess any punch, die, plate,
27617147 stone, or other thing designed to print, imprint, or reproduce the
27627148 trademark, trade name, or other identifying mark, i mprint, or device
27637149 of another or any likeness of any of the foregoing upon any drug or
27647150 container or labeling thereof so as to render such drug a
27657151 counterfeit controlled dangerous substance; and
2766-
27677152 6. To purchase Purchase, or attempt, endeavor, or conspire to
27687153 obtain or purchase, any license or registration required to
27697154 distribute, possess, prescribe, or manufacture any controlled
27707155 dangerous substance on behalf of, or at the request or demand of,
27717156 any other person through the use of a straw person or straw party.
2772-
27737157 B. Any person who violates this section is gu ilty of a felony
2774-punishable by imprisonment for not more than twenty (20) years or a ENR. H. B. NO. 3567 Page 63
7158+punishable by imprisonment for not more than twenty (20) years or a
7159+
7160+ENGR. H. B. NO. 3567 Page 56 1
7161+2
7162+3
7163+4
7164+5
7165+6
7166+7
7167+8
7168+9
7169+10
7170+11
7171+12
7172+13
7173+14
7174+15
7175+16
7176+17
7177+18
7178+19
7179+20
7180+21
7181+22
7182+23
7183+24
7184+
27757185 fine not more than Two Hundred Fifty Thousand Dollars ($250,000.00),
27767186 or both.
2777-
27787187 C. Any person convicted of a second or subsequen t violation of
27797188 this section is punishable by a term of imprisonment twice that
27807189 otherwise authorized and by twice the fine otherwise authorized.
27817190 Convictions for second or subsequent violations of this section
27827191 shall not be subject to statutory provisions fo r suspended
27837192 sentences, deferred sentences, o r probation.
2784-
27857193 D. Any person convicted of any offense described in this
27867194 section shall, in addition to any fine imposed, pay a special
27877195 assessment trauma-care fee of One Hundred Dollars ($100.00) to be
27887196 deposited into the Trauma Care Assistance Revolving Fund created in
27897197 Section 1-2530.9 of this title.
2790-
2791-SECTION 8. REPEALER 63 O.S. 2021, Sections 2-101, as
7198+SECTION 16. REPEALER 63 O.S. 2021, Sections 2-101, as
27927199 last amended by Section 10, Chapter 91, O.S.L. 2019, Section 1,
27937200 Chapter 235, O.S.L. 2023, and Section 1, Chapter 304, O.S.L. 2023,
27947201 2-304, as last amended by Section 1, Chapter 176, O.S.L. 2023, 2-
27957202 305, as amended by Section 2, Chapter 176, O.S.L. 2023, 2-309, as
27967203 last amended by Section 1, Chapter 333, O.S.L. 2021, 2-402, as last
2797-amended by Section 1, Chapter 220, O.S.L 2016, and 2-406, as last
7204+amended by Section 1, Chapter 220, O.S.L 2016 and 2-406 as last
27987205 amended by Section 7, Chapter 375, O.S.L. 2023 (63 O.S. Supp. 2023,
27997206 Sections 2-101, 2-304, 2-305, 2-309, 2-402 and 2-406), are hereby
28007207 repealed.
28017208
2802-SECTION 9. It being immediately necessary for the preservation
7209+ENGR. H. B. NO. 3567 Page 57 1
7210+2
7211+3
7212+4
7213+5
7214+6
7215+7
7216+8
7217+9
7218+10
7219+11
7220+12
7221+13
7222+14
7223+15
7224+16
7225+17
7226+18
7227+19
7228+20
7229+21
7230+22
7231+23
7232+24
7233+
7234+SECTION 17. It being immediately necessary for the pre servation
28037235 of the public peace, health or safety, an emergency is hereby
28047236 declared to exist, by reason whe reof this act shall take effect and
2805-be in full force from a nd after its passage and approval. ENR. H. B. NO. 3567 Page 64
2806-Passed the House of Representatives the 9th day of May, 2024.
7237+be in full force from and after its passage an d approval.
7238+Passed the House of Representatives the 12th day of March, 2024.
7239+
28077240
28087241
28097242
28107243 Presiding Officer of the House
28117244 of Representatives
28127245
28137246
2814-
2815-Passed the Senate the 24t h day of April, 2024.
7247+Passed the Senate the ____ day of __________, 2024.
7248+
28167249
28177250
28187251
28197252 Presiding Officer of the Senate
28207253
28217254
28227255
2823-OFFICE OF THE GOVERNOR
2824-Received by the Office of th e Governor this ____________________
2825-day of ___________________, 20_______, at _______ o'clock _______ M.
2826-By: _________________________________
2827-Approved by the Governor of the State of Oklahoma this _____ ____
2828-day of ___________________, 20_______, at _____ __ o'clock _______ M.
2829-
2830-
2831- _________________________________
2832- Governor of the State of Oklahoma
2833-
2834-OFFICE OF THE SECRETARY OF STATE
2835-Received by the Office of the Secretary of State this __________
2836-day of ___________________, 20_______, at _______ o'clock _____ __ M.
2837-By: _________________________________